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ABSTRACT
The development of resistance to anticancer drugs poses one of the major 
obstacles to improving the survival from malignant disease. Most clinically effective 
anticancer agents act upon DNA. Resistance has been shown to arise by mechanisms 
that reduce the amount of drug reaching the DNA. However, drug resistance developing 
through alterations in the capacity of tumour cells to repair or respond to DNA damage, 
may be as important.
Microsatellite instability ( RER+) is generally taken as an indication of defective 
DNA mismatch repair. Ovarian and breast carcinoma cell lines, selected for resistance 
to cisplatin and doxorubicin, were shown to display an RER+ phenotype as shown by 
multiple mutations at microsatellite loci in comparison to the parental line. The ovarian 
carcinoma cell line A2780 was shown to be RER- by microsatellite analysis of random 
sub-clones from the cell line. A2780/cp70, a cisplatin resistant cell line derived from 
A2780, displayed an RER+ phenotype when subject to the same analysis.
Ten independently derived, cisplatin resistant, A2780 cell lines were developed 
by selection with increasing concentrations of cisplatin to a final concentration of 
15pM. These were shown to display stable resistance to cisplatin of between 4 fold ( as 
determined by clonogenic assay ) and 7 fold ( as determined by MTT assay ), when 
compared to the parental line. The RER+ phenotype was detected in all but one of these 
lines. An association between the RER+ phenotype and cisplatin resistance was further 
strengthened by the finding of micro satellite instability in resistant A2780 cell lines 
selected by a single exposure to 15pM cisplatin.
Mutations in genes involved in mismatch repair have been shown to be 
responsible for microsatellite instability. The biochemical basis of the RER+ phenotype 
in drug resistant A2780 derived cell lines was determined by in vitro repair assay. An 
inability to correct DNA mismatches, when repair was directed from 3’ to the lesion, 
was observed, and hMutLa was identified as the defective component of mismatch 
repair by in vitro complementation. Further studies revealed the absence of hMLHl and 
hPMS2 proteins, which constitute hMutLa, within the RER+ resistant cell lines. This 
arises from the failure of these cells to express hMLHl mRNA. No defect in the 
expression of the other known mismatch repair genes was observed.
P53-dependent DNA damage responses were characterised in the RER+, drug 
resistant cell lines. A correlation was observed between RER+ status and loss of 
radiation induced G1 arrest, reduced expression of the CIP 1 gene and decreased levels 
of apoptosis after cisplatin exposure. This association between DNA mismatch repair 
and the DNA damage response pathway suggests that the mismatch repair system might 
act as a sensor for DNA damage. This supports the hypothesis that mismatch repair may 
be involved in determining the cellular sensitivity to cisplatin; defects in such repair 
leading to cisplatin resistance.
CHAPTER 1
GENERAL INTRODUCTION
1
1.1 CLINICAL DRUG RESISTANCE
The use of drugs to treat cancer has only been a reality over the past half-century 
since the introduction of the nitrogen mustards in the 1940’s (Rhoads, 1946). During this 
period of time chemotherapeutic agents have brought about a number of notable success 
in the treatment of certain forms of cancer. Tumours such as malignant teratoma of the 
testis and childhood acute lymphoblastic leukaemia, which were once uniformly fatal, are 
now considered potentially curable in the majority of cases (Poplack et al. 1995). These 
few successes apart, and in spite of the enormous effort in terms of money and 
manpower to develop new forms of therapy, the majority of patients who develop a 
malignancy in the 1990’s will eventually die from their disease.
There are many factors which underlie this failure to improve the prognosis 
associated with most forms of cancer. Poor public health awareness, inadequate 
screening tests and regional variations in treatment all help determine the likelihood of 
overall survival from cancer. However, one of the greatest obstacles to improving the 
outlook for patients with malignant disease is the inability of current therapies to 
permanently eradicate them of tumour. The innate response of tumours on exposure to 
chemotherapeutic drugs ranges from exquisite sensitivity to obstinate resistance. 
Unfortunately, tumours which initially show sensitivity to a particular therapeutic agent 
will often recur displaying resistance not only to that agent but often to a broader range 
of anti-cancer drugs. Understanding the molecular mechanisms that underlie acquisition 
of drug resistance and formulating new therapies to counteract its effects represents one 
of the fundamental challenges to oncologists.
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1.2 TUMOUR HETEROGENEITY AND DRUG RESISTANCE.
There have been many different hypotheses advanced to account for the 
mechanism of treatment failure during cancer chemotherapy. These have included 
differences in the kinetics of cell growth between tumours (Shackney et al. 1978) and 
variations in the penetration of effective concentrations of chemotherapeutic agents in to 
tumours (Hanna et al. 1983). It is now widely accepted, however, that the ability of 
tumours to develop resistance to a wide variety of different anti-cancer agents derives 
from extensive phenotypic heterogeneity within the constituent cells (Dexter and Leith,
1986) This heterogeneity arises as a result of both the cellular genetic and phenotypic 
instability which characterise the growth of tumours (Nowell, 1976). It is assumed that 
within a tumour there exist many cells with different phenotypic characteristics which 
give a survival advantage under specific conditions. The selective pressures exerted by 
exposure to chemotherapeutic drugs, which are often mutagenic themselves, result in 
survival of cells which continue to develop further heterogeneity, and most likely 
resistance, as they grow during tumour progression. Using mathematical models it has 
been calculated that larger tumours display more heterogeneity, as do more slowly 
growing tumours, and are therefore more likely to display resistance to therapy (Goldie 
and Coldman, 1984) This is, generally, what is observed clinically.
Much of the work that has characterised drug resistance in tumours to date has 
revealed mechanisms of resistance whereby cells reduce the intracellular accumulation of 
active drug. It has therefore been assumed that by maximising the delivery of drug to its 
intracellular target the problem of drug resistance could be overcome (Hryniuk, 1995). 
This has formed the basis of numerous trials of high dose chemotherapy in the belief that 
increases in the extracellular dose of drug could overcome mechanisms which reduce 
intracellular accumulation. However, the results of these trials often show an initial 
benefit of high dose, over standard dose, treatment but with the eventual relapse of 
resistant tumour (Souhami, 1995). This lack of improvement in efficacy, despite better
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drug delivery to the intracellular target, has suggested that mechanisms of drug 
resistance acting after the drug/target interaction may have a relatively greater clinical 
significance. It is generally assumed that DNA is the primary target for the action of
cytotoxic anticancer agents. Advances in our understanding of DNA repair mechanisms
has allowed determination of whether they play a role in the resistance to 
chemotherapeutic drugs. Of equal importance are the multiple pathways that interact 
after DNA damage to bring about death of the cell. It is becoming increasingly clear that 
there exist many points in these post-damage pathways where resistance to anti-cancer 
agents could arise.
Therefore one can broadly define three general areas in which cellular drug 
resistance can arise;
(1). Pre-target resistance.
(2). Drug/Target interactions and damage repair.
(3). Post-damage resistance.
The data presented in this thesis uses cell lines selected for resistance to the clinically 
successful anti-cancer drugs cis-diamminedichloroplatinum(II) (cisplatin) and 
doxorubicin. The following summary of the mechanisms by which cells develop 
resistance to anti-cancer drugs will, in general, focus on mechanisms relevant to these 
two agents.
1.3 MECHANISMS OF DRUG RESISTANCE IN TUMOUR CELLS 
OCCURRING PRIOR TO DRUG/TARGET INTERACTION.
1.3.1 Reduced intracellular accumulation of drug by decreased drug 
influx.
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It would appear logical that if a tumour cell could reduce the amount of cytotoxic 
drug reaching the intracellular compartment for a given extracellular concentration of 
drug then it would display a greater degree of resistance. In the case of cisplatin it has 
been shown by various authors that in vitro tumour sub-lines, derived by exposure to 
increasing concentrations of drug, accumulate less cisplatin than the cells from which 
they have been derived (Andrews and Howell, 1990).
The mechanisms by which cisplatin enters the cell are still unclear. It would 
appear that cisplatin can enter the cell by a process of passive diffusion (Gale et al. 1973) 
but evidence has been presented that active transport of cisplatin can also occur. Other 
factors which may affect the active uptake of cisplatin in resistant cell lines include 
alterations in the membrane potential (Andrews and Albright, 1992) and altered signal 
transduction e.g. in the protein kinase A (Mann et al. 1991) or Ca /Calmodulin 
pathways (Kikuchi et al. 1990). To tie all the data together a model has been proposed 
which suggests that the initial uptake of cisplatin into the cell occurs both by passive 
diffusion and by active transport through some form of gated channel (Gately and 
Howell, 1993). Characterisation of a number of gated channels suggests that flux 
through the channel can be regulated by alterations in membrane potential or by 
phosphorylation initiated by signal transduction pathways (Gately and Howell, 1993). 
Mutations arising in the protein could alter the rate of flux or specificity for substrate 
leading to a reduction in cisplatin uptake.
Evidence that gated channels may play some role in determining cisplatin 
sensitivity has come from comparing levels of specific membrane proteins in sensitive and 
resistant cell lines (Bernal et al. 1990). Sharp et al have shown overexpression of a 
36kDa membrane protein in 41McisR6, a cisplatin resistant ovarian carcinoma cell line, 
this being associated with loss of sensitivity to inhibitors of active transport (Sharp et al. 
1995). It has been shown that reduced cisplatin accumulation is probably one of the 
major determinants of resistance in cell lines such as 41McisR6 (Sharp et al. 1995).
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However, the contribution that reduced accumulation plays in the development of 
cisplatin resistance in vivo remains unclear.
1.3.2 Reduced intracellular accumulation of drug by increased drug
efflux.
Perhaps the most thoroughly characterised of all mechanisms of drug resistance 
to date have been those that increase the excretion of drug from the intracellular 
compartment. Clinical experience indicates that tumours which develop resistance after 
treatment with particular chemotherapeutic agents are also resistant to a range of agents 
to which they have never been exposed (Nooter and Herweijer, 1991). This phenomenon 
is referred to as multi-drug resistance (MDR). The anticancer drugs to which the MDR 
phenotype is observed share characteristics such as being lipophilic and of natural origin 
and include doxorubicin but not cisplatin. Cell lines which display an MDR phenotype 
can be derived, in vitro, by selection with drugs such as doxorubicin or vinblastine. It has 
been shown that such cells have a reduced ability to accumulate drugs, compared to the 
parent line, and that this is likely to be the main cause of the MDR phenotype (Dano, 
1973). It has since been determined that altered expression of a specific energy 
dependent, unidirectional, drug efflux pump is responsible for the reduction in 
intracellular drug accumulation in these cells (Willingham et al. 1986). This is a 170kDa 
transmembrane glycoprotein named P-glycoprotein (Kartner et al. 1985).
That expression of P-glycoprotein can result in the development of multi-drug 
resistance in vitro has been proven by experiments in which the MDR1 gene was 
transfected into drug sensitive cells. This resulted in the development of an MDR 
phenotype in these cells without any prior exposure to anticancer drugs (Ueda et al. 
1987). Despite such evidence the significance of the expression of P-glycoprotein in 
tumours is less clear. In general, tumours from tissues with high basal levels of MDR1
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also display high expression of the gene. Such tumours ( colon, pancreas, kidney etc.) are 
often intrinsically resistant to a wide range of anticancer drugs, showing a low response 
rate to chemotherapy. The increased expression of P-glycoprotein in resistant tumours 
can arise through enhanced gene transcription or by post-transcriptional stabilisation of 
MDR1 mRNA (Marino et al. 1990). Transcription can be influenced by genes such as 
p53 (Chin et al. 1992b).
One of the problems, however, in correlating the significance of P-glycoprotein 
expression and in vivo MDR is that it is unclear as to what level of P-glycoprotein 
expression, and in how many cells, is required to produce a resistant phenotype. A 
relationship has been shown in vitro between the expression of MDR 1 and sensitivity to 
MDR related drugs for breast cancer biopsies (Keith et al. 1990). There has also been 
some recent evidence that in certain tumours such as neuroblastomas and soft tissue 
sarcomas high expression of MDR1 in the untreated tumour is associated with poor 
prognosis (Chan et al. 1990; Bourhis et al. 1989).
P-glycoprotein is not the only cell membrane associated protein involved in the 
development of multi-drug resistance by increased drug efflux. Another protein that 
belongs to the ATP binding cassette ( ABC ) transporter superfamily of proteins is MDR 
related protein ( MRP ). Gene amplification is commonly responsible for MRP over­
expression in tumour cell lines selected for resistance by exposure to doxorubicin or 
etoposide (Cole et al. 1992). Transfection experiments using the MRP gene have shown 
that its expression in vitro can result in resistance to classical MDR type drugs such as 
doxorubicin and daunorubicin. There is little resistance to non-MDR drugs such as taxol 
or cisplatin (Zaman et al. 1994). Although the biochemistry of MRP action remains 
unclear it appears that not only may it pump drugs out of the cytoplasm but it may 
sequester drug by transportation into cytoplasmic vesicles (Cole et al. 1992). These 
vesicles can then be removed from the cell by exocytosis. As yet the role that MRP plays 
in the development of clinically relevant multi-drug resistance is unclear (Broxterman et 
al. 1995).
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1.3.3. Altered intracellular drug metabolism.
Many anti-cancer drugs require biochemical modification within cells before 
becoming active. Intracellular enzymatic systems can also modify the drugs resulting in 
detoxification and excretion. Innate or acquired differences in the activities of such 
systems can result in the expression of a drug resistant phenotype.
The cytochrome P450 family of enzymes play a crucial role in the 
biotransformation of many drugs including anti-cancer drugs. Such biotransformation can 
either involve activation or inactivation of a drug. The levels of specific cytochromes 
P450 in an individual depend on factors such as sex, age, genetic polymorphism etc. 
Each of these factors could alter the specific metabolism of an anti-cancer agent resulting 
in relative resistance to the drug (Doehmer et al. 1993). Cyclophosphamide is an example 
of an anticancer agent that requires activation via the cytochrome P450 pathway (Clarke 
and Waxman, 1989).
Cells also possess a drug metabolism system based on the important intracellular 
thiol, Glutathione ( GSH ). GSH plays a role in decreasing the toxicity of certain drugs 
by combining to form glutathione-drug conjugates ( catalysed by a family of Glutathione- 
S-transferase enzymes ) which have reduced activity and are excreted in the urine or bile. 
GSH and other components of its metabolic pathway can also interact with and detoxify 
reactive oxygen species that arise spontaneously within the cell or as a result of the 
action of certain cytotoxic drugs. Such reactive oxygen molecules are highly toxic to the 
cell. There is evidence that the ability of a cell to maintain active GSH levels in the face 
of a toxic challenge may influence its ability to survive and hence its resistance (Meijer et 
al. 1990).
The clinical significance of the role of GSH in determining drug resistance is 
unclear. Elevated intracellular levels of GSH have been observed in many in vitro tumour 
cell lines with a good correlation to cisplatin resistance being observed in a few of these
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(Mistry et al. 1990). In other cells it may be that levels of GSH within certain 
intracellular compartments, e.g. nuclear GSH, correlate more closely with cisplatin 
resistance (Meijer et al. 1990). Intranuclear GSH may be important in binding to 
monofunctional cisplatin/DNA adducts preventing formation of more toxic bifunctional 
forms. (Eastman, 1987a). In vitro studies have shown that intranuclear GSH levels do 
correlate with reductions in platinated DNA (Meijer et al. 1990).
Recently further evidence of an important role for GSH in the detoxification of 
cisplatin has arisen. It has been shown that GSH/cisplatin complexes within the cell can 
be actively transported across cell membranes by an ATP dependent glutathione S- 
conjugate export ( GS-X ) pump (Ishikawa and Aliosman, 1993). Doxorubicin and 
daunorubicin GSH conjugates may also be excreted by this pump (Ishikawa et al. 1995). 
It has been shown that over-expression of multidrug resistance-associated protein ( MRP 
) results in an increased activity of the GS-X pump and that both proteins may in fact be 
the same (Muller et al. 1994)
The metallothioneins ( MT ) are a group of cysteine rich proteins which act as 
nucleophiles towards electrophilic agents such as cisplatin and may be involved in their 
detoxification. There is conflicting in vitro evidence as to the significance of MT in 
cisplatin resistance. Some studies show over-expression of MT mRNA and increased 
protein levels in a panel of human cell lines with acquired resistance to cisplatin (Kelley 
et al. 1988). In a panel of cisplatin resistant ovarian cancer cell lines, however, no 
correlation between MT mRNA over expression and cisplatin resistance was observed 
(Schilder et al. 1990). Therefore, although MT may be associated with induction of 
cisplatin resistance its causal role remains to be established.
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1.3.4. Alterations in signal transduction pathways associated with drug
resistance.
The intracellular signalling mechanisms which co-ordinate the vast array of 
cellular functions, although extensively investigated for their role in cell transformation, 
may also influence the sensitivity of cells to anticancer drugs. Cancer chemotherapeutic 
agents have been shown to disrupt these signal transduction pathways which may 
contribute to the evolution of drug resistant clones (Brunton and Workman, 1993).
It has been proposed that the substrate specificity of, and/or the rate of efflux 
through, P-glycoprotein can be controlled by phosphorylation of specific amino acids 
within the protein (Chin et al. 1992a; Chin et al. 1990a). Certain isoforms of protein 
kinase C ( PKCa and P ) have been shown to be elevated in cell lines with either intrinsic 
(Dolfini et al. 1993) or acquired resistance to doxorubicin and other drugs (Lee et al. 
1992). A PKC mediated signal pathway has also been implicated in determining the 
sensitivity of cervical and ovarian carcinoma cells to cisplatin (Isonishi et al. 1990; Basu 
and Evans, 1994).
Transcriptional regulation of specific genes is the final step in many signal 
transduction pathways. It has been suggested that transcription of the MDR gene may be 
influenced by binding of the AP-1 complex, consisting of activated c-fos and c-jun 
(Volm, 1993; Ransone and Verma, 1990). There is evidence to show that cells with an 
MDR phenotype over-express c-fos and that cells transfected with and over-expressing 
c-fos display MDR. Also reduction of c-fos expression led to reversal of an MDR 
phenotype in actinomycin D resistant ovarian carcinoma cells (Scanlon et al. 1994). 
Other oncogenes which are involved in signal transduction pathways have also been 
shown to be altered in drug resistant cell lines in vitro (Kellen, 1994).
As yet the significance of differences in signal transduction pathways in the 
development of drug resistance in the clinical setting is completely unknown.
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1.3.5. Drug resistance arising through alterations in target associated
proteins.
The target of the majority of the clinically useful anticancer agents is DNA, 
although in some cases this interaction is mediated through DNA associated proteins. 
DNA topoisomerases (I & II) are enzymes involved in altering the tertiary structure of 
DNA to allow processes such as transcription and replication. The DNA topoisomerases 
act by generating breaks in the phosphodiester backbone of the DNA molecule ( single 
strand for topo I and double strand for topo I I ) which allows passage of DNA strands 
through the gaps thus altering the topology of the DNA. The topoisomerases form 
transient covalent intermediates, called cleavable complexes, with the free ends of the 
DNA thus stabilising the strand break. The topoisomerases are the targets for a number 
of clinically useful anticancer agents. The main mechanism of action of these drugs is 
through binding to the topoisomerase protein, whilst covalently bound to the DNA, 
resulting in stabilisation of the cleavable complex. This halts the catalytic reaction prior 
to the re-ligation step. The stabilised topoisomerase/DNA complex presents a barrier to 
progression of the enzyme complexes involved in replication, transcription etc. The 
lesions become lethal to the cell when it tries to use the affected region of the genome as 
template (Liu, 1989).
The majority of the topoisomerase inhibitors are naturally derived drugs e.g. 
etoposide, doxorubicin etc. As such, many are substrates for P-glycoprotein. Tumour 
cells displaying the MDR phenotype will often display resistance to these drugs (Beck 
and Danks, 1991). It would appear intuitive that, as it is the presence of stabilised 
cleavable complexes that results in damage to the DNA, then the more complexes the 
greater the resultant damage. Atypical multidrug resistance (atMDR) (Danks et al.
1987), is observed as cross-resistance between topoisomerase inhibitors due to 
reductions in the levels of topoisomerase enzyme within a cell. Cells with reduced 
intracellular topo I are more resistant to the topoisomerase I inhibitors such as
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camptothecin. Reduced levels of topoisomerase II has also been shown to correlate with 
resistance to the topo II inhibitors. In the P338/AMSA leukaemia cell line, resistant to 
m-AMSA, inactivation of one allele of topo I la  by hypermethylation results in a 
decreased level of protein in the cell (Johnson and Howard, 1982).
Atypical multidrug resistance has been shown to correlate with mutant forms of 
topoisomerase proteins as well as with differences in the relative amount of protein. Such 
mutant proteins may be less likely to form cleavable complexes or may have enhanced re­
ligation of strand breaks thus altering the sensitivity of tumour cells to the effects of 
topoisomerase inhibitors.
1.4 DNA REPAIR AND DRUG RESISTANCE.
Despite the obvious importance of drug accumulation and metabolism in 
determining the sensitivity of a cell to a particular anti-cancer drug, many resistant cell 
lines have been characterised in which no difference can be detected in these parameters 
when compared to the parental line. In other cases the differences that are shown are not 
significant enough to account for the levels of resistance observed. This suggests that 
there may be alternative mechanisms of drug resistance which do not directly relate to 
the level of drug exposure.
Genomic and mitochondrial DNA are constantly subjected to endogenous and 
exogenous damaging stimuli which if uncorrected would be incompatible with life. 
Therefore all organisms have developed highly efficient enzyme systems that correct such 
damage before it becomes permanent and leads to cell death. Induction of DNA damage 
is the most common means by which anticancer drugs act. The ability of cells to repair 
this damage will obviously influence their sensitivity to such drugs.
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1.4.1 DNA repair by direct reversal of damage.
In principle, the simplest biochemical mechanism by which damage to DNA can 
be repaired is one in which a single enzyme catalyses a single-step reaction which 
restores the structure of the genome to its normal state. There are several such single 
enzyme pathways known but only one has been linked to a drug resistance phenotype in 
human tumour cells.
Alkylating agents are electrophilic compounds with affinity for nucleophilic 
centres in organic macromolecules (Singer and Kusmierek, 1982). They include a wide 
variety of chemicals, many of which are proven, or suspected, carcinogens as well as 
several intermediates of normal cellular metabolism, such as S-adenosyl-methionine, 
(Lutz, 1990). The DNA molecule possesses numerous potential nucleophilic sites, 
suitable for alkylation. The N7 and 06  atoms of guanine and the N3 atom of adenine are 
the most reactive. O6 alkylguanine has considerable biological importance in mammalian 
cells as it is implicated in mutagenesis. In general alkylating agents that produce little O6- 
alkylguanine in DNA are weak carcinogens.
The alkylating agents can be either monofunctional or bifunctional. The former 
have a single reactive group and thus interact with a single nucleophilic centre in DNA. 
Bifunctional alkylating agents have two reactive groups, and each molecule is able, 
potentially, to react with two sites in the DNA. If the two sites are on opposite 
polynucleotide strands, interstrand cross-links will result. If the sites are situated on the 
same DNA strand then the reaction product is referred to as an intrastrand cross-link. 
Both types of cross-link are thought to represent an important class of chemical damage 
to DNA. As a result of this alkylating agents have found extensive clinical application in 
the treatment of a wide range of solid and haematological malignancies (Chabner and 
Myers, 1995).
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The alkyltransferase enzymes are a group of highly conserved proteins that 
function in the direct repair of DNA damage brought about by alkylating agents. They 
act by removing the alkyl group from the nucleophilic centre on the DNA molecule to a 
conserved cysteine residue within the active site of the enzyme. The alkyl group is 
covalently, and irreversibly, linked to the protein and thus the alkyltransferase acts as a 
suicide enzyme (Lindahl et al. 1982). 0 6-alkylguanine is the predominant substrate of the 
alkyltransferase detected in human cells, O6 methyl-guanine methyltransferase (MGMT). 
Cells with effective levels of MGMT activity rapidly repair 0 6-alkylguanine resulting in 
protection against cell killing, mutation, recombination and chromosomal aberrations 
induced by simple alkylating agents (Kaina et al. 1991). MGMT is also effective in 
removing chloroethyl monoadducts from the O6 position of guanine induced by the 
chemotherapeutic chloroethylnitrosoureas (CNU’s) (Gibson et al. 1985), thus preventing 
formation of potentially more cytotoxic DNA cross-links.
There is increasing evidence of a correlation between levels of MGMT within 
cells and resistance to monofunctional and bifunctional alkylating agents both in vitro 
and in vivo. Isogenic Chinese hamster and HeLa cell lines that varied only in the levels of 
MGMT, were used in a study by Preuss et al (Preuss et al. 1996). They showed that 
MGMT proficient cell lines were resistant to cell killing by the methylating drug 
streptozotocin, as well as a range of CNU’s, whereas the same lines were not protected 
against chlorambucil, cisplatin or melphalan. Another study in human glioma cells has 
shown that the activity of alkyltransferase within cells does not correlate with sensitivity 
to cisplatin (Beith et al. 1997). The use of methylated viral DNA in a host cell 
reactivation ( HCR ) assay, in human melanoma cell lines, has confirmed the previously 
observed association between cellular resistance to methylating agents and the activity of 
MGMT (Maynard et al. 1989). Leukaemic myeloid cells from patients with acute non- 
lymphocytic leukaemia ( ANLL ) do not respond to the nitrosoureas. It has been shown 
that in myeloid cells freshly cultured from leukaemic patients the levels of MGMT are 
significantly higher than that found in bone marrow cells enriched for myeloid precursors
14
(Gerson and Trey, 1988). Selective inactivation of the alkyltransferase resulted in 
increased sensitivity of the leukaemic cells to nitrosoureas.
1.4.2 DNA repair by excision of altered or damaged bases.
The term excision repair covers a number of processes by which damaged or 
inappropriate bases are removed from the DNA strand and replaced by the normal 
nucleotide sequence and chemistry. It is of greater biological importance than repair by 
direct damage reversal due to the broader range of DNA damage that acts as substrate. 
Nucleotide excision repair ( NER ) is one such form of excision repair and has been 
shown to have an extremely broad specificity, being able to recognise a wide variety of 
chemical alterations to DNA (Sancar, 1994). Nucleotide excision repair is involved in the 
correction of bulky lesions that arise in DNA such as UV-induced photoproducts and 
adducts derived from exposure to agents such as cisplatin (Bohr, 1995). Defects in NER 
have been shown to be responsible for the rare, inherited, cancer prone syndrome 
Xeroderma pigmentosum (XP) (Kraemer et al. 1994). Analysis of the mutations which 
result in XP have helped identify many of the genes involved in nucleotide excision 
repair. The basic steps involved in NER, and the genes involved, are shown in figure 1.1. 
They include: (1) pre-incision recognition of DNA damage; (2) incision of the damaged 
DNA strand near the defect; (3) excision of the defective site with concomitant 
degradation of the excised strand; (4) replication to replace the excised strand with the 
opposite ( intact) strand being used as a template; and (5) ligation of the correct strand 
into the DNA at the 3’end of the repair patch. The size of this “repair patch” in 
eukaryote species is about 30 nucleotides which is longer than that seen in the other 
types of excision repair (Freidman et al. 1995). The majority of genes involved in NER 
have now been cloned and recently a cell free system has been developed that allows 
analysis of the role of each gene product in the repair process (Aboussekhra et al. 1995).
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F i g u r e  1 . 1 M o d e l  f o r  n u c l e o t i d e  e x c i s i o n  r e p a i r  ( N E R ) .
( a ) .  D N A  d a m a g e  is r e c o g n i s e d  b y  X P A  p r o t e i n  in a s s o c i a t i o n  w i t h  R P A
( b) .  R e c r u i t m e n t  o f  T  FI  I H ( s i x  s u b u n i t s  ) - h e  l i e  a s e  a c t i v i t y  o f  o f  X P B  a n d  X P D  
o p e n  o u t  s t r u c t u r e ,  e n a b l i n g ;  ( c ) .  s t r u c t u r e  s p e c i f i c  n u c l e a s e s ,  E R C C  1 - X P F
a n d  X P G ,  t o c u t  D N A  o n  e i t h e r  s i d e  o f  t h e  d a m a g e .
( d ) .  D N A  p o l y m e r a s e  e p s i l o n  ( P O L  E )  a n d  a c c e s s o r y  p r o t e i n s ,  r e p l i c a t i o n  f a c t o r  C 
( R F C )  a n d  P C N A  f i l l  i n t h e  r e s u l t i n g  g a p ,  a n d  ( e )  t h e  n e w  D N A  is j o i n e d  t o t h e  o l d  
b y  D N  A l i g a s e .
Initial studies of the repair of bulky damage from DNA assumed that the 
efficiency of repair was uniform for the genome as a whole. Recently, however, there is 
evidence to suggest that preferential repair of certain active or essential genes is a 
general feature of DNA repair (Link et al. 1991). For example, in hamster cells, the 
dihydrofolate reductase gene is repaired more efficiently than the bulk of the genomic 
DNA (Bohr et al. 1987) and this may be related to differences in higher order chromatin 
structure around active genes. It has also been shown that, not only is damage repaired 
more efficiently from active genes but the actively transcribed strand is repaired 
preferentially to the non-transcribed strand (Mellon et al. 1987).Such repair has been 
classified as gene-specific or transcription coupled repair.
Chemotherapeutic drugs that target DNA often act through the formation of 
bulky adducts within the DNA molecule. It would therefore seem entirely reasonable that 
the ability of a cell to repair this damage might influence its susceptibility to the cytotoxic 
action of the drug. Cisplatin forms a variety of DNA adducts (Eastman, 1986), the most 
prevalent (>90%) of which are the N7 d(GpG) and d(ApG) 1,2-intrastrand crosslink. 
Other platinum-DNA adducts include monofimctional, l,3-d(GpNpG) and longer range 
intrastrand, interstrand and protein- DNA crosslinks. The trans-isomer of cisplatin is 
inactive in cell killing and is unable to form 1,2 intrastrand crosslinks which suggests that 
it is this lesion which is the most biologically active (Zamble and Lippard, 1995). It is still 
unclear, however, which of the cisplatin adducts has the most important role in 
cytotoxicity (Zamble and Lippard, 1995).
Evidence supporting the involvement of NER in the repair of platinated bases in 
DNA, comes from observations that cells deficient in such repair ( both pro- and 
eukaryotic ) are hypersensitive to cisplatin (Beck and Brubaker, 1973). For example cells 
deficient in the NER gene XPA show greater sensitivity to cisplatin than controls, as a 
function of the platinum bound to cellular DNA. They also display reduced repair of 
exogenous platinated DNA introduced into the cell (Chu, 1994). It has been proposed 
that both 1,2 and 1,3 intrastrand crosslinks can be removed by NER (Huang et al. 1994)
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which suggests that the hypersensitivity in the XP cells may result from the inability to 
repair these lesions. The situation is confused, however, by evidence that 1,2 intrastrand 
crosslinks are not repaired, to any significant degree, using extracts from cells with 
functional NER (Szymkowski et al. 1992). This could indicate that the 1,2 crosslink is 
not the main cytotoxic lesion arising from cisplatin induced DNA damage.
Although the evidence presented above indicates that defects in NER result in 
increased sensitivity to cisplatin the connection between DNA repair and cisplatin 
resistance is by no means confirmed. Many of the initial studies were done on the mouse 
leukaemia cell line L1210 and showed that those lines selected for cisplatin resistance 
were much more effective in removing platinated DNA adducts from cellular DNA 
(Eastman and Schulte, 1988). It has recently been discovered, however, that the L 1210 
cell line has undergone a spontaneous mutation in the XPG gene at some point since its 
initial development, thus resulting in a DNA-repair defect (Vilpo et al. 1995). Therefore 
the parental line is actually hypersensitive to cisplatin and resistant lines probably have 
reverted to wild-type levels of repair. Ovarian cell lines have also been used in studies of 
cisplatin resistance and DNA repair. Several studies suggest that cisplatin resistant cell 
lines remove platinum adducts from the genomic DNA more rapidly than do sensitive 
lines (Lai et al. 1988; Parker et al. 1991).
One of the difficulties that arises with the in vitro studies correlating cisplatin 
resistance and DNA repair are the different methods used to assess the repair of cisplatin 
adducts. Assays which expose cells to cisplatin then measure the removal of platinated 
adducts from the genomic DNA may be influenced by cisplatin induced alterations in 
cellular metabolism. In addition the effects of drug uptake and metabolism may influence 
the apparent differences in repair observed between cells. The host cell reactivation ( 
HCR ) assay is one way that such problems can be overcome. In such an assay plasmid 
or viral DNA containing some form of expressed reporter gene is treated with cisplatin 
exogenously then introduced in to the cells by transfection. The reporter gene will not be 
expressed if DNA damage persists and therefore the level of expression of the reporter
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gene is a measure of the repair of the platinated DNA adducts. Conflicting results were 
obtained, as to the role of DNA repair in cisplatin resistance, when HCR assays were 
used in ovarian carcinoma cell lines (Parker et al. 1991; Moorehead et al. 1996).It has 
also been suggested that the difference between sensitive and resistant cells may not be 
related to the rate of repair of cisplatin damage in the genome as a whole. Zhen et al 
(Zhen et al. 1992) showed that the difference in repair between their resistant and 
sensitive lines occurred at the level of the gene specific repair of interstrand crosslinks.
Additional evidence has been produced from studies in lung cancer to suggest 
that differences in repair of cisplatin adducts might underlie the relative sensitivity of 
tumour cells to this drug. Non-small cell lung cancer ( NSCLC ) characteristically 
responds poorly to chemotherapy whereas small cell lung cancer ( SCLC ) tends to be 
responsive initially, although usually relapses with resistant disease. Using established 
tumour cell lines and primary cultures, set up from freshly excised tumours, HCR assays 
revealed that NSCLC lines displayed greater repair of transfected plasmid than SCLC 
lines (Nie et al. 1995). SCLC cells had greater repair than an excision repair deficient 
Chinese hamster ovary cell line which acted as control. Evidence from this, and other, 
studies have also suggested that alterations in signal transduction pathways, including 
p i 85°"erbB"2 signalling, may influence the NER of cisplatin adducts (Arteaga et al. 1994).
Excision repair mechanisms are responsible for removal of the damage induced 
by chemotherapeutic agents other than cisplatin. However, less is known about the 
biochemical differences in repair between sensitive and resistant cell lines. Bifunctional 
alkylating agents, such as Melphalan, act by forming interstrand DNA crosslinks (Fox 
and Scott, 1980). Evidence from mouse and human in vitro tumour cell lines suggests 
that resistant lines have an enhanced capacity for removal of interstrand damage 
(Friedman et al. 1994). Evidence from human rhabdomyosarcoma xenograft studies 
suggests that elevations in the amount of DNA polymerase a  and p may result in 
resistance to melphalan (Friedman et al. 1994) although further studies have failed to 
clarify their potential role in the resistant phenotype (Moynihan et al. 1996). Interestingly
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there has also been evidence presented suggesting that the levels or activity of DNA 
polymerase a, P and 5 may influence sensitivity to cisplatin (Scanlon et al. 1989).
1.4.3 Damage recognition proteins and cisplatin resistance.
It may not only be the activity of the components of the NER pathway which 
influence the ability of cells to repair bulky DNA damage. A series of proteins have been 
identified which recognise specific alterations in the tertiary DNA structure caused by 
cisplatin adducts. Several of these proteins have also been found to be over-expressed in 
cisplatin resistant cells suggesting a possible relationship (Zamble and Lippard, 1995). A 
common feature of all these proteins is the presence of a stretch of about 80 amino acids 
known as the HMG domain, due to its initial identification in high mobility group 
proteins. The HMG proteins are abundant, non-histone, components of chromatin and 
may have a major structural role in the bending or looping of DNA ( which may be 
important for transcription or recombination ) (Lilley, 1992). It would appear that the 
HMG domain can recognise and bind to certain structural alterations in DNA.
The damage recognition proteins identified to date appear to recognise the 
structural alterations in DNA induced by cisplatin adducts but not those caused by 
transplatin . In addition the binding of HMG-domain proteins to cisplatin modified DNA 
is specific for the major 1,2-intrastrand adducts (Zamble and Lippard, 1995). There is, as 
yet, no direct evidence for such proteins being responsible for altered repair of platinated 
DNA. It has been proposed that these damage recognition proteins could either recruit 
other components of the NER complex to the site of damage or, in contradistinction, 
bind to and shield the damaged DNA from the repair complex resulting in persistence of 
the damage. Some support for this second model comes from studies in the yeast, 
S.cerevisiae. A damage recognition protein, IXR-1, which contains two tandemly 
repeated HMG domains, binds to cisplatin damaged DNA. Disruption of the IXR-1 gene 
resulted in cells which grew normally but displayed increased resistance to cisplatin, an
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effect that has recently been linked to the NER pathway (McAnulty and Lippard, 1996; 
Brown et al. 1993)
A role for other forms of DNA repair, including base-excision and 
recombinational repair in removal of the damage induced by chemotherapeutic agents has 
been implied. For example, the E.coli recombination-repair deficient strain rec A13, is 
very sensitive to cisplatin (Beck and Brubaker, 1973). The incomplete characterisation of 
such repair pathways in mammalian cells limits the study of their significance or 
contribution to drug resistance. In conclusion, therefore, DNA repair has been shown to 
be an important mechanism by which cells restore the integrity of the DNA after damage 
introduced by exogenous agents. The role that these repair pathways play in the 
determination of innate or acquired resistance to DNA damaging chemotherapeutic 
agents in vivo, although hinted at, is as yet unclear.
1.5 DNA MISMATCH REPAIR AND ITS SIGNIFICANCE TO
DRUG RESISTANCE.
1.5.1 Origin of Mismatch Errors.
One further, specific, DNA excision repair mechanism has become of increasing 
interest, in the fields of oncology and drug resistance, over the past few years. During 
replication, the fidelity with which DNA polymerases synthesise the new DNA strand is 
influenced by a number of factors. Most polymerases show a 200 - 400 fold 
discrimination against inserting an incorrect nucleotide into the nascent strand, although 
certain sequence contexts may be more prone to misincorporation errors. Frameshift 
mutations can also arise, due to misalignment between the primer and template strand 
resulting in addition or deletion of bases (Kunkel, 1992). Most polymerases possess a 3’
- 5’ proof-reading action which allows the enzyme to recognise, and remove, a 
misincorporated base, in most cases without dissociating from the DNA. This, on
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average, appears to contribute about 100 fold to polymerase fidelity (Echols and 
Goodman, 1991) However, despite these features of DNA polymerases, mismatch errors 
can persist after replication. Such mismatches also arise during recombination between 
non-homologous stretches of DNA and from spontaneous or induced modifications of 
bases within double stranded DNA (Freidberg et al, 1995). It has been shown, therefore, 
that all cells possess additional enzyme pathways to correct such mismatches before they 
result in permanently fixed mutations within the genome.
1.5.2 Strand specificity of post-replication mismatch repair
To function properly, post-replication mismatch repair must discriminate the 
newly synthesised from the template DNA strand. Repair of the mismatch in the nascent 
strand results in correction of the error whilst repair of the template strand would simply 
compound the mistake by fixing the mutation. E.coli DNA is methylated on adenine 
residues within a specific GATC motif. Immediately after replication the newly 
synthesised strand is transiently undermethylated and mismatch correction is directed to 
lesions on this strand as a result of this characteristic (Radman et al. 1980) Other 
prokaryote species, such as S. pneumoniae are not methylated and the signal for strand 
discrimination is not known. This is also the situation in eukaryotes.
1.5.3 Long-patch mismatch repair in E.coli.
The mismatch repair system has been most fully characterised in prokaryotes, 
especially E.coli. The development of in vitro assays, which allowed determination of the 
mismatch repair activity in crude cell extracts, and complementation with purified 
mismatch repair proteins, facilitated this characterisation (Lahue et al. 1989). A similar in 
vitro mismatch repair assay has been developed for eukaryote mismatch repair and has 
been utilised in the work presented in this thesis ( see Chapter 4 for description ).
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Recognition of the mismatched DNA represents the first step in the repair 
process, ( figure 1.2(a)). The E.coli MutS protein has been shown to bind, in the form of 
a multimer, to DNA substrates containing mismatches (Su and Modrich, 1986). MutS 
binds to different mismatches with varying degrees of efficiency, thus G/T mismatches 
are bound strongly, whereas C/C mismatches are hardly recognised at all (Su et al.
1988). The binding of MutS to a mismatch, results in its interaction with a multimer of 
MutL protein to form a MutS/MutL complex. This is followed by further association of 
the MutS/MutL-mismatch complex with another protein, MutH. This protein, which has 
endonuclease activity, is found at hemimethylated GATC sites on the newly synthesised 
strand, which may be at a distance from the site of the mismatch. It is thought that the 
formation of the MutS/MutL/mismatch complex results in a conformational change in the 
DNA which approximates it to MutH. This activates the endonuclease function of MutH, 
resulting in the introduction of a single strand nick into the new strand (Au et al. 1992). 
It has been shown that the MutS/MutL complex will interact with the MutH/GATC site 
closest to it, irrespective of whether it is 5’ or 3’ to the mismatch. After introduction of 
the nick into the newly synthesised DNA strand, an exonuclease removes a section of 
DNA extending from the nick to up to 100 bases past the mismatch. Depending on the 
direction of repair this function may be performed by exonuclease I ( 3’-5’ activity ) or
by exonuclease VII or R ed  ( 5’-3’ activity) (Cooper et al. 1993). The process also
requires the action of a helicase and a single strand binding protein. After removal of the 
segment containing the mismatch DNA polymerase III synthesises the correct strand 
which is then ligated into place by a DNA ligase.
1.5.4 Long-Patch mismatch repair in humans.
The mismatch repair system in eukaryotes has predominantly been characterised 
by the study of S.cereviseae and other yeasts. A high degree of genetic, biochemical and 
functional similarity has been observed between prokaryote and eukaryote systems. This
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homology has also helped in the characterisation of the mismatch repair system in 
humans. The two striking differences between human mismatch repair and that seen in 
E.coli is the greater number of proteins involved in the former and the lack of GATC 
methylation as the signal for strand discrimination. It has been shown, in vitro, for both 
yeast and human mismatch repair, that introduction of a single strand nick into a 
mismatch containing construct directs repair to the nicked strand (Holmes et al. 1990). 
There has also been a suggestion that cytosine hemimethylation, in CpG islands, may 
direct mismatch correction (Hare and Taylor, 1985). However, the signal that determines 
repair strand specificity in vivo is unknown.
1.5.5 Human mismatch binding proteins.
As in prokaryotes the initial step in human mismatch repair is recognition of, and 
binding to, the mismatch ( figure 1.2(b) ). To date a number of mismatch binding 
proteins have been characterised in humans. Investigations into the genetic basis for one 
form of hereditary colon cancer, led to the discovery of a human mismatch binding 
protein which shared homology to E.coli MutS and S. cerevisiae MSH2 (Fishel et al. 
1993a). This hMSH2 gene has been shown to bind to the full range of single base/base 
mismatches, including C/C mispairs not recognised by MutS, and also to 
insertion/deletion oligonucleotide heteroduplexes (Fishel et al. 1994). Cells with 
homozygous mutations in hMSH2 display a profound inability to correct any form of 
mismatch (Boyer et al. 1995).
It has subsequently been shown that hMSH2 functions as one subunit of a 
heterodimer, the other component of which is a 160kD MutS homologue called GTBP ( 
G/T binding protein ) (Drummond et al. 1995). In vitro data has shown that the hMSH2 
and GTBP complex ( known as hMutSa) form the major mismatch recognition activity 
in HeLa cells and that both proteins are required for binding to a G/T mismatched 
heteroduplex (Palombo et al. 1995). Analysis of cells mutated in GTBP reveals that the
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mismatch binding specificity of both components of hMutSa are not identical. Mutants in 
GTBP are unable to repair all ei ght forms of base/base mismatch or single base 
insertion/deletion mismatches. They can, however, repair two, three or four nucleotide 
mismatches with up to 50% of the efficiency of wild-type cells (Drummond et al. 1995). 
The heteroduplex specificity of hMutSa has not been fully established, but the protein 
has been shown to bind with high specificity to G-T mispairs as well as 1- and 3- 
nucleotide insertion/deletion mismatches.
Two further human mismatch binding proteins, that are likely to be involved in 
mismatch repair, have been identified. The first eukaryotic MutS homologue to be 
identified, variously known as duel, dugl or MRP1 (Fujii and Shimada, 1989), was 
detected in the upstream control region of the DHFR gene. This gene, which has now 
been classified as hMSH3 due to its homology with MSH3 of S. cereviseae, has been 
sequenced. Using baculovirus synthesised human hMSH3 protein, many aspects of its 
function have also been characterised. It has been shown to bind with hMSH2 to form 
the, heterodimeric, hMutSp complex. This would appear to have specificity for binding 
to mismatches in the form of insertion/deletion loops of two or more bases (Palombo et 
al. 1996). It is proposed that hMLH3 and hMLH6 display some level of redundancy, 
with the result that mutations in either protein do not lead to total loss of mismatch 
repair. hMSH2, on the other hand, appears to be vital for efficient mismatch binding and 
repair. Double mutants of the yeast homologues for hMSH3 and hMSH6 have been 
shown to have a repair defect as severe as that found for hMSH2 mutants (Marsischky et 
al. 1996). It has been suggested that the formation of such double mutants in human 
tumours is, statistically, a highly improbable event (Palombo et al. 1996). However, an 
endometrial carcinoma cell line, HUAA, has been shown to possess mutations in both 
hMSH6 and hMSH3, and displays loss of repair of both single base^ase and 
insertion/deletion mismatches (Risinger et al. 1996). hMSH3 mutations have been 
observed in endometrial tumours (Risinger et al. 1996) and there is also a suggestion that
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they may play a role in the development of certain haematological malignancies 
(Inokuchi et al. 1995).
A further protein that has a mismatch binding specificity different from that of 
hMSH2 or GTBP, has recently been identified. O’Regan et al (O’Regan et al. 1996) 
detected a dimer of proteins of lOOkD and 140kD, different from hMutSa. This complex 
was found in cells lacking in hMSH2 and GTBP and has a binding preference for A/C 
and other pyrimidine/pyrimidine mismatches, as well as AT insertions or deletions in a 
poly(AT)n tract. The reason for multiple mismatch binding proteins in human mismatch 
repair is unclear although each protein may subserve a specific function.
1.5.6 Human MutL homologues.
Eukaryotic cells also display an increased complexity with regards to the 
component of mismatch repair homologous to MutL. To date three different MutL-like 
proteins have been identified in human cells. They have been named hMLHl, hPMSl and 
hPMS2 in view of similarities to the MutL homologues found in S.cerevisiae. To further 
complicate matters, hPMS2 appears to be only one of a family of related genes located 
on chromosome 7, the functions of which are unknown (Nicolaides et al. 1995a). 
Tumour cells with mutations in hMLHl or hPMS2, have been shown to be defective in 
repair of base/base and insertion/deletion mismatches, similar to the phenotype seen for 
hMSH2 mutants. Biochemical information is available only for hMLHl and hPMS2 as 
yet, and this is limited. An HeLa cell activity that restores mismatch repair to extracts of 
hMLHl-deficient tumour cells has been isolated and shown to be a heterodimer of 
hMLHl and hPMS2 (Li and Modrich, 1995). This has been designated hMutLa 
although the actual function of this complex, as with MutL itself, is unknown.
The other components of the mismatch repair system in humans are as yet 
uncharacterised. No human, or eukaryote, homologue of E.coli MutH protein has yet
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been detected. Studies in yeast have suggested possible candidates for the exonucleases 
involved in removing the DNA strand containing the mismatch (Kolodner, 1996). There 
is also some evidence that the DNA polymerase responsible for repair synthesis may be 
one or more of a , e or 5 in view of the sensitivity of this process to the inhibitor 
aphidicolin (Thomas et al. 1991).
1.5.7 Mismatch repair mutations and cancer.
The significance of human mismatch repair has been reinforced over the past 
three years by the finding that defects in this repair pathway underlie the development of 
a variety of different types of tumour. Hereditary non-polyposis colorectal cancer 
(HNPCC) is one of the commonest of the hereditary cancer syndromes affecting as many 
as 1 in 200 individuals (Lynch et al. 1993). In its various forms it may be associated with 
an increased risk of endometrial, ovarian, renal tract and certain types of skin cancer as 
well as colonic adenocarcinoma. During an attempt to identify the genes responsible for 
this disorder using linkage analysis an increased frequency of mutation was observed in 
simple repetitive sequences known as microsatellite repeats (Aaltonen et al. 1993). It had 
been shown in yeast that such repetitive tracts of DNA displayed an elevated mutation 
rate in the presence of an abnormal mismatch repair pathway (Strand et al. 1993). The 
gene linked to the HNPCC phenotype on the short arm of chromosome 2 was shown to 
be homologous to the yeast MSH2 gene and is now known as hMSH2. Further 
characterisation of the genetic lesions underlying other HNPCC pedigrees led to the 
identification of the hMLHl, hPMS2 and hPMSl genes. To date germ-line mutations in 
hMSH2 and hMLHl have been shown to account for approximately 50% and 30% of 
cases of HNPCC although there are regional variations (Nystrom-Lahti et al. 1995). 
Mutations in hPMS2 and hPMSl are much less commonly the inherited defect 
underlying HNPCC (Liu et al. 1996).
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Mutations in mismatch repair genes have not only been detected in tumours 
arising in HNPCC kindreds. It has been shown that between 7 and 19% of sporadic 
colorectal tumours also show mutations in either hMSH2 or hMLHl. There is also an 
ever increasing literature which shows that mutations in components of the mismatch 
repair pathway may be responsible for a small but significant number of sporadic tumours 
from a wide range of tissues (Dams et al. 1995). Most commonly this has been through 
the identification of mutations in microsatellite repeat sequences in tumour tissue not 
found in normal tissue from the same patient.
Micro satellite sequences consist of short motifs of DNA, usually 1-6 bases long, 
repeated between 10 and 50 times in either perfect tandem or interrupted by other bases 
(Weber, 1990) Due to their repetitive nature frequent mispairing errors arise during 
replication(Schlotterer and Tautz, 1992), which are substrates for mismatch repair. Cells 
with defective mismatch repair show an increased mutational frequency at microsatellite 
repeats ( micro satellite instability ) and are said to have a replication error (RER+) 
phenotype. Of particular relevance to the work presented in this study is the observation 
of an RER+ phenotype in ovarian carcinomas. About 10-15% of sporadic ovarian 
carcinomas are RER+ (Han et al. 1993; King et al. 1995) and mutations in mismatch 
repair genes have been detected with increased frequency in particular histological 
subtypes (Fujita et al. 1995).
In RER+ sporadic tumours both alleles of the mismatch repair gene have to be 
inactivated. In some cases mutations have been identified in both alleles whereas in 
others, especially with hMLHl, loss of the non-mutated allele has been observed in the 
tumour (Hemminki et al. 1994). There has also been a suggestion that certain mutations 
may display a dominant negative phenotype hence negating the function of the normal 
allele (Parsons et al. 1995). In many sporadic tumours, which display evidence of a loss 
of mismatch repair, mutations of the four known mismatch repair genes are apparently 
absent (Katabuchi et al. 1995). This suggests that mutations in the other, as yet
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undefined, components of mismatch repair may lead to malignant transformation and 
DNA polymerase 5 has been implicated in one case (Dacosta et al. 1995).
1.5.8 Defective mismatch repair and tumorigenesis..
How do mutations in genes involved in mismatch repair result in the development 
of a wide range of different tumours? As mentioned above, loss of the mismatch repair 
pathway results in microsatellite instability throughout the genome. Bacteria and yeast 
with mismatch repair defects display a global increase in mutation rate, including non- 
repetitive sequences of DNA. Human tumour cell lines which display microsatellite 
instability have also been shown to have an increased rate of mutation at the HPRT gene 
(Bhattacharyya et al. 1994). One possibility is, therefore, that this increased global 
mutation rate results in a more rapid accumulation of mutations in oncogenes and 
tumour suppressor genes, resulting in tumour development. Such a “ mutator 
phenotype” model for tumour development was proposed prior to the discoveries of 
defective tumour mismatch repair (Loeb, 1994).
Although an increase in the global mutation rate may affect any gene, it is 
intuitive that genes that possess microsatellite sequences, or other regions of repetitive 
DNA, have a greater risk of mutation. The gene for the androgen receptor has a 
trinucleotide CAG repeat within the first exon, and alteration in the length of this repeat 
has been reported in one case of prostatic cancer (Schoenberg et al. 1994). Perhaps of 
more relevance is that mutations in short stretches of repeated nucleotides have been 
found in the type II TGFp receptor (TGFP RH) (Markowitz et al. 1995). These 
frameshift mutations result in loss of TGFp RII mRNA expression, and have been found 
in about 80% of RER+ colon tumours. TGFp mediates growth inhibition in normal 
colonic epithelium, therefore the loss of the RII receptor would give a growth advantage 
to such cells.
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Finally, it has been shown that repeats, consisting of 10-30 copies of the GT 
dinucleotide, are found in the non-translated regions and introns of a number of genes. 
These GT repeats have been shown to display weak transcriptional enhancer activity, 
which might be related to their ability to form the Z-DNA conformation (Hamada et al. 
1984). It is possible that mutations arising in these GT repeat elements, as a result of 
defective mismatch repair, might alter the transcription of certain genes leading to 
tumour development.
1.5.9 Mismatch repair and Methylation tolerance.
The significance of DNA mismatch repair to drug resistance, and the impetus 
behind the studies presented in the following chapters, is the association between defects 
in this repair pathway and tolerance to specific DNA methylating agents. The concept of 
“tolerance” is one in which the damaged base is not removed from the DNA, but appears 
not to induce the cytotoxic effects that would normally arise from such a lesion (Karran 
and Bignami, 1994). As stated in section 1.4.1, agents which methylate DNA, such as 
MNNG and MNU, are mutagenic and cytotoxic due to the formation of O6- 
methylguanine. Under normal circumstances this lesion is directly repaired by the enzyme 
MGMT. Functional loss of this enzyme, most commonly by epigenetic silencing, results 
in cellular hypersensitivity to killing and mutagenesis by such agents (Karran and 
Bignami, 1992).
It was through studies in bacteria, that the mismatch repair system was first 
implicated in the cytotoxicity of 0 6-methylguanine lesions induced by methylating agents 
(Karran and Marinus, 1982). Mutation in the dam methylase responsible for methylation 
of d(GATC) sequences, in the newly replicated DNA strand, results in hypersensitivity to 
the cytotoxic actions of MNNG in E.coli. Additional mutations, in either MutS or MutL, 
result in double mutants which are no more sensitive to the killing action of MNNG than 
wild-type E.coli. This implicated Ihese genes in the enhanced killing observed in
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methylase deficient cells. Double mutant cells remain sensitive to the mutagenic effects of 
the alkylating agent which suggested the persistence of 0 6-methylguanine lesions in the 
DNA despite loss of cytotoxicity. These observations led to the suggestion that 0 6meG 
lesions in the helix can provoke a mismatch response (Karran and Marinus, 1982).
The concept of methylation tolerance in mammalian cells was first proposed by 
Goldmacher et al (Goldmacher et al. 1986). Exposure of the human lymphoblastoid cell 
line TK6, to a single high dose of MNNG, led to the isolation of the MT1 line. MT1 cells 
are a hundred times more resistant to the toxic effects of MNNG than TK6, but are 
slightly more sensitive to mutagenesis by this drug. It was shown that both cell lines have 
similar kinetics of MNNG adduct formation and removal, suggesting that MT1 cells 
tolerate adducts that are otherwise cytotoxic. The MT1 cell line was also shown to have 
an increased spontaneous mutation rate at the HPRT gene, thus indicating the likely 
presence of a mutator phenotype.
Subsequently, two further methyltransferase deficient, alkylation tolerant cell 
lines, one from CHO cells and one a Burkitt’s lymphoma line were isolated (Branch et al. 
1993). As well as showing increased resistance to MNU, both cell lines displayed an 
increased spontaneous mutation rate at HPRT and APRT loci and were subsequently 
shown to display microsatellite instability (Aquilina et al. 1994) They also both displayed 
loss of a specific GT mismatch binding function (Branch et al. 1993) resulting in loss of 
binding to 06m eGT and 6TG-T mismatches (Griffin et al. 1994). It has since been 
shown that MT1 cells are deficient in strand specific mismatch repair (Kat et al. 1993) 
with reduced M utSa activity (Drummond et al. 1995) due to mutation in both alleles of 
GTBP (Papadopoulos et al. 1995).
Tolerance to methylation damage has been further studied in colorectal 
adenocarcinoma cell lines (Branch et al. 1995). Several lines were shown to display 
defective G/T mismatch binding and were resistant to MNU. However these lines 
possessed abundant functional MGMT which, even after treatment with the inhibitor O6-
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benzylguanine, retained sufficient activity to efficiently remove the methylation damage. 
Thus the methylation tolerance of these lines could not be ascertained. Two lines, 
however, were shown to be lacking MGMT activity, yet one was sensitive to the effects 
of MNU and the other was resistant. The resistant line, SW48, was subsequently shown 
to be truly methylation tolerant and to display a mutator phenotype, both in a selectable 
gene and in microsatellite sequences(Branch et al. 1995). This cell line is proficient in G- 
T mismatch binding but has been shown to have lack of expression of hMLHl mRNA 
(Liu et al. 1995) suggesting deficient MutLa activity.
The HCT116 colorectal adenocarcinoma cell line has also been shown to be 
deficient in hMLHl and to be resistant to methylating agents(Koi et al. 1994). 
Introduction of chromosome 3 into these cells, via microcell fusion, resulted in 
restoration of mismatch repair function and increased sensitivity to MNNG. This was 
taken as proof that HCT116 cells were methylation tolerant. However, HCT116 cells 
possess functional MGMT and it has been shown that chromosome 3 may harbour other 
genes that interfere with MGMT action (Zunino et al. 1991). Therefore the introduction 
of an increased dose of these chromosome 3 genes may reduce the MGMT activity 
resulting in the increased sensitivity to MNNG. The methylation tolerance status of 
HCT116 therefore is not yet clear.
Although the association between defective mismatch repair and tolerance to 
certain methylating agents is clear, the mechanism underlying this phenomenon remains 
undefined. The tolerance phenotype is only observed with agents that introduce 0 6MeG 
or 6-thioguanine ( 6TG ) into the DNA. This suggests that structurally similar 
modifications at the 6-position of guanine are an important determinant in tolerance 
(Karran and Bignami, 1994). It has been proposed that these methylated bases are not a 
block to replication, but instead the DNA polymerase inserts the best fitting base into the 
nascent strand opposite the modified guanine. It has been shown that 0 6MeG T 
introduces the least structural distortion to the DNA (Gaffney and Jones, 1989). In the 
absence of efficient methyltransferase function, the mismatched base pair is recognised by
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the mismatch repair pathway as abnormal. Repair synthesis , which occurs in the strand 
opposite 0 6MeG, is doomed to failure owing to the inability to find a good 
complementary match for the methylated base. It is proposed that repeated, futile, 
attempts to repair this mismatch eventually results in cell death, perhaps by the 
generation of strand breaks (Karran and Bignami, 1992). Tolerance would therefore arise 
when the mismatch repair system could no longer initiate these aborted attempts at 
repair.
There are several clinically active anticancer drugs, such as procarbazine and the 
methyltriazines, that act via introduction of 0 6MeG into DNA (Hayward and Parsons, 
1984). The clinical effectiveness of these drugs is compromised by the rapid appearance 
of tumour resistance. Our interest in the potential involvement of mismatch repair, in 
determining sensitivity or resistance to other classes of clinical anticancer agent, was 
fuelled by a number of observations. It has been shown that the mismatch repair system 
in bacteria can recognise lesions in DNA, other than those caused by methylating agents. 
A study by Feng et al (Feng et al. 1991) has shown that components of E.coli mismatch 
repair can recognise UV photoproducts in DNA. In addition dam mutant E.coli are 
sensitive to UV radiation, whereas dam, mutS double mutants are as resistant as wild 
type cells (McGraw and Marinus, 1980) This suggests that the mismatch repair system 
may have a function in the cellular response to UV damage in E.coli. The mismatch 
repair system may be also be involved in determining the cytotoxicity of cisplatin, since 
mutations in mutL reverse the cisplatin hypersensitivity of dam mutant E.coli (Fram et al. 
1985a). Although there is no evidence to involve mismatch repair in human cisplatin 
sensitivity, studies in murine leukaemia and human ovarian carcinoma cell lines, have 
indicated that the ability of the replication apparatus to bypass cisplatin adducts on DNA 
is a component of cisplatin resistance (Mamenta et al. 1994). Conceptually this 
replicative bypass could be analogous to damage tolerance, although the mechanism is as 
yet undetermined. In view of the evidence that mismatch repair might be involved in the
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recognition of a range of different DNA lesions, it has been suggested that it may act as a 
general sensor of DNA damage (Kat et al. 1993).
1.6 THE INFLUENCE OF POST-DNA DAMAGE RESPONSES ON
RESISTANCE TO ANTICANCER DRUGS.
The importance of DNA repair, in the response of cells to DNA damaging 
cytotoxic agents, has already been stated. Until recently, the general consensus held that 
the tumour specific action of most anticancer agents was attributable to their genotoxic 
effects on actively proliferating cells. However, an increasing body of evidence suggests 
that cells possess a complex post-DNA damage response mechanism which determines 
the eventual fate of the cell.
When a cell suffers DNA damage, the defects must be detected, and signals sent 
to cellular control mechanisms in order to prevent the damage from being genetically 
fixed or propagated. One option is for the cell to pause in its replication cycle long 
enough for the damage to be repaired. Alternatively, the cell may respond to even low 
levels of damage by initiating an apoptotic response. Apoptosis has been described as 
“physiological” cell death, since it is a genetically determined cellular process, essential 
for normal development and maintenance of tissue homeostasis (Raff, 1992) Many toxic 
stimuli have been shown to induce apoptosis, even at doses or concentrations insufficient 
to cause general metabolic dysfunction (Dive and Hickman, 1991) These results suggest 
that divergent types of cellular damage may lead to the generation of a common signal, 
or signals, that initiates the cell death programme. Accordingly, the ability of tumour 
cells to detect this damage, and activate the apoptotic response, may determine their 
ultimate sensitivity to cancer therapy. Evidence is accumulating from in vitro studies to 
support this concept (Lowe et al. 1993).
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The components that constitute this post-DNA damage response pathway are 
gradually being identified. Central amongst them is the product of the tumour suppressor 
gene p53, which appears to act at a vital decision point in the pathway. Mutations in the 
p53 gene are found in about 50% of all human tumours, suggesting that its normal 
physiological function extends to the control of cell growth, as well as the response to 
DNA damage (Hollstein et al. 1991).
There are two major points in the cell cycle at which cells can temporarily arrest, 
in response to a variety of deleterious stimuli. The Gl/S-phase arrest ensures that the cell 
repairs DNA damage prior to replication, whereas the G2 arrest allows repair before 
chromosomal segregation. P53 is central to the control of the Gl/S checkpoint. 
Following DNA damage in normal cells there is a transient induction of the levels of p53 
protein, occurring by a post-translational mechanism, which is temporally correlated with 
the G1 arrest (Kastan et al. 1991) The p53 gene has been shown to be regulate the 
transcription of a number of genes by binding to a specific consensus sequence (Farmer 
et al. 1992). One of these, p21 Wafl/Cipl, can bind to, and inactivate, cyclin dependent 
kinases, thus forming a link between the actions of p53 and arrest of the cell cycle 
(Harper et al. 1993). The p53 dependent induction of p21 Wafl/Cipl also results in 
inhibition of proliferating cell nuclear antigen (PCNA), an essential DNA replication 
protein, which allows it to arrest DNA replication while permitting active DNA repair (Li 
et al. 1994).
Not only can p53 bring about a G1 arrest in response to DNA damage, but it is 
also involved in the determination of an apoptotic response to damage in particular types 
of cell. In certain cells, ionizing radiation initiates death through apoptosis, and this 
response has been shown to depend on the presence of wild-type p53 (Clarke et al. 
1993). In addition, p53 mediates the effects of some chemotherapeutic agents in 
initiating apoptotic death (Lowe et al. 1993).That p53 plays this central role in 
determining the response of a cell to DNA damage, has been further reinforced by the 
study of cells lacking, or possessing mutant, p53. Thus, it has been shown that in a series
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of 8 different tumour cell lines, the sensitivity to ionising radiation correlated closely with 
the constitutive levels of p53, the level of p53 induction after radiation and the presence 
of a G1 arrest (Siles et al. 1996).
Lowe et al, have shown in mouse embryonic fibroblasts that p53 is required for 
an efficient apoptotic response to ionising radiation and drugs such as etoposide and 
doxorubicin (Lowe et al. 1993). They have confirmed the requirement for functional p53 
in apoptosis, arising from radiation and doxorubicin induced damage, in transformed 
embryonic fibroblast xenografts transplanted into nude mice (Lowe et al. 1994). Those 
xenografts which were resistant to these damaging agents harboured mutations in the 
p53 gene and displayed less apoptosis. The authors suggested that these results could 
explain the association, observed clinically, between p53 mutation and poor patient 
prognosis seen in certain tumours. Transfection of a dominant negative mutant p53, into 
a wild-type p53, radiation sensitive, ovarian cancer cell line ( A2780 ) led to loss of the 
G1 arrest and increased resistance to ionising radiation (Mcllwrath et al. 1994). This, 
along with a correlation between G1 arrest and radiation sensitivity across a range of 
tumour cell lines, further suggests that p53 and its role in mediating a G1 arrest are 
important in sensitivity to radiation.
Unfortunately nature is never straightforward and an increasing number of 
reports show that the response to DNA damage need not depend on p53 at all, or is 
influenced by factors which act after p53 in the pathway. Using isogenic colorectal 
carcinoma cell lines, that differed only in their p53 status, Slichenmyer et al (Slichenmyer 
et al. 1993) showed that loss of the G1 checkpoint was not associated with altered 
sensitivity to ionising radiation, or the topol inhibitor camptothecin. In these cells it 
appeared that the G2 checkpoint was more important in determining radiosensitivity. It 
has been suggested that arrest in G2 is in fact a prerequisite for cell death, and that 
essential events occur during G2 which are required for death to occur by apoptosis 
(Eastman, 1990). Additional studies have shown that in certain cell types, sensitivity or 
resistance to different DNA damaging agents cannot be directly correlated with the
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functional state of p53. Wu and El-Deiry have shown that the sensitivity of a variety of 
haemopoietic and solid tumour cell lines to various anti-cancer drugs was not dependent 
on the p53 status (Wu and Eldeiry, 1996).
How can these conflicting results, concerning the importance of p53 functions in 
determining the sensitivity of cells to DNA damage, be reconciled? It is proposed that, 
although p53 does play an important role in determining whether a cell enters a cell-cycle 
arrest or the apoptotic pathway after DNA damage, the final outcome of such a decision 
depends upon the genetic context in which it is made. Factors which influence the 
apoptotic pathway downstream of p53, such as members of the bcl2 and bax gene 
families, may determine the ability of a cell to undergo apoptosis irrespective of the p53 
status. In certain cells, or in response to certain apoptotic stimuli, it has been shown that 
a p53 independent apoptotic response can occur which is also influenced by bcl2 
(Strasser et al. 1994). It has also been shown that in cells in which G1 arrest and 
apoptosis depend upon normal p53 function, the response to ionising radiation depends 
upon the presence of exogenous growth factors (Canman et al. 1995). It may be the 
balance between death and growth factors, within a particular cellular environment, 
which determines the sensitivity to damage.
As already indicated, numerous studies have investigated the importance of p53 
status, cell cycle checkpoints and apoptosis in the response to various forms of DNA 
damage. It is hoped that the further characterisation of these damage response 
mechanisms will identify the particular determinants which influence sensitivity or 
resistance. It can already be seen, however, that post-DNA damage responses are likely 
to play an important role in determining clinical responses to treatment. Tumours derived 
from cells which undergo apoptosis rapidly after DNA damage, in a p53 dependent 
manner, might be expected to be more responsive to therapy. Most of the tumours that 
do respond well to radiation and systemic chemotherapy ( childhood ALL, lymphomas, 
germ cell tumours, etc.) are derived from cells in which the DNA damage induced p53 
response is most likely apoptotic (Kastan et al. 1995a). Tumours in which the p53
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mediated response to damage is one in which G1 arrest predominates, might be likely to 
survive following exposure to DNA damaging agents. Accordingly, it has been proposed 
that many of the inherently resistant solid tumours, derive from cell types which do not 
readily undergo p53 dependent apoptosis after DNA damage (Kastan et al. 1995a).
Finally, one component of the post-DNA damage pathway which is of increasing 
interest are the signals produced by DNA damage which activate the damage response 
pathways. It has been shown that double-strand DNA breaks are sufficient to initiate 
induction of p53 in tumour cells (Nelson and Kastan, 1994). However, patients with the 
inherited cancer prone condition ataxia-telangiectasia (AT), have a defect in the 
induction of p53 in response to ionising radiation (Canman et al. 1994). This suggests a 
defect in the signal transduction pathway from DNA damage to p53. Recently the 
genetic defect underlying AT has been shown to reside in a gene commonly involved in 
signal transduction (Lehmann and Carr, 1994).
The suggestion that the mismatch repair system might act as a general sensor of 
DNA damage (Kat et al. 1993) would place it within the pre-p53 signal transduction 
path. In determining whether alterations in mismatch repair might be involved in the 
signalling of DNA damage to the effectors of apoptosis, or cycle arrest, a system in 
which the cellular responses to damage are well characterised is essential. Our group 
have previously characterised the p53, cell-cycle and apoptotic responses of the ovarian 
carcinoma cell line A2780, to ionising radiation and a variety of chemotherapeutic agents 
(Mcllwrath et al. 1994; Brown et al. 1993). The post-DNA damage responses of a series 
of cisplatin resistant, RER+, derivatives of this cell line have been characterised in the 
work set out in this thesis.
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1.7 THESIS AIMS.
DNA is the principle target for the majority of successful anticancer drugs. 
Evidence from the literature has been presented, to support the concept that cellular 
processes that occur after DNA damage by anticancer drugs, may have more clinical 
significance than those which influence the initial levels of damage. The involvement of 
different mechanisms of DNA repair in cytotoxic drug resistance has been discussed. 
Specific reference has also been made to the evidence that mutations in DNA mismatch 
repair, in human tumour cell lines, can result in the development of resistance to certain 
DNA alkylating agents. The possibility that mismatch repair may also be involved in 
determining the sensitivity of cells to other cytotoxic lesions introduced into DNA has 
been raised. A brief review of the interaction between DNA damage, DNA damage 
repair and post-DNA damage response mechanisms has also been presented.
The aim of this thesis is to determine whether resistance to clinically important anticancer 
drugs, such as cisplatin and doxorubcin, could be determined by defects in the mismatch 
repair pathway in human tumour cells. Characterisation of the mismatch repair system is 
performed on a series of tumour cell lines selected for resistance to cisplatin and 
doxorubicin. To further investigate whether mismatch repair is involved in the 
development of cisplatin resistance, and possible interactions with determinants of post- 
DNA damage response, a series of cisplatin resistant ovarian carcinoma cell lines are 
developed.
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CHAPTER 2
MATERIALS AND METHODS
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2.1 MATERIALS
The following section lists routinely used materials . Those used less frequently are 
described in the appropriate methods section.
2.1.1 Chemicals
All chemicals were of the highest available quality and were obtained from Gibco BRL, 
BDH Chemicals, Pharmacia LKB, Severn Biotech, Rathbum or Sigma Chemicals.
2.1.2 Radiochemicals
(a32P)DTP, used for labelling DNA probes and (a35S)dATP for labelling M l3 
sequencing ladder were obtained from Amersham International.
2.1.3 Equipment
Routine equipment which would be an integral part of any laboratory is not listed. 
Automated DNA sequencer Applied Biosystems,
Autoradiography film Kodak, Cambridge. UK
Fuji, Tokyo. Japan.
Cell Counter Coulter Electronics. Luton, Beds. UK.
Confocal Microscope Biorad. Hemel Hempstead. UK.
Densitometric Analysis
Laser Densitometer PDI, New York. USA.
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Quantitation Software PDI, New York. USA.
Electrophoresis Tank
Electroblotting System
FACS Machine and Software
Film Processor
Gel Drier
Hybridisation Membranes
Hybond-N
Immobilon-P
Hybridisation Oven and Bottles
Liquid scintillation analyzer
IBI Ltd., UK.
Flowgen. Lichfield. UK.
Life Technologies. Paisley. UK.
Millipore, Watford, UK.
Biorad. Hemel Hempsted. UK.
Becton Dickenson, San Jose, CA
Kodak, Cambridge, UK.
Biorad. Hemel Hempstead. UK.
Amersham International, Amersham UK. 
Millipore, Bedford, UK.
Hybaid Ltd., Middlesex, UK.
Canberra Packard, Pangbome, Berks. 
UK.
Microplate reader Molecular Devices. Alpha Labs,
Eastleigh. UK.
PCR Thermal cycler Hybaid, Teddington. UK.
Perkin Elmer Cetus, Conn. USA.
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LEP Scientific, Milton Keynes. UK.
UV Crosslinker Stratagene, Cambridge. UK.
UV Transilluminator/imager Appligene, Chester-le-Street. UK.
2.1.4 Restriction endonucleases and other enzymes 
Restriction endonucleases Gibco BRL
Taq polymerase Boehringer Mannheim
RNAse A Pharmacia LKB
Proteinase K Boehringer Mannheim
2.1.5 Size markers
DNA Size Markers 
Phage X (Hindlll)
123bp DNA ladder
RNA Size Markers
0.24-9.5Kbp RNA ladder Gibco BRL
Protein Size Markers
14.3-200.0KDa prestained Gibco BRL
6.9-202 KDa prestained Biorad
Gibco BRL 
Gibco BRL
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2.1.6 Buffers, solutions and media
Where mentioned, autoclaving was carried out at 121 °C for 20 minutes.
Blocking Solution
5% Marvel® non-fat milk powder
50mM Tris HC1 pH 7.5
50mM NaCl
ImMEDTA
0.01% Tween-20
ImMDTT
Buffer A
25mM Hepes/KOH, pH8 
ImMEDTA 
ImM benzamidine 
2mM 2-mercaptoethanol 
0.5mM PMSF 
0.5mM spermidine 
O.lmM spermine
0.1% DEPC Treated Water
999ml double distilled H2 O 
lml DEPC
Leave at 37°C for 24h 
Autoclaved solution
Denaturing Solution
1.5M NaCl
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0.5N NaOH
DNA Loading Dye Mixture
30% v/v Glycerol
0.25% w/v Bromophenol blue
0.25% w/v Xylene cyanol
Formaldehyde Gel Loading Buffer (for Northern blotting)
50% glycerol 
ImM EDTA (pH 8)
0.25% bromophenol blue 
0.25% xylene cyanol FF
Genescreen
0.5M Na2H P04 
0.5M NaH2P 0 4
Glycine Buffer
O.lMNaCl
0.1M Glycine
pH to 10.5 with NaOH
High Salt Lysis Buffer
500mM NaCl 
1% NP-40 
50mM Tris pH 7.5 
Protease Inhibitors (lx)
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Hybridisation Buffer
50mM PIPES 
50mM NaH2P 0 4 
50mM Na2HP04 
lOOmM NaCl 
ljiMEDTA 
5% SDS
( lOOpg/ml sonicated salmon sperm DNA. Southern blot only ) 
Made with DEPC treated water
lOx MOPS RNA Running Buffer
0.2M 4-(N-Morpholino)propane-sulphonic acid
0.05M Na acetate pH7.0
0.01MNa2EDTA
Made with DEPC treated water
pH to 7 with glacial acetic acid
Autoclaved solution
Neutralization solution
1M Tris (pH 7.4)
1.5M NaCl
NP-40 Lysis buffer
150mM NaCl 
1.0% NP-40 
50mM Tris ( pH8.0 )
PBT
PBS
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0.1% Tween-20 
1.0% BSA fraction V
PBST
PBS
0.1% Tween-20
Phosphate Buffered Saline (PBS)
0.8% NaCl 
0.115% Na2HP04 
0.02% KC1 
0.02% KH2P 0 4
Protease inhibitors (lOOx)
0.1 mg/ml Aprotinin 
0.1 mg/ml Pepstatin 
O.lmg/ml Chymostatin 
0.05M Benzamidine 
0.05M PMSF 
0.1 mg/ml Leupeptin 
Stored at -70°C
RNA Loading Dye
95% Formamide 
20mM EDTA 
0.05% Bromophenol blue 
0.05% Xylene cyanol FF 
0.1 Volume of 50% glycerol
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RPMI medium.
88 ml RPMI 1640 ( lOx)
800ml sterile distilled water
26.6ml 7.5% Na(C03)2
10ml lOOmM Na pyruvate
10ml 200mM L-glutamine
3.5ml 1M NaOH
100ml Foetal calf serum
5ml Penicillin/Streptomycin ( 50mg)
Resolving gel (6% )
21.5ml Water
10ml 30% Acrylamide, 0.8% bis-acrylamide
12.5 ml 1.5M Tris ( pH 8.8 )
0.5ml 10% SDS
0.5ml 10% Ammonium persulphate ( freshly made) 
5ml 1% polyacrylamide 
40pl TEMED
Stacking gel ( 5% )
6.8ml Water
1.7ml 30% Acrylamide, 0.8% bis-acrylamide 
1.25ml 1.0M Tris ( pH 6.8 )
0.1ml 10% SDS
0.1 ml 10% ammonium persulphate 
lOjul TEMED
SSC (20x)
3M NaCl
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0.3M Tri-sodium citrate
20x SSPE
3.6M NaCl
0.2M NaH2P 0 4
0.02M EDTA pH7.7
made up with DEPC treated water
Tank buffer ( 5x )
0.25 Tris base 
0.5M Glycine 
0.5% SDS
TAE(lx) pH8
242g Tris borate
57.1ml glacial acetic acid
100ml 0.5M EDTA (pH 8)
Make to 1L with H20
TBE(lxl pH8
89mM Tris borate 
89mM Boric acid 
2.5mM EDTA
TBST
lOOmM Tris pH8 
150mM NaCl 
0.05% Tween 20
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TE pH8
lOmM Tris 
ImMEDTA
Transfer buffer
48mM Tris base 
39mM Glycine 
0.038% SDS 
20% Methanol
Trypsin
360ml Sterile distilled water 
40ml lOxPE
40ml Trypsin ( 2.5% stock)
Western loading dye
2.5ml Tris 
lg SDS
200pl 0.5MEDTA 
5 ml Glycerol 
2.5% Bromophenol blue 
2.5ml ddH20
2.1.7 Cell lines
A2780
Human ovarian adenocarcinoma cell line derived from omental metastasis from an 
untreated patient (Eva et al. 1982). Received from R.F. Ozols and T.C. Hamilton, Fox 
Chase Cancer Centre, Philadelphia.
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A2780/cp70
Cisplatin resistant derivative of A2780 selected for resistance by exposure to increasing 
concentrations of cisplatin to maximum of 70pM (Behrens et al. 1987)
A2780/AD
Doxorubicin resistant derivative of A2780, isolated by repeated exposures to 
doxorubicin (Rogan et al. 1984). Expresses high levels of p-glycoprotein (Sugawara et 
al. 1988)
MCF7
Human breast adenocarcinoma cell line established from the pleural effusion of a 69 year 
old female (Soule et al. 1973).
MCF7/AD
Doxorubicin resistant derivative of MCF7 isolated by selection against increasing 
concentrations of drug (Sinah et al. 1986)
OVl/p
Ovarian carcinoma cell line ( originally named IGROV1 ) (Benard et al. 1985). Received 
from Dr. J. Benard. Institut Gustave Roussy, Villejuif, France.
OV1/DDP
Cisplatin resistant derivative of OVl/p selected for resistance by (Teyssier et al. 1989)
2.1.8 Antibodies and immunological agents
The following is a list of the primary antibodies used for Western immunobloting and 
immunocytochemistry.
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Antigen Antibody Isotype Company
p53 DO-1 Mouse IgG2a Oncogene Science
hMLHl G168-15 Mouse IgGi Pharmingen
hPMS2 Ab-1( Clone 9 ) Mouse IgGi Calbiochem
hMSH2 Polyclonal Rabbit Dr.J.Jiricny
GTBP Polyclonal Rabbit Dr.J.Jiricny
Vinculin Vin-11-1 Mouse IgGi Sigma
BrdUrd Bu20a Mouse IgGi Dako
Anti-mouse IgG horseradish peroxidase-linked (HRPL) rabbit antibody (Amersham) and 
anti-rabbit IgG (HRPL) donkey antibody (Amersham) were used as secondary detection 
agents in Western immunoblot studies. Anti-mouse IgG fluorescein 5-isothiocyanate- 
conjugated (FITC) goat antibody (Sigma) was used in immunohistochemistry and cell 
cycle analyses.
2.1.9 Plasmids and molecular probes
The following plasmids were used in the formation of probes for Northern blotting. The 
pBSK-MSH2 plasmid was provided by Prof. B. Vogelstein, Johns Hopkins University, 
Baltimore, Maryland, USA. The probes were derived from DNA fragments obtained 
using the restriction enzymes indicated.
Plasmid cDNA Probe fragment Reference
pCRII-GAPDH Human GAPDH EcoRI (720bp) (Tso et al. 1985)
pBSK-MSH2 Human hMSH2 Clal/Xbal ( 3.1 kb ) unpublished
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2.1.10 PCR primers
The primers used for PCR of microsatellite repeat sequences, along with the type of 
repeat, chromosomal location and locus heterozygosity (PIC) are shown in Table 2.1 and 
2.2. The majority of these primer pairs were obtained from Research Genetics, Huntsville, 
AL. USA. The others, where indicated, were a gift from Dr.D.Black (BICR, Glasgow).
Primers for PCR synthesis of oligonucleotide probes for Northern and Southern blotting 
are shown below. The sequences for these were determined using the PRIME function of 
the GCG software package and were synthesised either by Oswel DNA Service 
(Southampton, UK.) or in-house using an Applied Biosystems DNA synthesiser.
hM LHl
F 5’- ACG TTT CCT TGG CTC TTC -3’
R 5’- CCT CAC ATC CAA TTT CTA TC -3’
Product length - 730bp
hPMS2
F 5’- TCGAGT ACA GAA CCT GCT AAG -3’
R 5’- GTG AAA TGA AAC CTG AGA GT -3’
Product length - 804bp
PCR primers for use in RT-PCR analysis were derived using the GCG PRIME 
programme and were synthesised on an Applied Biosystems DNA synthesiser. Primer 
sequences are given below.
HMSH2
55 5’- CAC CTG TTC CAT ATG TAC -3’
56 5’- AAA ATG GGT TGC AAA CAT GC -3’
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Product length - 508bp
hMLHl
F 5’- ACG TTT CCT TGG CTC TTC -3’
R 5’- GGG CTT TCA GTT TTC CAT C -3’
Product length - 440bp
hPMS2
F 5’- TCG AGT ACA GAA CCT GCT AAG -3’
R 5’- GTG AAA TGA AAC CTG AGA GT -3’
Product length - 804bp
2.2 EXTRACTION OF NUCLEIC ACIDS AND PROTEINS
All work with RNA and DNA was carried out using autoclaved solutions and where 
appropriate DEPC treated solutions and equipment. Disposable gloves and plasticware 
were used throughout. DNA and RNA quantitation was performed using a combination 
of visual assessment on a 1% agarose, lx TBE, 0.25pg/ml ethidium bromide gel when 
run against known standards and spectrophotometrically using OD260nm- Extraction 
protocols, when using commercially available kits, were followed as per the 
manufacturers instructions unless indicated otherwise.
2.2.1 RNA Extraction
Total RNA was extracted from monolayer cultures using TRIzol reagent (Gibco) 
following manufacturers protocol.
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2.2.2 DNA Extraction
Genomic DNA was extracted from monolayer cultures using the Nucleon I DNA 
extraction kit ( Scotlab ) following manufacturers protocol. For extraction of plasmid 
DNA from large scale ( 50 100ml ) bacterial culture the Quiagen plasmid Maxi-kit was 
used.
2.2.3 Protein preparation
Cells, grown in monolayer culture, were washed with PBS then lysed for 5 minutes using 
high salt lysis buffer supplemented with lx protease inhibitors. Cell supernatant 
containing extracted proteins was collected by centrifugation of lysate in cooled 
Eppendorf tubes at 4°C ( 15000rpm/ 15min). Supernatant stored at -70°C.
For total cell, or direct cell, lysis 10 volumes of sample buffer were added to the 
harvested cells and the suspension mixed vigorously. The sample was then boiled for 5 
min. Chromosomal DNA was sheared by, firstly, passing the sample repeatedly through a 
20-guage hypodermic needle and then through a 26-gauge needle. The sample was then 
spun at 10,000g for 10 min. The supernatant was collected.
Estimation of protein concentration performed using Bio-Rad Protein assay with standard 
curve constructed using Bovine serum albumin.
2.3 PREPARATION OF 32P RADIOLABELLED PROBES
2.3.1 Purification of DNA for probe synthesis
DNA synthesised from PCR amplification was purified from excess primers and 
unincorporated nucleotides using the Wizard PCR clean kit ( Promega ). DNA excised 
from plasmid vector using appropriate restriction endonucleases was purified from vector 
DNA by electrophoresis on a 0.8% low melting point agarose, lx TBE, 0.25p,g/ml
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ethidium bromide, gel. DNA was visualised by transillumination with UV light and an 
agarose plug containing the desired DNA fragment was excised from gel using a sterile 
scalpel blade. Agarose plug dissolved by heating to 65°C for 5 minutes in 5 volumes 
20mM Tris.Cl ( pH 8.0 ) and ImM EDTA. Solution cooled to room temperature and 
equal volume of phenol added. Aqueous phase recovered by centrifugation and re­
extracted with phenol/chloroform and then chloroform. DNA recovered by ethanol 
precipitation and dissolved in water.
2.3.2 Random priming of double stranded DNA
(a32P) dCTP labelled dsDNA probes (50 - lOOng) were produced using the Prime-it kit ( 
Stratagene ) following manufacturers protocol.
2.3.3 Nick column purification
32Radiolabelled probes were separated from unincorporated P-labelled nucleotides using 
disposable Nick columns (Pharmacia). Briefly, Nick column washed with 800pl water, 
then products of random priming reaction loaded onto column. 400pl water added to 
column and eluate collected. 400pl elution repeated.
2.3.4 Determination of specific activity of probe.
The specific activity of radiolabelled probes was determined by taking a 5 pi sample of the 
second 400pl eluate from the nick column purification and measuring the number of 
disintegrations per minute ( dpm ) using a liquid scintillation counter. A specific activity 
of > 10 dpm was required for the probe to be used in hybridisation.
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2.3.5 Denaturation of probes
Probes were denatured before hybridisation by adding 0.1 volume of 3M NaOH and 
leaving for 5 minutes at room temperature. 0.05 volumes of 1M tris HC1 (pH 7.5) were 
then added and left to incubate for 5 minutes on ice followed by the addition of 0.1 
volume of 3M HC1 and a further 5 minute incubation at 0°C.
2.4 SEPARATION AND HYBRIDISATION OF RNA
2.4.1 Separation and Northern transfer of RNA
Methodology for separation and transfer of RNA emulated instructions detailed by 
Sambrook et al, (Sambrook et al. 1989). 1.2% (w/v) agarose gels were prepared by 
dissolving 2.4g of agarose in 150ml of water then cooling to 60°C. 20pl of 0.5mg/ml 
ethidium bromide, 19.5ml of lOx MOPS RNA running buffer and 36ml of formaldehyde 
were added and the gel poured immediately. To 20pg of total RNA in 12pl, 25pi 
formamide, 8pi formaldehyde and 5pl lOx MOPS RNA running buffer were added. The 
samples were heated to 65°C for 15 minutes and chilled on ice before addition of 5pi 
RNA gel loading buffer. After electrophoresis for 4h at 56V, the gels were imaged using 
UV transillumination and photographed. Gel subsequently soaked in 50mM NaOH for 
20min, rinsed in D.E.P.C. treated water and soaked in 20x SSC for 45min. RNA was 
transferred onto Hybond-N membranes by capillary action using 20x SSC as transfer 
buffer. Membranes were rinsed in water then exposed to UV for 6min, in Stratalinker ( 
Stratagene), to allow fixation.
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2.4.2 Hybridisation of blots
Pre-hybridisation of blots was carried out using hybridisation buffer at 65°C for at least 
lhr. Blot subsequently incubated with denatured, radiolabelled probe in 10ml 
hybridisation buffer at 65°C overnight.
2.4.3 Washing
Following hybridisation blots were rinsed 3x in 10ml wash buffer for 2min, followed by 
wash in 10ml wash buffer at 65°C, with change of buffer every 30min, until background 
level of radioactivity reduced sufficiently to allow specific signal to be detected. Wash 
buffer consisted of either lx, 5x or 20x SSC depending on stringency required to reduce 
background radioactivity.
2.4.4 Autoradiography
Following washing, blots were blotted dry, wrapped in plastic film and exposed to Kodak 
XAR film in film cassette with tungstate intensifying screens. Loaded film cassettes were 
held at -70°C until developed.
2.5 SEPARATION AND HYBRIDISATION OF DNA
2.5.1 Restriction digestion of genomic DNA
40jig genomic DNA ( 50pl ) added to 25pl H20  and 10pl lOx restriction buffer. 
Incubated for 3hr at 4°C with occasional mixing using capillary tube. 50units restriction 
enzyme added and stirred for 3min before incubating at 37°C for 3hr. Further 50 units 
restriction enzyme added and incubation continued for 6hr. Digested DNA was ethanol 
precipitated and resuspended in 25pl H20.
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2.5.2 Separation and Southern transfer of DNA
Methodology for separation and transfer of DNA emulated instructions detailed by 
Sambrook et al, (Sambrook et al. 1989). 2.4g agarose dissolved in 300ml lx  TAE, 6pl 
0.5mg/ml ethidium bromide and poured. DNA sample heated to 56°C for 3min then 
mixed with 5pi DNA loading dye and loaded onto gel. Gel was run at 20V, for 18hr, 
using lx TAE as electrophoresis buffer which was recirculated using a mini-peristaltic 
pump. After electrophoresis, gel photographed under UV transillumination then soaked in 
denaturing solution for 45min. Gel rinsed in H20  then soaked in neutralization solution, 
30min, with gentle agitation. Neutralization solution changed and gel soaked for further 
15min then placed in lx Genescreen to equilibrate. DNA fragments transferred to 
Hybond-N filter by capillary action, using lx Genescreen as transfer buffer. Transfer 
performed over 18hr. Membranes were rinsed in water then exposed to UV for 6min, in 
Stratalinker ( Stratagene), to allow fixation.
2.5.3 Hybridisation of blots
Prehybridisation of the blot was performed using 30ml hybridisation solution, containing 
lOOpg/ml sonicated salmon sperm DNA as in 2.4.2. Radiolabelled probe was added to 
10ml of hybridisation solution, containing 50pg/ml salmon sperm DNA, and incubated 
with the blot for 18hr at 65°C.
Washing and autoradiography of blots performed in identical manner to that detailed in
2.4.3 and 2.4.4.
58
2.6 GEL SEPARATION AND IMMUNODETECTION OF PROTEINS
2.6.1 Sample preparation
Protein extracts were prepared and quantified as detailed in section 2.2.3. 75fig protein 
was mixed with 1/5 volume Western loading dye and boiled for 3min to facilitate protein 
denaturation.
2.6.2 Separation of proteins by SDS-gel electrophoresis
A resolving gel was cast ( the percentage gel depending upon size of protein to be 
detected ) and allowed to set for lhr before overlaying with stacking gel. Samples and 
protein size markers were then added and proteins electrophoresed at 200V/ 40mA until 
dye front had migrated through gel. lxTank buffer used as electrophoresis medium.
2.6.3 Western transfer of proteins by electroblotting
Proteins were transferred onto a PVDF membrane ( Immobilon-P, Millipore. ) using a 
semi-dry electroblotter. The membrane was wetted in methanol then Transfer buffer. Six 
sheets of 3mm chromatography paper (Whatman, Maidstone, UK.) wetted in Transfer 
buffer were laid on anode followed by PVDF membrane, gel and another six sheets pre­
wetted paper with cathode placed on top. The electroblotter was run at 200mA for lhr. 
To assess evenness of protein transfer the gel was subsequently stained in Coomassie 
stain ( 0.2% Coomassie Brilliant blue R250 in a 50:50:7 v/v ratio of methanol: 
H20:galcial acetic acid ) for 4hr, then destained using 25:68:7 v/v ratio of methanol: 
H20:galcial acetic acid.
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2.6.4 Immunodetection of proteins on Western blot
Western membranes were incubated with Blocking solution at 4°C for 4hr with constant 
gentle agitation. The membrane was then incubated overnight, at 4°C, with primary 
antibody, diluted in Blocking solution, and subsequently washed in PBST ( 3x 5min ). 
The membrane was then incubated with Blocking solution, containing secondary 
antibody, for 2hr then washed with PBST. The membrane was then incubated with a 
chemiluminescence substrate ( Enhanced Chemiluminescence kit, Amersham. UK ) for 1 
minute, and exposed to radiographic film to enable bound complexes to be visualised.
2.7 AMPLIFICATION AND DETECTION OF DNA AND RNA
2.7.1 Standard PCR
All PCR manipulations were carried out using dedicated micro-pippetors, aerosol 
resistant tips and plasticware that had been sterilised by brief exposure to UV irradiation. 
Water and other non-DNA containing reagents were also exposed to UV irradiation in an 
attempt to reduce contamination of samples with extraneous DNA. PCR was carried out 
in a total reaction volume of 25pl in 0.5ml Eppendorf tubes or thin-walled 96 well plates 
( Hybaid, U K .) Template DNA was used in concentrations ranging from 50 -lOOng. PCR 
primers obtained from Research Genetics ( Huntsville, USA. ) were used at a final 
concentration of 160nM, whereas with other primers the final concentration ranged from 
0.5 to 1.0 mM. 2.5pl of lOx PCR buffer, 0.8pl dNTP mix and 0.2pl Taq polymerase (all 
Boehringer Mannheim ) as well as 0.1 pi a 32P dCTP were added to template DNA and 
primers and the reaction volume attained using sterile H20. 1 drop sterile mineral oil was 
placed on top of reaction mixture prior to amplification in thermal cycler.
Thermal cycler perameters were individualised for each primer / template combination. 
Annealing temperatures were obtained, either from the Prime programme of the GCG 
software package or were calculated from the equation;
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Annealing temperature ( °C ) = 2x( A+T) + 4x( G+C ) 
where G,C,A,T are the number of each nucleotide in the primer. Standard melting and 
extension temperatures of 94°C and 72°C, respectively, were used in each reaction unless 
otherwise stated. The number of cycles of amplification was generally either 30 or 35.
A technique of “Touchdown” PCR was used for many of the reactions involving 
amplification of microsatellite repeats. A fuller description of the theory behind this 
technique is given in Appendix B and Don et al, (Don et al. 1991).
2.7.2 RT-PCR
cDNA was formed from 2pg total RNA using the Superscript II Pre-amplification kit ( 
Gibco.BRL. ) as per manufacturers protocol. 01igo(dT)i2.i8 primers were used to prime 
the reverse transcription reaction. A control in which no reverse transcriptase was added 
was used to detect contamination with genomic DNA. Once formed the cDNA was 
treated with RNAaseH to remove residual RNA. l-2pl of the reaction product was used 
as template in standard or Touchdown PCR reaction using gene specific DNA primers.
2.7.3 Synthesis of DNA size ladder
To allow accurate calculation of the size of PCR amplified microsatellite repeat sequences 
on polyacrylamide gels a DNA sequence ladder was synthesised using the M13mpl8 
bacteriophage as template. The ladder was synthesised using the Sequenase version 2.0 
DNA sequencing kit ( USB.) following the manufacturers protocol and labelling the 
products by addition of S35 dATP to the reaction.
2.7.4 Agarose gel electrophoresis
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0.8 - 2.0g agarose was dissolved in 100ml lx TBE and 2pl 0.5mg/ml ethidium bromide 
added prior to casting. DNA samples were mixed with 1/5 volume DNA loading dye 
prior to loading on gel. Gels were electrophoresed in lx  TBE buffer at 200V.
2.7.5 Polyacrylamide gel electrophoresis
Denaturing polyacrylamide gels ( the percentage polyacrylamide dependent on the size of 
DNA fragments requiring resolution ) were used to resolve individual microsatellite 
repeats. Gels were cast between pre-cleaned glass plates one of which was coated with a 
silicone solution ( Repelcote, Sigma. UK.). The glass plates were sealed to form a mould 
for the gel using adhesive tape.
Gels were formed using pre-mixed 30% Acrylamide / 0.85% bis-Acrylamide / 7M Urea ( 
Easigel). For an 8% polyacrylamide gel the following recipe was used;
40ml Acrylamide / bis-Acrylamide solution 
280pl 10% Ammonium persulphate solution ( made 
freshly)
14pl TEMED
Once the gels were poured wells were formed using sharkstooth combs. Once set the gels 
were pre-run for 30 minutes at 35mA/ « 1800V. After the pre-run the wells were cleared 
of unpolymerised polyacrylamide and urea using lx TBE buffer. DNA samples for 
electrophoresis were mixed with 2/3 volume Fromamide loading dye and heated to 75°C 
for 5 minutes prior to loading on gel. The gel was run at 35mA in lx TBE buffer until the 
xylene cyanol FF band was at the bottom of gel, then blotted onto a sheet of 3mm 
chromatography paper ( Whatmann, UK ) and dried under vacuum at 80°C for 1 hour. It 
was then exposed to radiographic film in a cassette with tungstate intensifying screens at - 
70°C.
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2.8 TISSUE CULTURE TECHNIQUES
2.8.1 General cell culture methods
Aseptic manipulations were performed using sterile glassware in a class II microbiological 
safety cabinet with vertical airflow. Cells were grown at 37°C as monolayers in 
supplemented RPMI medium in the presence of 5% C 02. All cell lines were regularly 
analysed for mycoplasma infection. Cell stocks were formed by freezing 106 cells, in 1ml 
RPMI with 10% di-methyl sulphoxide (DMSO), at -70°C in cryotubes ( Nunc, UK ). 
After 24 hours, samples were transferred to liquid nitrogen. To reduce the chances of 
genetic drift cell lines were replaced from frozen stocks regularly.
2.8.2 Selection of cisplatin resistant lines
lxlO6 A2780 cells were grown in F75 tissue culture flasks (Bibby Sterlin, Aberbargoed. 
UK) for 36 hours to attain log growth phase. A lOmM stock solution of cisplatin was 
made freshly for each selection. Stock cisplatin solution was added to RPMI medium to 
obtain the desired final concentration. Cells were then exposed to the cisplatin containing 
medium for 24 hours at which point it was replaced by fresh medium. Cells were allowed 
to grow for approximately 7 days , with changes of medium as required. Cells surviving 
after this period were harvested by trypsinisation and 1 x 106 cells were placed in a new 
F75 flask for the next round of selection. The concentrations of cisplatin used in the 
selection process were lfiM, 2pM, 4fiM, 6jiM, 8|iM, and 15|iM.
2.8.3 Clonogenic assay
1 x 1 0  cells were plated in 10cm tissue culture dishes, with 5 replicates for controls and 
for each drug concentration, per cell line. Cells were allowed to grow for 24 hours, at 
which point medium was removed and replaced with fresh medium containing the
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required concentration of cisplatin. After the desired period of exposure this medium was 
replaced by fresh, drug free, medium and the cells allowed to grow for 10 days with 
changes of medium as required. lmL Giemsa’s stain was added to the medium in each 
dish and left for 10 minutes to allow cell staining. Medium was then removed and dishes 
washed gently in water. Colonies were counted manually with an attempt made to 
standardise the size of colonies counted between dishes.
2.8.4 MTT assay
Using a cell suspension of density 2.5x10 cells/ml medium, cells were plated out in 
volumes of 200pl into microwell plates and incubated for 3 days. On day 4 the plates 
were exposed to medium containing cisplatin for 1 hour, then replaced in the incubator 
with fresh drug-free medium. On days 5-7 the medium was refreshed and the plates re­
incubated. On day 8 the medium was removed and the MTT solution added ( 200pl 
RPMI, 1/100 Hepes and 50pl of 5mg/ml MTT dissolved in PBS and filter sterilised). The 
plates were wrapped in silver foil, incubated for 4 hours at 37°C, then the MTT solution 
removed and replaced with 200pl DMSO and 25pi glycine buffer. The optical density at 
570nm of each well was then determined using a microplate reader.
2.9 EMMUNOCYTOCHEMISTRY
2.9.1 Immunohistochemistry of cultured cells
To the wells of a chamber slide ( Nunc, Naperville, II. USA ) 5xl04 cells of each cell line, 
in 250pl of RPMI medium, were added and grown for 48 hours. After removal of the 
medium the cells were washed with PBS, the plastic gasket removed and the slide dried in 
air. Slides could be wrapped in parafilm at this point and stored at -70°C. Dried slides 
were placed in methanol at -20°C for 20 minutes to allow fixation of cells and then air 
dried for a further 40 minutes. Normal horse serum, diluted 1:10 with 0.1% BSA in PBS,
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was added to the cells as a blocking agent and left to incubate for 20 minutes at room 
temperature in a humid atmosphere. Excess liquid was removed and 50 j l x 1 primary 
antibody, diluted in 0.1% BSA in PBS, added and left to incubate as before for 2 hours. 
Slides were subsequently immersed in 0.1% Tween in PBS for 2x 10 minutes before 
incubation for 30 minutes at room temperature with secondary antibody, again diluted in 
0.1% BSA in PBS. Two further 10 minute washes in 0.1% Tween in PBS followed. The 
slides were then mounted using Vectashield ( Vector Labs, Burlingame. Ca. USA ) and 
the edges of the coverslip sealed with nail varnish. Slides were then analysed using 
confocal microscopy.
2.9.2 Cell cycle analysis
Determination of the proportion of cells, within a given population, in different stages of 
the cell cycle was assessed using the method previously described by Kastan et al (Kastan 
et al. 1991a). Exponentially growing cells were plated at 5xl05/10cm plate in RPMI 
medium and incubated at 37°C for 3-4 days. At this point the cells were irradiated with 
2Gy ionising radiation in the form of y-rays from a 60Co source. The cells were incubated 
for a further 24 hours at which point the medium was replaced with RPMI medium 
containing bromo-deoxyuridine ( BrdUrd) at a final concentration of lOpM. After 
incubation for a further 4 hours at 37°C, the medium was removed and cells removed 
from the plates by trypsinisation. Cell pellets were obtained by centrifugation of the 
trypsin/cell suspension at 500G for 5 minutes and removal of the supernatant. The pellets 
were resuspended in 5ml, ice-cold, 70% ethanol and could be stored for up to 2 weeks at 
4°C.
For analysis cell pellets were resuspended in 1ml cold PBS, transferred to 1.5ml 
microcentrifuge tubes, pelleted by centrifugation at 300G for 5 minutes at 4°C ( these 
conditions were used for all subsequent centrifugations) and the PBS wash repeated one 
further time. Cells were then permeabilised by incubation in 2M HC1 for approximately 30 
minutes, at room temperature. Cells were collected by centrifugation and washed twice in
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lml PBS, then in 1ml PBT which acts as a blocking agent. The pelleted cells were 
incubated with lOOpl of 1:40 mouse anti-BrdUrd monoclonal Ab, in PBT, for 1 hour at 
room temperature, washed twice in PBT then incubated with a 1:40 dilution ofFITC 
conjugated goat anti-mouse 2°Ab, in PBT, for 30 minutes. The cells were washed once in 
PBT and once in PBS prior to incubation with 1 mg/ml propidium iodide for at least 20 
minutes at room temperature or overnight at 4°C. Cells were pelleted and resuspended in 
PBS to allow analysis using the FACScan flow cytometer. The red ( propidium iodide ) 
and green ( FITC ) emissions from each cell were separated using the standard optics of 
the FACScan, and cell cycle distribution was determined by counting in excess of 2x104 
events.
2.10 MISMATCH REPAIR ASSAYS
2.10.1 In vitro mismatch binding assay.
Cell extracts were prepared by a modification of the method described by Jiricny (Jiricny 
et al. 1988). Briefly, cells were harvested and suspended in three packed cell volumes of 
buffer A, followed by homogenisation in a Dounce homogeniser. One volume of glycerol 
was added, followed by 1/10 volume saturated, neutralised ammonium sulphate solution. 
This was incubated for 30 minutes then centrifuged at 90,000 rpm for 60 minutes. All 
procedures were performed at 4°C.
Gel retardation assays were performed at 20°C. 5pi of cell extract was added to 20pl of 
the following reaction mix: 25mM Hepes-KOH, pH 8.0, 0.5mM EDTA, O.lmM ZnCl2, 
0.5mM dithiothreitol, 10% glycerol, 50pg/ml poly ( dl-dC )2 ( Sigma ), 0.4pl o f ‘cold 
competitor’, a 34mer ds complementary oligonucleotide, was added to each sample. This 
was incubated at room temperature for 5 minutes. Labelled heteroduplex oligonucleotide 
was added and a further 20 minutes incubation performed. 2pl of loading buffer ( 
Bromophenol blue in 50% glycerol) was added and half of the sample loaded onto a 6%
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polyacrylamide: TBE gel. Electrophoresis was performed at 70V in TBE until the dye 
front had just migrated out of the gel.
2.10.2 In vitro mismatch repair assay
Nuclear extracts were prepared according to the method of Challberg and Kelly 
(Challberg and Kelly, 1979), except that all buffers contained 0.1% PMSF. Nuclear 
pellets were resuspended in 0.05M Hepes, pH 7.5; 0.5mM dithiothreitol; 0.1% PMSF; 
10% sucrose. After addition of 0.031 volumes 5M NaCl, the nuclear suspension was 
mixed for 1 hour. Nuclei were centrifuged at 15,000g for 20 minutes, and the resulting 
supernatant concentrated by ammonium sulphate precipitation. The ammonium sulphate 
pellet was dissolved and dialysed against buffer containing 0.1% PMSF. The resulting 
dialysate was clarified by centrifugation at 14,000g for 15 minutes, the protein 
concentration determined and small aliquots stored at -70°C. 
lOOng of mismatched flMR construct was added to 50pg of nuclear extract and 
incubated at 37°C for 15 minutes. After incubation reactions were stopped by addition of 
30pl of 25mM EDTA, 0.67% SDS followed by treatment with proteinase K. DNA was 
purified by phenol extraction and the extent of mismatch correction quantitated by 
determined of sensitivity to the appropriate restriction enzymes.
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CHAPTER 3
MICROSA TELLITE INSTABILITY AND DRUG RESISTANCE
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3.1 INTRODUCTION
Cells from a significant number of sporadic tumours, of different tissue origin, 
have been shown to display microsatellite instability. This has also been shown to be the 
case for in vitro cell lines derived from human tumours of various types (Boyer et al. 
1995; Orth et al. 1994). An association between defective mismatch repair, 
characterised by microsatellite instability, and resistance to certain types of alkyalting 
agents has been proven conclusively in a number of different in vitro cell systems 
(Karran and Bignami, 1994). The alkylating agents for which this specific type of 
resistance has been shown are of limited clinical significance. It is therefore important to 
determine whether there is an association between microsatellite instability in tumour 
cells and resistance to those anticancer agents of clinical importance.
The ovarian epithelial adenocarcinoma cell line A2780 was originally derived 
from a patient with no prior exposure to chemotherapy (Eva et al. 1982). This line, and 
derivatives selected for resistance to anti-cancer drugs such as cisplatin, have been used 
extensively in the study of the molecular determinants of drug resistance. As a result of 
this many of the differences between A2780 and its drug resistant derivatives are 
characterised at the molecular level (Rogan et al. 1984; Brown et al. 1993; Behrens et al. 
1987; Andrews and Howell, 1990). In view of this substantial molecular 
characterisation these cell lines, and several others, were used in the analysis of 
microsatellite instability.
To detect the presence of microsatellite instability comparison is made of the 
length of microsatellite repeat sequences at identical loci between cell lines. Although 
there is some debate as to whether the likelihood of detecting microsatellite instability 
depends on the locus studied (Tautz, 1990), microsatellite repeats on chromosome 17 
were used primarily. Chromosome 17 is known to harbour genes involved in the 
development of drug resistance and the malignant phenotype (Fry et al. 1991; Brown et 
al. 1993). Recessive mutations that arise in such genes may be important in the
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development of an altered cell phenotype, such as the acquisition of drug resistance. One 
way of uncovering recessively acting mutations in genes is by looking for the 
development of loss of heterozygosity ( LoH ) between the normal or parent cell and 
that with the altered phenotype. Microsatellite repeats have been used as chromosomal 
markers in LoH studies due to their spread throughout the genome and their high level of 
polymorphism (Gruis et al. 1993). It was hoped that the microsatellites used in this study 
would provide not only information about microsatellite instability but perhaps also 
evidence of chromosome 17 specific LoH in the resistant cell lines.
The analysis of microsatellite repeat sequences was performed using the 
polymerase chain reaction ( PCR ). Certain parameters influence the success and 
accuracy of amplification of microsatellite DNA . In each cycle of amplification the DNA 
template and primer sequences go through steps of denaturation, annealing and 
elongation. The temperature at which the primers anneal to the template strand is critical 
and is a function of the length and sequence context of the primers themselves. If the 
temperature of the annealing step is above the optimal annealing temperature for the 
specific primers then there will be a much reduced efficiency of amplification. If the 
annealing temperature is below optimal then the primers become more likely to anneal 
not only to the specific template sequences but also to non-specific sequences leading to 
an increase in non-specific amplified products. In the analysis of microsatellite repeat 
sequences reported here a technique of “Touchdown” PCR was used (Don et al. 1991) 
to improve the efficiency of DNA amplification. It also permitted the use of a single set 
o f reaction conditions for a number of different PCR primer pairs without significant loss 
of amplification specificity. This technique is more fully discussed in Appendix B.
The sections that follow present the results of the search for microsatellite 
instability in drug resistant tumour cell lines. It subsequently proceeds to study further 
parameters of the drug resistant phenotype in cisplatin resistant cell lines derived from 
A2780. Finally it assesses whether certain specific features of the post DNA-damage
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response pathway are altered in the drug resistant cell lines as compared to the lines 
from which they are derived.
3.2 MICROSATELLITE ANALYSIS OF DRUG RESISTANT TUMOUR
CELL LINES
3.2 1 Comparison of chromosome 17 specific, microsatellite repeat
sequences in A2780 and drug resistant cell-line derivatives.
Microsatellite repeat sequences from different chromosome 17 loci were 
amplified using PCR in DNA from A2780, A2780/cp70 and A2780/AD. Figure 3.1 
shows the autoradiographic images obtained from the radiolabelled PCR products, after 
electrophoresis on denaturing polyacrylamide gels. When the PCR amplified products, 
from each of the chromosome 17 microsatellite repeats in A2780/cp70 and A2780/AD, 
were compared to those from A2780 differences were observed in the size of alleles at 
certain loci. In Figure 3.1(a) the microsatellite loci D17S579 and D17S183 are shown 
for each of the three cell lines. D17S183 is a heterozygous repeat locus with the 
dominant alleles in A2780 migrating at 93bp and 99bp. The allelic pattern in A2780/AD 
is exactly identical to that of the parent line whilst that in A2780/cp70 shows a reduction 
in the size of the longer allele by 2bp ( one repeat length ). It can be observed that the 
allelic pattern seen usually consists of a series of bands with one often being more 
prominent than the others. The fainter bands, often known as “stutter bands”, represent 
artefacts that arise during PCR by several mechanisms (Tautz, 1990).
D17S579 is homozygous with the predominant band in A2780 migrating at a 
size of 108bp. The same allele in both A2780/cp70 and A2780/AD has changed in size. 
In A2780/AD the dominant band would appear to be one repeat length larger (llObp) 
whilst in A2780/cp70 the strongest band on the autoradiograph is two repeat lengths 
shorter (104bp). Other examples of the changes in microsatellite repeat sequence seen in
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Figure 3.1(a) M u t a t i o n s  o f  m i c r o s a t e l l i t e  l o c i  in  d r u g  r e s i s t a n t  A 2 7 8 0  c e l l  l in e s .
P C R  a m p l if ic a t io n  o f  th e  m ic r o s a t e l l i t e  lo c i  D 1 7 S 1 8 3  a n d  D 1 7 S 5 7 9  in  D N A  fr o m  A 2 7 8 0 ,  
A 2 7 8 0 / c p 7 0  a n d  A 2 7 8 0 / A D .  T h e  p a t te r n  o f  m ic r o s a t e l l i t e  a l l e l e s  in  A 2 7 8 0 / c p 7 0  a n d  A 2 7 8 0 / A D  
c a n  b e  s e e n  t o  d i f f e r  f r o m  th a t  in  A 2 7 8 0  in  D 1 7 S 5 7 9  w h i l s t  o n ly  A 2 7 8 0 / c p 7 0  d i f f e r s  fr o m  A 2 7 8 0  
in  D 1 7 S 1 8 3 .  T h e s e  d i f f e r e n c e s  r e p r e s e n t  m ic r o s a t e l l i t e  m u ta t io n s .  A n  M 1 3  p h a g e  D N A  
s e q u e n c in g  la d d e r  ( C , G , T , A , ) i s  in c lu d e d  t o  a l l o w  d e te r m in a t io n  o f  a l l e l e  s i z e .
Figure 3.1 (b), (c), (d) & (e) Mutation in microsatellite loci on chromosome 17 and 2 
in drug resistant, A2780 derived, cell lines.
PCR amplification o f microsatellite loci D17S351, D17S261, D17S702 and D2S172 in DNA 
from A2780, A2780/cp70 and A2780/AD. A number o f different types o f microsatellite 
mutations are observed in the different loci from chromosome 17 and 2. Sizes ( in base pairs) are 
represented by arrows and were calculated from an M13 phage sequence ladder. This allows an 
estimation o f the length o f the microsatellite alleles.
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A2780/cp70 and A2780/AD are shown in Figure 3.1(b), (c) and (d). The microsatellite 
D17S351 ( Figure 3.1(b) ) shows the opposite picture to that o f D17S183 with 
A2780/cp70 showing a gain of one repeat unit in the size of the larger allele as compared 
to both A2780/AD and the parental line.
The presence of changes in the repeat number is not confined to microsatellite 
repeats residing on the long arm o f chromosome 17, o f which the three previous loci are 
examples. D17S261 is on chromosome 17p and shows a smaller sized repeat in 
A2780/cp70 than in the parental line, ( Figure 3.1(c) ). Microsatellite mutation was also 
seen with the, theoretically, more stable tetranucleotide repeats as can be seen at locus 
D17S702 in A2780/cp70. Here the smaller of the two alleles has lost 3 repeat lengths ( 
12bp ) compared to that in the parental line, ( Figure 3.1(d) ). Not all the microsatellite 
loci studied on chromosome 17 showed differences when the three cell lines were 
compared. Table 3.1 reveals that A2780/AD only showed evidence of a microsatellite 
mutation at D17S579 with all other loci being identical to A2780. In the case of 
A2780/cp70 however six out o f the ten loci studied showed evidence of length changes 
in the microsatellite alleles. The onlj' evidence of LoH occurring at any of these loci in 
one of the drug-resistant cell lines was at locus D17S801 in A2780/AD where there 
appeared to be a decrease in the intensity of the shorter allele compared to that in 
A2780.
The microsatellite mutations detected at loci on chromosome 17 could potentially 
have arisen due to some specific feature o f that chromosome and not represent an 
increased propensity for mutation throughout the genome as a whole. To determine 
whether the changes observed in chromosome 17 microsatellites were detected 
elsewhere, four microsatellite repeat sequences from chromosome 2 were subjected to 
the same type of analysis in the three cell lines. Previous studies on LoH in ovarian 
carcinoma samples have shown that chromosome 2 is often affected. Therefore 
supplementary information would potentially be available by using microsatellite repeats 
from this chromosome in the analysis o f microsatellite mutation. Two o f the
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microsatellite repeats were chosen from the short arm of the chromosome and two from 
the long arm. As can be seen in figure 3.1(e) microsatellite mutations also arise on 
chromosome 2 . In this case the homozygous microsatellite repeat at D2S172 shows a 
reduction in the size of the repeat in A2780/cp70 but an increase in the allelic length in 
A2780/AD. Evidence for a mutation in the size of the microsatellite repeat at D2S123, 
which is on the opposite arm of chromosome 2 to D2S172, was also observed in 
A2780/cp70 ( Table 3.1 ). The same repeat in A2780/AD was very difficult to amplify 
and no reproducible data was obtained. Therefore it would appear that the increased 
frequency of mutation at microsatellite repeat loci observed in A2780/cp70 and 
A2780/AD when compared to A2780 is not limited to chromosome 17 suggesting that it 
may be a feature of the genome as a whole.
3.2.2 Characterisation of microsatellite repeat loci in further tumour cell
lines and drug resistant derivatives.
Although an increased frequency of microsatellite mutation was observed in the 
drug resistant derivatives of A2780 it was possible that this was an isolated feature of 
this cell lineage. To test this, the same range of microsatellite repeat sequences were 
studied in two different cell lines and sub-lines derived from them by selection for 
resistance to anti-cancer drugs. The cell line OVl/p ( also known as IGROV1 ) was 
derived from tumour tissue taken from a previously untreated patient with a stage III 
ovarian carcinoma (Benard et al. 1985). OV1/DDP, a cisplatin resistant derivative of 
OVl/p, was derived by repeated exposure to increasing concentrations of cisplatin 
(Teyssier et al. 1989). The MCF7 human breast carcinoma cell line was derived from a 
metastatic breast cancer (Soule et al. 1973). The doxorubicin resistant line MCF7/AD 
was derived by selection with increasing concentrations of doxorubicin (Sinah et al. 
1986).
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The evidence that there are changes in the microsatellite repeats between the 
parental and drug-resistant derivatives for both these cell lines is shown in figures 3 . 2  
and 3.3. In MCF7 and MCF7/AD the chromosome 17 microsatellite loci displayed are 
all homozygous, which was also true for all but one of the loci studied. The changes 
observed are predominantly due to increases in the size of the microsatellite repeat in 
the drug-resistant derivative line and tend to take one of two forms. This is either a shift 
in the size of the microsatellite allele by one repeat unit length or a more profound shift 
of two or greater repeat lengths. Such changes in microsatellite repeats have been 
termed Type II and Type I mutations respectively (Thibodeau et al. 1993). The 
mutations observed at loci D17S796 and D17S261 in MCF7/AD ( Figure 3.2 ) are 
therefore of Type II whereas at CHRNB1 it is a Type I mutation. As with the A2780 
derived cell lines the presence of microsatellite mutation is not confined to loci on 
chromosome 17. The homozygous microsatellite repeat locus at D2S121 shows a Type I 
mutation in the MCF7/AD cell line compared to the parental line.
As with the multi-drug resistant MCF7/AD, the cisplatin resistant cell line OV1/DDP 
also exhibits evidence of mutations at microsatellite loci when they are compared to the 
parental line OVl/p. Mutations are observed at microsatellite loci on chromosomes 2,3 
and 17 which again suggests a global predisposition to microsatellite mutation. Type I 
and II microsatellite mutations are both observed in this cell line. Characterisation of 
the MCF7 and OVl/p derived cell lines with the complete set of microsatellite repeat 
sequences on chromosomes 2,3 and 17 used for analysis in A2780 lines shows frequent 
mutations ( table 3.1 ). Six out of the twelve loci for which data is available in 
MCF7/AD show mutation whereas for OV1/DDP it is five out of fourteen. LoH is 
observed in both sets of drug resistant cell lines when compared to the parental lines. In 
MCF7/AD there is an obvious loss of an allele with the microsatellite repeat D2S172 
which is on the long arm of chromosome two. This was the only one of all the 
microsatellite repeats used in the MCF7 lines to be heterozygous. OV1/DDP shows LoH 
at D2S121 on the short arm of the chromosome with the remaining allele also
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Figure 3.2 M u t a t i o n s  a t  m i c r o s a t e l l i t e  l o c i  in  t h e  M C F 7 / A D  c e l l  l i n e .
P C R  a m p l if i c a t io n  o f  m ic r o s a t e l l i t e  l o c i  C H R N B 1 ,  D 1 7 S 7 9 6 ,  D 1 7 S 2 6 1  D 2 S 1 2 1  a n d  D 2 S 1 7 2 ,  
in  D N A  fr o m  M C F 7  a n d  M C F 7 /A D  c e l l  l in e s ,  s h o w s  e v id e n c e  o f  m u ta t io n  in  th e  la tte r  c e l l  l in e .  
T y p e  I ( C H R N B 1 ,  D 2 S 1 2 1  ) a n d  II ( D 1 7 S 7 9 6 ,  D 1 7 S 2 6 1  ) m ic r o s a t e l l i t e  m u ta t io n s  a re  
o b s e r v e d .  L o s s  o f  h e t e r o z y g o s i t y  is  s e e n  in  D 2 S 1 7 2  w ith  n o  u p p e r  a l l e l e  d e t e c t e d  in  M C F 7 /A D .
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Figure 3 . 3  M u t a t i o n s  a t  m i c r o s a t e l l i t e  l o c i  in  t h e  O V l / D D P  c e l l  l i n e .
P C R  a m p l if ic a t io n  o f  m ic r o s a t e l l i t e  lo c i  D 3 S 1 2 9 8 ,  D 1 7 S 7 0 2 ,  D 2 S 1 2 1  a n d  D 2 S 1 7 2  in  D N A  
fr o m  O V l / p  a n d  O V l / D D P  s h o w s  e v id e n c e  o f  m u ta t io n s  in  th e  la tte r  c e l l  l in e .  A s  w ith  
M C F 7 /A D ,  ty p e  I ( D 3 S 1 2 9 8  ) a n d  ty p e  II ( D 1 7 S 7 0 2 ,  D 2 S 1 7 2  ) m ic r o s a t e l l i t e  m u ta t io n s  a re  
o b s e r v e d .  L o s s  o f  h e t e r o z y g o s i t y  c a n  b e  d e t e c t e d  in  D 2 S 1 2 1  fr o m  th e  d is a p p e a r a n c e  o f  th e  u p p e r  
a l l e l e  in  O V l / D D P .  T h e  lo w e r  a l l e l e  s h o w s  a s h if t  in  s i z e  c o m p a r e d  to  O V l / p  in d ic a t in g  
m ic r o s a t e l l i t e  m u ta t io n .
Cell Lines Studied
A2780 A2780/
cp70
A2780/
AD
OVl/p OVl/
DDP
MCF-7 MCF-7/
AD
CHRNB-l m y ■ ■ ■ ■ ■ ■
D17S796 m y ■ ■ ■ ■ ■ ■
UI7S261 m ■ ■ ■ ■ ■ ■
D17S856 a y ■ ■ ■ ■ □ □
D17S855 m y ■ ■ ■ ■ □ □
D17S183 m y ■ ■ ■ ■ ■ ■
D17S579 m ■ ■ ■ ■ ■ ■
DI7S351 m y ■ ■ ■ ■ ■ ■
D17S801 m y ■ ■  * ■ ■ ■ ■
D17S193 m y ■ ■ ■ ■ ■ ■
D2S123 m ■ □ ■ ■ ■ ■
D2S172 m ■ ■ ■ ■ ■ ■
D2S121 m □ □ m y ■  * ■  *
D3S1298 m □ □ m ■ ■ ■
Table 3.1 Microsatellite mutations in drug resistant cell-lines.
T h e  m ic r o s a t e l l i t e  r e p e a ts  a t e a c h  o f  th e  l o c i  a b o v e  w e r e  a m p l i f i e d  u s in g  th e  P C R  p r im e r s  
d e t a i l e d  in  T a b le  2 .1  &  2 .2 ,  a s  d i s c u s s e d  in  th e  m e t h o d s  s e c t io n .  E v id e n c e  f o r  m ic r o s a t e l l i t e  
m u ta t io n  w a s  ta k e n  a s  a  s h i f t  in  th e  s i z e  o f  o n e  o r  b o th  a l l e l e s  c o m p a r e d  to  t h o s e  o f  th e  p a r e n ta l  
l in e  a f te r  e le c t r o p h o r e s i s  o n  a  d e n a tu r in g  p o ly a c r y la m id e  g e l .  L o s s  o r  r e d u c t io n  in  in t e n s i t y  o f  
o n e  a l l e l e  in  a  h e t e r o z y g o u s  r e p e a t  w a s  ta k e n  to  r e p r e s e n t  a  lo s s  o f  h e t e r o z y g o s i t y .  T h e  m a jo r ity  
o f  e x p e r im e n t s  w e r e  r e p e a te d  to  e n s u r e  th a t  a n y  v a r ia t io n  b e t w e e n  a l l e l e s  w a s  n o t  a n  a r te fa c t  o f  
th e  P C R  p r o c e s s .  S u b t le  c h a n g e s  a r is in g  b e t w e e n  a l l e l e s  w e r e  in d e p e n d e n t ly  a s s e s s e d  b e f o r e  
f in a l  c l a s s i f i c a t i o n .
W i ld  ty p e  m ic r o s a t e l l i t e  a l l e l e
M u ta n t  m ic r o s a t e l l i t e  a l l e l e  p r e s e n t  a s  c o m p a r e d  to  w i ld  ty p e  
D a ta  u n a v a i la b le
R e p r e s e n t s  h e t e r o z y g o u s  l o c u s  p o t e n t ia l ly  in f o r m a t iv e  f o r  L o H . A l l  o th e r  
l o c i  w e r e  h o m o z y g o u s  a n d  th u s  u n in f o r m a t iv e .
R e p r e s e n t s  L o H  a t l o c u s  in d ic a t e d .
Legend:
■
■
□ =
✓
displaying a decrease in the size of the repeats suggesting microsatellite mutation. 
About half of the microsatellite repeat loci in OVl/p were heterozygous and thus 
potentially informative for LoH.
3.2.3 Determination of the microsatellite instability phenotypes in A2780
and A2780/cp70.
As seen in table 3.1, the cisplatin resistant cell line A2780/cp70 shows mutations 
in eight of the twelve microsatellite repeat loci studied, when compared to A2780. This 
was a greater percentage of mutated microsatellite loci than found in any of the other 
drug-resistant cell lines, when compared to the parental lines. In view of this, and the 
fact that a great deal of experience had been gained with the A2780 and A2780/cp70 
cell lines in our group, it was decided to use these lines for further characterisation of 
the microsatellite mutation phenotype.
An increased frequency of microsatellite mutation is termed microsatellite 
instability and several primary ovarian carcinoma cell lines have been shown to display 
this feature (Orth et al. 1994). The detection of instability in A2780/cp70, upon direct 
comparison of microsatellite repeats with A2780, does not eliminate the possibility that 
A2780/cp70 is displaying a phenotype of instability already present in the parental line. 
Therefore to determine whether the presence of microsatellite instability was a feature 
of the A2780 cell line, or had potentially been acquired during the development of the 
cisplatin resistant A2780/cp70, use was made of a sub-clone analysis. Sub-clones of a 
cell line with a phenotype of microsatellite instability are likely, with further growth, to 
continue to develop microsatellite mutations at a detectable frequency. Sub-clones from 
a cell line without this phenotype should not.
Fifteen sub-clones of A2780 and 20 sub-clones of A2780/cp70 were derived by 
isolating individual clones, at random, from sub-confluent cultures of either cell line, as 
described in chapter 2. The DNA from the different sub-clones was analysed for
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evidence of microsatellite mutation by PCR amplification at four microsatellite repeats 
on chromosome 17, four on chromosome 2, two on chromosome 6  and one on 
chromosome 3. The size of the resultant microsatellite alleles were then compared to 
those from the cell line from which the sub-clones had originated. The microsatellite 
repeat loci on chromosomes 17,2 and 3 were those used previously in the analysis of the 
drug resistant cell lines. The four loci from chromosome 17 were all (CA)n repeats and 
were chosen by the fact that the had consistently amplified well by PCR. Three of the 
repeats ( CHRNB1, D17S183 and D17S351 ) had all shown microsatellite mutations in 
A2780/cp70 as compared to the A2780 locus. D17S796 had shown the same sized 
repeat in both cell lines. Figure 3.4 shows the microsatellite repeats D17S796 and 
D17S183 at the fifteen A2780 sub-clones, as well as in the original A2780 clone from 
which they were derived. The sub-clones are marked as A2780 p i to pl5. In D17S796 
the heterozygous nature of the repeat is observed in all the lanes, with fainter stutter 
bands observed around a distinct band representing the microsatellite allele. A similar 
picture is observed at microsatellite D17S183. Taking into account minor artefactual 
variations there is no evidence of any microsatellite mutation having occurred in any of 
the A2780 sub-clones as compared to the original clone. Analysis of all eleven 
microsatellite repeats in the A2780 sub-clones did not detect any alterations in the size 
of the repeats as compared to the original A2780 clone ( table 3.2).
Analysis of A2780/cp70 and the twenty sub-clones isolated from it was 
performed in the same manner using the panel of eleven microsatellite repeat sequences. 
The results of amplifying the A2780/cp70 sub-clones at the microsatellite loci D17S183 
and D17S796 are demonstrated in Figures 3.5. With D17S183 all but two of the sub­
clones have produced products after PCR. The size of the microsatellite alleles in this 
heterozygous locus are identical to that of the original A2780/cp70 line ( as indicated by 
the arrows ) in all but two of the sub-clones; numbers 6  and 20. In these two lines there 
is an identical reduction in the size of the smaller allele of the repeat by one repeat unit 
length. More typical of the results seen with the A2780/cp70 sub-clones, locus D17S796
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D17S183
A T G C 1 2  3 4 5 6  7 8  9 1 0  11 1 2  13 1415 16
D17S796
Figure 3.4 Analysis of random A2780 sub-clones for microsatellite mutation.
P C R  a m p l i f i c a t io n  o f  D 1 7 S 1 8 3  a n d  D 1 7 S 7 9 6  m ic r o s a t e l l i t e  l o c i  in  D N A  fr o m  f i f t e e n  r a n d o m ly  
i s o la t e d  s u b - c lo n e s  o f  A 2 7 8 0 .  N o  d i f f e r e n c e  is  o b s e r v e d  in  th e  s i z e  o f  th e  m ic r o s a t e l l i t e  a l l e l e s  
b e t w e e n  a n y  o f  th e  s u b - c lo n e s  o r  w it h  p a r e n ta l  A 2 7 8 0  D N A .  S u b - c l o n e  5  in  D 1 7 S 7 9 6  d id  n o t  
a m p l if y .
T h e  M 1 3  p h a g e  s e q u e n c e  la d d e r  a l l o w s  a c c u r a te  c o m p a r is o n  o f  a l l e l e  s i z e s .
Legend A ,T ,G ,C ,  M 13 p h a g e  s e q u e n c e  la d d e r
L a n e  1 - 1 5  S u b - c l o n e s  o f  A 2 7 8 0
L a n e  1 6  p a r e n ta l  A 2 7 8 0
A T G C 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 A2780
D17S183
T A G C 1 2 3 4 5 6  7 8 9 10 11 12 13 14 15 16 17 18 19 20  FP70
D17S796
Figure 3.5 Analysis of random A2780/cp70 sub-clones for microsatellite mutation
P C R  a m p l if i c a t io n  o f  D 1 7 S 1 8 3  a n d  D 1 7 S 7 9 6  m ic r o s a t e l l i t e  lo c i  in  D N A  fr o m  t w e n t y  r a n d o m ly  
i s o la t e d  s u b - c lo n e s  o f  A 2 7 8 0 / c p 7 0 .  E v id e n c e  o f  m u ta t io n  c a n  b e  o b s e r v e d  in  s u b - c lo n e s  b y  
c o m p a r i s o n  w ith  th e  s i z e  o f  th e  m ic r o s a t e l l i t e  a l l e l e s  in  p a r e n ta l A 2 7 8 0 / c p 7 0 ,  ( A 2 7 8 0 / c p 7 0  
a l l e l e  s i z e ,  in  D 1 7 S 1 8 3 ,  i s  r e p r e s e n te d  b y  a r r o w s  ) . S u b - c lo n e s  1 2  &  18 in  D 1 7 S 1 8 3  d id  n o t  
a m p l if y  w ith  P C R .
Legend A ,T ,G ,C ,  M 13 p h a g e  s e q u e n c e  la d d e r .
L a n e s  1 -  2 0  S u b - c lo n e s  o f  A 2 7 8 0 / c p 7 0
A2780 sub-clones
CHRNB-1 D17S351 D17S183 D17S796 D2S172 D2S111
0/15 0/15 0/15 0/15 0/15 0/15
D2S123 D2S121 D6S311 D6S274 D3S1296
0/15 0/15 0/15 0/15 0/15
A2780/cp70 sub-clones.
CHRNB-1 D17S351 D17S183 D17S796 D2S172 D2S111
15/20 15/19 2/18 15/20 N/D 11/11
D2S123 D2S121 D6S311 D6S274 D3S1296
17/18 ND 17/18 ND 19/19
Table 3.2. Incidence of microsatellite mutation in independent, non-selected, 
sub-clones of A2780 and A2780/cp70.
DNA from 15 random sub-clones of A2780 and 20 random sub-clones of A2780/cp70 was 
amplified, by PCR, using primers specific for the microsatellite repeat sequences indicated. The 
numerator for each microsatellite locus indicates the number of sub-clones displaying mutation 
in the size of the microsatellite repeat. This is by comparison to the microsatellite in the parental 
cell line. The denominator represents the number of sub-clones for which assessable data was 
obtained.
ND = data not obtained for this microsatellite locus.
reveals an extremely high degree of microsatellite mutation as compared to the original 
line. Five of the sub-clones retain the same allele sizes as A2780/cp70 whereas the 
remaining fifteen show type I ( e.g. sub-clone 18 ) or type II ( e.g. sub-clone 6  ) 
mutations. With most of the sub-clones the mutation only occurs in one allele and this is 
most commonly in the larger allele. This phenomenon of more frequent mutation 
occurring in the larger allele of a heterozygous locus was also observed by Orth et al. 
(Orth et al. 1994) when looking at sub-clones of an ovarian carcinoma cell line with a 
chromosome 17 specific microsatellite. Sub-clone 14 shows an alteration in the size of 
both microsatellite alleles, both being increased in size, whereas in all other cases the 
mutation occurs in only one allele. A high frequency of alterations in the size of the 
microsatellite alleles in the A2780/cp70 sub-clones was observed at all the other loci 
studied, (Table 3.2).
Therefore, to summarise the results obtained from sub-clone analysis from 
A2780 and A2780/cp70; no size alterations in the microsatellite repeats was observed in 
the 165 loci studied in A2780 sub-clones. With A2780/cp70 sub-clones, however, over 
70% of the microsatellite loci analysed showed evidence of mutation. It would therefore 
appear that A2780 does not possess a phenotype of microsatellite instability which 
would suggest from the results with A2780/cp70 and A2780/AD ( Table 3.1) that the 
instability seen in these lines has arisen at some point in their derivation from the parent 
line. The high frequency of mutation seen with A2780/cp70 sub-clones would tend to 
confirm the presence of a microsatellite instability phenotype associated with this cell 
line.
3.2.4 Characterisation of the role of p53 in development of microsatellite
instability in A2780 derived cell lines.
The demonstration that the phenotype of microsatellite instability, also classified 
as a replication error ( RER+) phenotype, was acquired by the cisplatin and doxorubicin
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resistant derivatives of A2780 during their development, raised the question of how 
such a change in genomic stability had arisen. The p53 tumour suppressor gene is 
known to be involved in maintaining the integrity of genomic DNA prior to entry into 
S-phase or mitosis . Mutations in the p53 gene are associated with an increase in 
genomic instability usually in the form of aneuploidy, damaged chromosomes or gene 
amplification (Tainsky et al. 1995). A2780 has been shown to possess functionally 
normal p53 with wild type sequence whereas, although A2780/cp70 has wild type 
sequence it displays abnormal p53 function (Brown et al. 1993). The possibility arose, 
therefore, that the RER+ phenotype observed in A2780/cp70 was a variant of genomic 
instability consequent on the abnormal p53 function.
The dominant negative effect displayed by mutants of p53 on wild-type protein 
function, was used to determine whether p53 mutation could play a role in the 
development of an RER+ phenotype in A2780/cp70. p53 cDNA under the control of a 
CMV promoter, and containing a mutation at codon 143 resulting in the substitution of 
alanine for valine (Baker et al. 1990), has previously been stably transfected into A2780 
cells by calcium phosphate precipitation (Brown et al. 1993). Transfection of this 
particular mutant p53 into cells containing wild-type p53, has been shown to abolish the 
G1 arrest occurring after ionising radiation and has been suggested to act in a dominant 
negative manner to inactivate the wild-type p53 function (Kuerbitz et al. 1992). It was 
hypothesised that, if loss of p53 function was in some way responsible for the 
development of an RER+ phenotype, then these mutant p53 transfectants should display 
evidence of microsatellite instability when compared to wild-type A2780. The RER+ 
status of the mutant p53 transfected A2780 was determined by analysis of seven 
microsatellite repeat sequences, in fourteen random non-selected sub-clones of the 
original transfected line. These sub-clones have been shown to express mutant p53 by 
ELISA and to have defective p53 function by loss of inhibition of DNA synthesis after 
ionising radiation (Mcllwrath et al. 1994a). The results from two of the microsatellite 
repeat loci, D17S796 and D17S351, are displayed in Figure 3.6. There is no evidence of
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D17351
A T G C 1 2 3 4 5 6 7 8 9 10 11 12 13 14
D17S796
Figure 3.6 A n a l y s i s  o f  t h e  e f f e c t  o f  m u t a n t  p 5 3  o n  m i c r o s a t e l l i t e  s t a b i l i t y  in  A 2 7 8 0 .
P C R  a m p l if ic a t io n  o f  m ic r o s a t e l l i t e  lo c i  a t D 1 7 S 3 5 1  a n d  D 1 7 S 7 9 6 ,  in  D N A  fr o m  1 4  m u ta n t  p 5 3  
t r a n s fe c ta n ts  o f  A 2 7 8 0 .  E a c h  o f  th e  t r a n s fe c ta n t s  h a s  b e e n  s h o w n  to  e x p r e s s  m u ta n t  p 5 3  a n d  
h a v e  d e f e c t i v e  p 5 3  f u n c t io n .  N o  e v i d e n c e  o f  m ic r o s a t e l l i t e  m u ta t io n  is  o b s e r v e d  b e t w e e n  th e  
t r a n s fe c ta n t s ,  a ll  o f  w h ic h  h a v e  id e n t ic a l  m ic r o s a t e l l i t e  a l l e l e s  to  p a r e n ta l A 2 7 8 0 .
Legend A ,T ,G ,C , M 13 p h a g e  s e q u e n c e  la d d e r .
L a n e s  1 - 1 4  M u ta n t  p 5 3  t r a n s fe c ta n ts  o f  A 2 7 8 0 .
alteration in the size of the microsatellite repeat alleles in either of these loci, when 
compared to the wild-type A2780. Table 3.3 shows that no evidence of mutation was 
found in the mutant p53 transfectant clones at any of the seven microsatellite repeat loci. 
The lack of microsatellite instability in cells with no functioning p53 suggests that it is 
not responsible for this form of genomic instability.
Microsatellite loci
CHRNBl D17S181 D17S183 D17S796 D6S311 D2S172 D2S121
0/13 0/14 0/14 0/14 0/13 0/8 0/10
Table 3.3 Incidence of microsatellite mutation in clones of A2780 
transfected with mutant p53.
Numerator in each lane represents number of mutant microsatellite alleles detected compared 
to wild type A2780. Denominator represents number of clones for which results obtained.
3.2.5 Incidence of microsatellite mutation in A2780 cell lines selected for 
resistance by single exposure to cisplatin.
A2780/cp70 cells have been repeatedly grown in culture since their initial 
derivation. It is possible that the development of the RER+ phenotype arose during 
prolonged growth in culture and was not directly related to the selection for resistance to 
cisplatin. To examine whether a relationship existed between acquisition of an RER+ 
phenotype and selection for resistance to cisplatin in A2780 cells, cells selected for 
cisplatin resistance by a single drug exposure were used. It has been shown previously 
that single step selection protocols reliably and quantitatively select for resistant cells in
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a population (Thacker and Stretch, 1985). Clonogenic analysis of A2780 cells, given a 
single 24 hour exposure to cisplatin concentrations of between 15 pM and 30pM, has 
suggested the existence of a sub-population of resistant cells which appear as a tail on 
the survival curve (McLaughlin et al. 1991). It has subsequently been shown that these 
cells are, most probably, resistant due to the development of stable genetic mutations 
and that the resistant phenotype was maintained after growth in the absence of drug 
selection (McLaughlin et al. 1991). The advantage of using such single-step selected 
resistant clones is that, due to the short selection process, they have not had the 
opportunity to diverge genetically any more than, for example, the non-selectively 
isolated sub-clones of A2780 used in section 3.2. Therefore the identification of 
phenotypic differences in the resistant cells, as compared to parental A2780, are likely 
to correlate more strongly to the development of cisplatin resistance and not represent 
an epiphenomenon.
DNA was obtained from eleven previously derived single step selected, cisplatin 
resistant, A2780 clones (A2780/SCP1 to SCP11 ) (McLaughlin et al. 1991). These had 
been selected by a single exposure to 15pM cisplatin for 24 hours. PCR amplification 
was then performed using primers for ten microsatellite loci, four on chromosome 17, 
three on chromosome 2 and three on chromosome 6 . During the initial investigation of 
the single-step selected clones it became clear that A2780/SCP11 was in fact the same 
line as A2780/SCP5 but was included in subsequent analyses to control for 
reproducibility.
Of the eleven A2780/SCP clones only three displayed microsatellite mutation. 
Two of the clones, A2780/SCP2 and SCP5, showed an alteration in the size of the 
CHRNB1 microsatellite repeat on chromosome 17 as shown in figure 3.7(a). The 
increase in the size of the larger allele observed in A2780/SCP5 is also seen with SCP11 
( not shown ). Multiple microsatellite mutations at loci on all three chromosomes 
studied were observed with A2780/SCP6. Figure 3.7 (a-d) shows the alterations seen at 
CHRNB1, D17S796, D2S172 and D6S261 when comparing A2780/SCP6 with A2780.
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Figure 3.7 Mutations at microsatellite loci in A2780/SCP cell lines.
PCR amplification of microsatellite loci D17S796, CHRNB1, D2S172 and D6S261 in cisplatin 
resistant A2780/SCP cell lines. These lines were derived from A2780 by a single exposure to 
15pM cisplatin for 24 hours. Alterations in the size of microsatellite alleles compared to those in 
A2780 are indicative of mutation.
Legend
D17S796 & CHRNB1:- Lanes 1 & 5:- A2780; Lane 2:- A2780/SCP2
Lane 3:- A2780/SCP5; Lane 4:- A2780/SCP6.
D2S172: Lane:- (1) A2780/SCP1; (2) A2780/SCP2; (3) A2780/SCP3; (4) A2780/SCP4;
(5) A2780/SCP2; (6) A2780/SCP5; (7) A2780/SCP6; (8) A2780/SCP7;
(6) A2780/SCP8; (10) A2780/SCP9; (11) A2780/SCP10; (12) A2780/SCP6* 
(13) A2780
D6S261: Lane:- (1) A2780/SCP ; (2) A2780/SCP ; (3) A2780/SCP6; (4) A2780/SCP6*
(5) A2780/SCP ; (6) A2780/SCP; (7) A2780/SCP ; (8) A2780/SCP ; 
(9)A2780/SCP ; (10) A2780/SCP ; (11) A2780/SCP ; (12) A2780 .
A2780/SCP6* represents DNA extracted from a later passage of the A2780/SCP6 cell line.
D17S796 CHRNB1
A T G C 1  2 3  4 5  6 7 8 9  10 11 12 13
D2S172
A T G C 1 2 3 4 5 6  7 8 9  10 11 12
D6S261
IIt
In amplification of the microsatellite loci on chromosome 2 and 6 a second, 
independently extracted, sample of A2780/SCP6 DNA was amplified to ensure the 
reproducibility of the observed mutations. The results of all the microsatellite loci 
amplified in the A2780/SCP clones is presented in table 3.4, although the data from the 
repeat sample of A2780/SCP6 and from A2780/SCP11 is left out of the final analysis. 
Of the ten single-step selected clones studied, seven showed no change in the size of 
microsatellite repeat length at any of the ten microsatellite loci when compared to the 
parental A2780. A2780/SCP2 and A2780/SCP5 both display a microsatellite mutation 
at just one locus. An alteration in the size of a microsatellite repeat allele is observed in 
six of the ten loci studied with the A2780/SCP6 cell-line. This high frequency of 
microsatellite mutation is consistent with A2780/SCP6 displaying an RER+ phenotype 
as classified by accepted criteria (Thibodeau et al. 1993). Although showing 
microsatellite mutation at one locus, A2780/SCP2 and SCP5 do not, with respect to the 
information obtained, fulfil the RER+ criteria. The data presented in this section, 
therefore, indicates that an RER+ phenotype can be selected for, along with that of 
cisplatin resistance, by a single exposure to a high concentration of the drug.
3.3 DEVELOPMENT OF CISPLATIN RESISTANT A2780 CELL-LINES BY 
SELECTION AGAINST INCREASING CONCENTRATIONS OF 
CISPLATIN.
The data presented in the previous section suggests an association between 
cisplatin resistance in A2780 cells and the development of an RER+ phenotype. To 
enable further analysis of this proposed association a new set of cisplatin resistant 
derivatives were developed from a clonal population of A2780 cells ( for detailed 
method see chapter 2.8.2 ). Starting with a clonal population of A2780 should reduce 
the influence that genetic differences between the cells have on the development of a 
resistant phenotype. Variations in the drug induced selection pressure on each cell line 
were kept to a minimum by running each drug selection in parallel. The concentration of
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cisplatin used for the initial drug selection was that which had been shown previously to 
give a surviving fraction of between 20% and 30% for A2780 (McLaughlin et al. 1991). 
This was a drug exposure of lpiM cisplatin for 24 hours. Further steps of selection 
against increasing doses of cisplatin were performed to a final exposure of 15pM 
cisplatin for 24 hours. At this stage the surviving cells in each of the nine derived lines ( 
A2780/MCP1-9 ) were maintained in cisplatin free medium, with frozen stocks being 
suspended in medium containing 10% DMSO.
3.4 MEASUREMENT OF LEVEL OF RESISTANCE TO CISPLATIN IN
A2780 DERIVED CELL-LINES.
Correlation of the development of an RER+ phenotype with selection for drug 
resistance in A2780 requires not only evidence of microsatellite instability but also 
proof of stable resistance to cisplatin in the derived cell lines. To this end the resistance 
to cisplatin of the A2780 derived lines; A2780/cp70, A2780/MCP1 to MCP9 and 
A2780/SCP5, 6  and 3 were determined and compared to the parental line. Two different 
techniques were used in analysis of the cisplatin resistance of the A2780 derived lines.
3.4.1 Clonogenic cell survival assay.
One method of determining the level of cisplatin resistance of the derived A2780 
cell-lines is to assay cell survival after exposure to cisplatin. This assay depends on the 
demonstration of the reproductive integrity of the surviving cells, as evidenced by 
clonogenicity. To increase the information on cisplatin resistance obtained by this 
analysis two different cisplatin exposures were used in the clonogenic assay. One set of 
data were obtained using exposure to a high concentration of cisplatin over a short 
period of time ( 20pM for 1 hour). There is some evidence that this may be similar to 
the drug exposure experienced by tumour cells in vivo after intra-venous administration
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(Wilson, 1992). The other data was obtained using exposure to a lower concentration of 
cisplatin for a longer period of time ( lpM  for 24 hours ). Three separate clonogenic 
assays were performed using the lower cisplatin exposure and two assays at the higher 
exposure. Determination of the stability of any cisplatin resistance observed, under 
growth in the absence of a selection pressure, was also attempted. To this end, for a 
particular level of cisplatin exposure, each successive clonogenic assay performed on an 
individual cell-line used cells that had undergone further growth in the absence of 
cisplatin.
The cumulative data on all clonogenic survival assays is presented in Figure 3.8 
and in Table 3.5. Figure 3.8(a) displays, in diagrammatic form, the fraction of cells 
surviving exposure to lpM  cisplatin / 24 hours compared to non-treated cells for cell 
lines A2780, A2780/cp70 and A2780/MCP1 to MCP9. Each column represents the 
mean of three experiments, consisting of at least 4 plates per cell line. A2780 shows the 
smallest surviving fraction indicating that it is more sensitive to the cytotoxic effects of 
this concentration of cisplatin than are the other lines. A2780/cp70 cells exposed to 
cisplatin show no significant difference in survival as compared to no drug controls. It 
also displays the highest surviving fraction of any of the cell lines suggesting that it 
possesses the greatest resistance to this level of cisplatin exposure. The difference in 
survival between A2780/cp70 and A2780 cells at lp.M cisplatin / 24 hours is highly 
significant using paired t-test analysis ( p = 0.001 ). The A2780/MCP cell lines have 
surviving fractions intermediate between A2780 and A2780/cp70 indicating that they 
have greater resistance to this level of cisplatin exposure than A2780. A2780/MCP6 
displays the greatest surviving fraction whilst A2780/MCP9 displays the least, although 
this is still approximately 50% greater than that for A2780. Using the paired t-test 
method the difference in surviving fraction between each of the A2780/MCP cell lines 
and A2780 is highly significant ( p values all < 0.001).
The mean surviving fractions of the cell lines after exposure to 20pM cisplatin / 
1 hour is displayed in figure 3.8(b). A2780 is again the most sensitive cell-line to this
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1 2 3 4 5  6 7 8 9  10 11 
Clonogenic survival assay ( 20uM cisplatin /1 hr)
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A2780/cp70 2
A2780MCP1 3
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Figure 3.8 C l o n o g e n i c  d e t e r m i n a t i o n  o f  c i s p l a t i n  r e s i s t a n c e  in  A 2 7 8 0  a n d  d e r i v e d  c e l l  l i n e s .
F or e a c h  c e l l  l in e  th e  m e a n  s u r v iv a l  fr a c t io n  w a s  d e te r m in e d  b y  c o m p a r in g  th e  n u m b e r  o f  
c o lo n ie s  fo r m e d  in  r e p lic a te s  o f  c is p la t in  trea ted  c e l l s  c o m p a r e d  to  n o n -tr e a te d  c o n tr o ls .  
E rror b ars r e p r e s e n t  o n e  s ta n d a rd  error o f  th e  m e a n .
level of cisplatin although with about three times less cells surviving than for the lp,M 
cisplatin exposure. The mean surviving fraction to 20pM cisplatin / 1 hour is reduced 
for all of the cell-lines, suggesting that this cisplatin exposure was more cytotoxic to the 
A2780 derived cells than lpM  over 24 hours. As before, A2780/cp70 shows the greatest 
surviving fraction whilst the A2780/MCP cell lines display surviving fractions 
intermediate between that of A2780 and A2780/cp70. Therefore, at this different level 
of cisplatin exposure the A2780/MCP cell lines display greater resistance than A2780. 
The surviving fraction of each replicate, of each cell line exposed to 20 pM cisplatin /1  
hour, was compared by paired t-test analysis to that of the replicates of A2780. The 
differences in surviving fraction observed were all highly significant ( p < 0.001).
The relative resistance to cisplatin for each of the cell-lines when compared to 
A2780 is shown in Table 3.5. This, as would be expected, confirms the data in figure 
3.8 and shows that A2780/cp70 has the highest degree of resistance to cisplatin at both 
levels of exposure. The differences in relative resistance between the A2780/MCP cell- 
lines tend to be similar at both levels of cisplatin exposure. Cell-lines with low fold 
resistance to lpM  cisplatin also tend to be amongst those with the lowest fold resistance 
to 20pM cisplatin, e.g. A2780/MCP3. Those with the highest fold resistance at lpM  
cisplatin also tend to be among the highest at 20pM cisplatin, e.g. A2780/MCP8. The 
mean plating efficiency was also calculated for the no-drug controls of each cell-line. 
Although there was a degree of variation, for most cell-lines it was in the range of 25 - 
45%. In view of this there was no evidence that the results were influenced by the poor 
plating efficiency of cells in any particular cell-line.
3.4.2 MTT cell viability assay.
The results presented in the previous section indicate that the A2780/MCP cell 
lines are more resistant to cisplatin than the parental cell line, though not to the same 
degree as A2780/cp70. However, this data has been obtained using only two different
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levels of cisplatin exposure. To further compare the differences in cisplatin resistance 
between the A2780/MCP cell lines and A2780, the sensitivity of cells from each line to 
a wide range of concentrations of cisplatin was measured. The eight different 
concentrations of cisplatin used consisted of serial 5-fold dilutions starting from 10'4 M. 
From the data obtained in each of these assays a graph of dose versus response to 
cisplatin can be plotted.
To characterise the curves of dose versus response for each of the cell-lines a 
non-clonogenic method, the MTT assay, was utilised. The reasons for this were 
essentially practical. To calculate dose/response curves using clonogenic assays for 
multiple cell-lines is logistically difficult, with regards to the culture of multiple 
replicates of each line for each drug concentration. The common answer to this problem 
is to perform the assay in batches of cell-lines. This can lead to differences in the exact 
amount of drug that the cells are exposed to due to batch to batch variation in stock 
solutions of the drug. This could be a particular problem with cisplatin as it has a low 
solubility in water at room temperature. Thus the ability to expose all replicates of the 
different cell-lines to the same batch of drug, at the different concentrations required, 
would remove this source of variation. The MTT assay makes this approach feasible. 
One theoretical drawback of non-clonogenic assays of drug resistance is that they 
cannot differentiate between cytostatic and cytotoxic effects of the drug. A clonogenic 
assay is dependent on the survival of cells with the ability to grow and divide in a clonal 
manner. Non-clonogenic assays often determine the viability of a cell, after exposure to 
a cytotoxin, by using a metabolic end-point. Cytotoxic drugs may slow the metabolic 
processes in a cell without killing it and hence lead to an overestimation of the 
resistance of a cell-line. This may be less of a worry when using cisplatin as the effects 
on tumour cells produced tend to be mainly cytotoxic.
The M.T.T. assay was used to determine the viability of the different cell-lines
4 9after exposure, for 24 hours, to cisplatin concentrations ranging from 10’ M to 10" M. 
Only metabolically viable cells can reduce the yellow M.T.T. dye to a purple Formazan
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product, whose concentration can be measured spectroscopically. For each cell-line, 
control cells to which no drug was added were included to allow calculation of the 
relative survival of viable cells. Figure 3.9 shows the dose/response curves for A2780, 
A2780/cp70 and all of the A2780/MCP cell-lines. Each curve represents the mean 
values obtained from one experiment with eight repeats per drug concentration. At very 
low concentrations of cisplatin there is a high level of cell survival with wide overlap 
between different lines. Very high concentrations of cisplatin ( e.g. O.lmM ) are 
uniformly lethal for all the cell-lines. However, in the range of exposure from 0.16pM 
to 20pM cisplatin for 24 hours it can be seen clearly that the curves for A2780 and 
A2780/cp70 are separate and distinct from those of the A2780/MCP lines. A2780 shows 
the lowest cell survival across this range of cisplatin concentrations and there is no 
crossing-over with the plots of the other cell-lines. A similar situation is observed for 
A2780/cp70 except that it shows the highest levels of cell survival. The curves for the 
A2780/MCP cell-lines show levels of cell survival intermediate between that for the 
other two lines, confirming that they have developed resistance to cisplatin by the 
selection protocol although not to the level seen with A2780/cp70. There is a reasonable 
degree of overlap between the curves for the A2780/MCP cell-lines at these cisplatin 
concentrations. The standard errors have been calculated for the mean cell survival at 
each drug concentration in each of the cell lines. They suggest that the differences in 
cell survival, i.e. the resistance, seen between A2780 and A2780/cp70 is significant as 
there is no overlap between the error bars representing the standard error. This can also 
be seen for A2780 and the A2780/MCP cell lines. To confirm that the differences in 
resistance observed between the cell lines is statistically significant data from one 
particular drug dose point ( 1.6 x 10’ M )was chosen. The relative cell survival as 
compared to controls was calculated for each replicate in each of the cell lines. A one­
sided, paired t-test was then used to compare the data from each of the cell lines as 
compared to A2780. The results from the A2780/cp70 and A2780/MCP cell lines all 
displayed highly significant results ( p < 0.01 ) suggesting that the differences in cell 
survival observed are real and not arising by chance.
8 6
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A2780/cp70
A2780MCP1
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Figure 3 . 9  C i s p l a t i n  d o s e  /  r e s p o n s e  c u r v e s  f o r  A 2 7 8 0 ,  A 2 7 8 0 / e p 7 0  a n d  A 2 7 8 0 / M C P  
c e l l  l i n e s .
C i s p l a t i n  d o s e / r e s p o n s e  c u r v e s  f o r  A 2 7 8 0 ,  A 2 7 8 0 / c p 7 0  a n d  A 2 7 8 0 M C P  l i n e s  d e r i v e d  u s i n g  
M T T  v i a b i l i t y  a s s a y s .  M e a n  s u r v i v a l  f r a c t i o n  c a l c u l a t e d  b y  d i v i d i n g  m e a n  v a l u e  o f  8  r e p e a t  
a s s a y s  a t  e a c h  d r u g  c o n c e n t r a t i o n  b y  t h a t  f o r  n o  d r u g  c o n t r o l .
E r r o r  b a r s  r e p r e s e n t  + / -  o n e  s t a n d a r d  e r r o r  o f  m e a n .
One commonly used method of comparing the data on cellular drug sensitivity 
from dose/response curves in a numerical form is by calculating ID50 values. This 
represents the concentration of cisplatin required to inhibit cell viability by 50% and is 
calculated by determining the drug concentration that reduced cell survival to 50% of 
that seen in controls. The ID50 values for the set of dose/response curves from one cell 
viability assay are displayed in Table 3.6 along with the relative resistance compared to 
A2780. The mean relative resistance calculated from the results of all the M.T.T. assays 
is also included. It can be seen that A2780/cp70 displays a much higher relative 
resistance ( approximately 20 fold ) using this type of assay compared with the 
clonogenic assay. However this level of resistance is characteristic of A2780/cp70 under 
these assay conditions (Plumb et al. 1993). The mean of the relative resistance for the 
A2780/MCP lines ranges from 4.1 to 7.3. This data again demonstrates the development 
of a stable cisplatin resistant phenotype by the A2780/MCP cell-lines as compared to 
the cell of origin, A2780.
Concurrent with the determination of the dose/response curves to cisplatin for 
the A2780/MCP cell-lines those of three of the A2780/SCP lines were also derived. 
Two of the lines that had displayed evidence of microsatellite mutation, A2780/SCP5 
and SCP6, were studied along with A2780/SCP3 which had shown no microsatellite 
changes. The cisplatin resistance of these cell-lines had been characterised previously 
(McLaughlin, 1991) and all of the lines had displayed a low fold resistance relative to 
A2780. However, it was possible that the phenotype of resistance could have been 
altered over the period since the lines were originally derived. In view of the alteration 
in phenotype observed in A2780/SCP5, SCP6 and SCP2, displayed by microsatellite 
mutation, it was felt to be prudent to confirm that the SCP lines retained their resistance 
to cisplatin. Figure 3.10 represents the dose/response curves for A2780, A2780/cp70 
and A2780/SCP3, SCP5 and SCP6. The three A2780/SCP lines have curves that lie 
intermediate between those for A2780 and A2780/cp70, although closer to that of the 
former but with no overlap. As can be seen in Table 3.6 the A2780/SCP cell lines show
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b y  d i v i d i n g  t h e  m e a n  v a l u e  o f  8  r e p e a t s  f o r  e a c h  d r u g  c o n c e n t r a t i o n  b y  t h a t
f o r  t h e  n o  d r u g  c o n t r o l .  E r r o r  b a r s  r e p r e s e n t  + / -  o n e  s t a n d a r d  e r r o r  o f  t h e  m e a n .
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2 to 3 fold resistance to cisplatin over A2780 by comparison of ID50 values for this set 
of dose/response curves. The mean relative resistance from two MTT assays confirms 
this low fold resistance to cisplatin. Use of the data for each of these cell lines at the
• -7cisplatin dose of 1.6 x 10" M allows calculation of the relative cell survival as before. 
Using this in a paired t-test it can be shown that, when compared to A2780, the 
increased levels of cell survival for A2780/SCP3 and SCP6 are significant ( 0.001 < p < 
0.05 ). In the case of A2780/SCP5 the difference approaches statistical significance ( 0.1 
> p > 0.05 ).
3.5 DETERMINATION OF THE FREQUENCY OF MICROSATELLITE
MUTATION IN CISPLATIN RESISTANT A2780/MCP CELL-LINES.
Having established that the A2780/MCP cell-lines displayed a stable cisplatin 
resistant phenotype it was important to determine whether they had also acquired an 
RER+ phenotype as characterised by microsatellite instability. DNA was isolated from 
all of the A2780/MCP cell-lines. Using a similar set of PCR primers to those used for 
characterisation of the A2780/SCP cell-lines, each line was investigated for alterations 
in the length of microsatellite repeats on chromosomes 17, 2 and 6. Examples of the 
resulting autoradiographs can be seen in Figure 3.11. At locus D2S111, the size of the 
microsatellite alleles observed in wild-type A2780 are represented by the two arrows. 
The alleles in A2780/MCP6, MCP7 and MCP8 are all identical to that of the parental 
cell-line. In A2780/MCP1, MCP2, MCP4, MCP5 and MCP9 there has been an increase 
in the size of the larger allele by 4bp ( 2 repeat units ) whilst in A2780/MCP3 this allele 
has decreased in size by the same amount. There is no alteration in the size of the 
smaller allele. The microsatellite repeat at locus D2S172 is homozygous but shows a 
similar pattern of mutation to that found at D2S111. Again the size of the allele found in 
parental A2780 is represented by the arrow. It would appear that A2780/MCP6 to 
MCP8 all have microsatellite repeats of identical length to that in A2780. The other
8 8
A2780/MCP cell-lines all have an increase in the size of this repeat length except for 
MCP5 and MCP3 which show decreases in size.
When analysis of the microsatellite repeats at all eleven loci studied was 
performed it was found that all but one of the A2780/MCP cell-lines displayed evidence 
for microsatellite mutation (Table 3.7 ) A2780/MCP7 was the line with no obvious 
evidence of microsatellite mutation. In the other lines the number of mutations varied 
from a single altered locus ( M CP8) to four out of eleven loci showing mutation (MCP2 
and 3 ) An interesting feature of these results is that the great majority of the mutations 
arise in microsatellite loci on chromosome 2, with only two mutated microsatellite 
repeats on chromosome 17 and none on chromosome 6. There was no particular reason 
why chromosome 2 microsatellites should be more prone to mutation in these cell-lines. 
As stated previously there are certain characteristics of microsatellite repeats that make 
it more likely that replication errors will occur. However, why such a clustering of 
mutations should occur is unclear.
These results indicate that use of a multiple-step selection protocol for isolating 
cisplatin resistant cell-lines is also associated with the selection for a phenotype of 
microsatellite instability. This occurs more frequently with selection by multiple drug 
exposures than with the single-step selected resistant cell-lines.
3.6 CHARACTERISATION OF P53 FUNCTION IN CISPLATIN
RESISTANT A2780 CELL LINES.
Of all the cisplatin resistant A2780 cell lines studied, A2780/cp70 displays the 
greatest degree of cisplatin resistance and the highest frequency of microsatellite 
instability. A2780/cp70 possesses a phenotype of resistance to a number of different 
anticancer drugs despite having been selected only for resistance to cisplatin (Vasey et 
al. 1995; Hamaguchi et al. 1993). The mechanism for this multi-drug resistance is not 
clear. It would appear not to be due to an increased expression of P-glycoprotein as
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Figure 3.11 Mutation at microsatellite loci in the cisplatin resistant A2780/MCP 
cell lines.
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there is no evidence for amplification of the Mdr gene. Of the other RER+ cell lines, 
A2780/AD (Vasey, 1996) and MCF7/AD have also been shown to display a phenotype 
of multi-drug resistance.
As previously indicated A2780/cp70 cells possess wild-type copies of the gene 
for the p53 tumour suppressor protein ( TP53 ). However, it has been shown that the 
cells display decreased levels of p53 function after a DNA damaging stimulus (Brown et 
al. 1993). A number of recent studies have revealed a relationship between functional 
integrity of p53 in tumour cells and their sensitivity to anti-cancer agents (Lowe et al. 
1994; Lowe et al. 1993). Defects in the function of p53 in certain cell types would 
appear to increase the resistance of these cells to a range of anti -cancer agents that act 
by damaging DNA. A2780/cp70 would appear to represent one cell line in which 
abnormal p53 function could be associated with the development of multi-drug 
resistance.
The expression and function of TP53 in the A2780/MCP cell lines was 
determined in order to ascertain whether they displayed TP53 defects that could be 
involved in development of cisplatin resistance.
3.6.1 Analysis of p53 protein levels expressed in A2780 and drug
resistant derivatives.
The basal levels of TP53 in A2780, A2780/cp70 and the A2780/MCP cell lines 
were compared to determine whether there were obvious differences between the cell 
lines. In general, cells which have not been exposed to a p53 inducing stimulus express 
low basal levels of p53 protein (Reich and Levine, 1984). This is due to the very short 
half-life of p53, about 20 minutes in most cell types (Levine, 1992), caused by rapid 
degradation of the protein by the ubiqitin system. Specific mutations in conserved 
domains of the p53 gene sequence can increase basal p53 levels in tumour cells (Bartek 
et al. 1990). This arises because the mutant protein has a much longer half-life in the
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cell, usually in the order of hours rather than minutes (Finlay et al. 1988). A range of 
monoclonal and polyclonal antibodies are available that react with particular epitopes of 
the p53 protein. The detection of raised levels of p53 in cells by immunohistochemistry, 
most commonly correlates with the presence of mutant p53 protein. Several studies have 
shown, however, that elevated intracellular p53 can arise from an apparently wild-type 
gene (Righetti et al. 1996a). This suggests that there may be other means, apart from 
mutation, by which p53 can be stabilised in the cell leading to abnormal function 
(Vogelstein and Kinzler, 1992). A2780/cp70 which is known to possess wild-type p53 
gene sequence has been shown to have accumulated p53 by immunoblot analysis when 
compared to A2780 (Brown et al. 1993).
In order to assess the relative basal levels of p53 in the A2780/MCP and 
A2780/cp70 cell-lines compared to A2780, a Western immunoblot assay was employed 
( for method see Chapter 2.6 ). The DO-1 antibody ( p53Ab6. Oncogene Science. 
Manhasset, N.Y. ) was used for detection of TP53 proteins on the Western membrane. 
This is a monoclonal antibody that cross-reacts with both normal and mutant forms of 
p53 at an epitope near the amino terminus of the protein (Vojtesek et al. 1992). Several 
repeats of the p53 western immunoblot were performed using newly derived extracts of 
all the cell-lines under study. As can be seen from figure 3.12, TP53 protein was 
detectable in all of the cell-lines. In agreement with previous studies A2780/cp70 shows 
a higher TP53 level than does A2780 (Brown et al. 1993). The levels of TP53 in the 
A2780/MCP cell-lines vary with regards to each other and to A2780. Laser 
densitometry of the autoradiographs, produced from each Western immunoblot, was 
performed to allow semi-quantitative analysis of the differences in basal TP53 levels 
between the cell lines. Each autoradiograph was scanned using the laser densitometer 
and the average optical density ( O.D. ) of each spot on the autoradiograph calculated 
using associated software ( Chapter 2.6, materials and methods ). The data from laser 
densitometry on five, independently performed Western immunoblots, permitted 
calculation of a mean level of basal TP53 expression. This mean value could then be
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F i g u r e  3 . 1 2 .  p 5 3  p r o t e i n  l e v e l s  i n  A 2 7 8 0  a n d  d e r i v e d  c i s p l a t i n  r e s i s t a n t  c e l l - l i n e s
E q u a l  q u a n t i t i e s  o f  c e l l  e x t r a c t  f r o m  t h e  c e l l  l i n e s  i n d i c a t e d  w e r e  s u b j e c t e d  t o  
e l e c t r o p h o r e s i s  t h r o u g h  a n  S D S - p o l y a c r y l a m i d e  g e l .  A f t e r  t r a n s f e r  t o  a  n y l o n  
m e m b r a n e  p 5 3  p r o t e i n  d e t e c t i o n  w a s  p e r f o r m e d  u s i n g  M A b  D O l .  B o u n d  a n t i b o d y  w a s  
d e t e c t e d  u s i n g  c h e m i l u m i n e s c e n c e .
T h e  f i g u r e  s h o w s  i m m u n o d e t e c t i o n  o f  p 5 3  p r o t e i n  i n  e a c h  o f  t h e  c e l l  e x t r a c t s  i n d i c a t e d .  
R e p e a t s  o f  t h e  W e s t e r n  i m m u n o b l o t  r e s u l t e d  i n  s o m e  v a r i a t i o n  i n  t h e  l e v e l s  o f  p 5 3  
s e e n  w i t h i n  a  c e l l  l i n e .  T h i s  w a s  m o s t  p r o b a b l y  a  r e s u l t  o f  v a r i a b i l i t y  i n  t r a n s f e r  o f  
p r o t e i n  t o  t h e  n y l o n  m e m b r a n e .
L e g e n d :
( 1 )  A  2 7 8 0 / c p  7 0  ( 2 )  A 2 7 8 0  ( 3 )  A  2 7 8 0 / M  C P I  ( 4 )  A  2 7 8 0 / M  C P 2
( 5 )  A 2 7 8 0 / M C P 3  ( 6 )  A 2 7 8 0 / M C P 4  ( 7 )  A 2 7 8 0 / M C P 5  ( 8 )  A 2 7 8 0 / M C P 6
( 9 )  A 2 7 8 0 / M  C P 7  ( 1 0 )  A  2 7 8 0 / M  C P 8  ( 1 1 )  A 2 7 8 0 / M C P 9
compared to that obtained for the A2780 cell line to give a relative level of basal TP53. 
This data is presented in Table 3.8. It confirms that A2780/cp70 possesses the highest 
levels of basal TP53 as compared to A2780. The variation in the basal TP53 levels in 
the A2780/MCP cell lines is also observed. However, none of the A2780/MCP cell lines 
show a statistically significant difference in the basal expression of TP53 when 
compared to A2780 ( p>0.5 ).
3.6.2 Flow cytometric analysis of cell cycle changes in cisplatin resistant
A2780 derived cell-lines after ionising radiation.
The p53 protein has a central role in two of the main responses to cellular insult, 
especially those arising through DNA damage. It is involved in the maintenance of cell- 
cycle checkpoints at the Gi/S and G2/M boundaries. The Gx/S arrest prevents cells from 
replicating damaged DNA by stopping progression through the cell-cycle prior to S- 
phase and providing more time for DNA repair (Kastan et al. 1995 ). This cell-cycle 
arrest comes about through the transcriptional activation of specific genes, such as 
W afl/Cipl, by p53 (El-Deiry et al. 1994). In many cells it would also appear to play a 
central role in the apoptotic response after DNA damage. To study the function of p53 
in the cisplatin resistant A2780 cell-lines, the ability of cells to delay replicative DNA 
synthesis after a damaging stimulus was determined. The DNA damaging stimulus used 
in these studies was ionising radiation from a Cobalt source. The use of anti-cancer 
agents such as cisplatin as the source of DNA damage would have introduced potential 
sources of variability between the cell-lines. For example, although cells would be 
exposed to the same concentration of cisplatin, variation in drug uptake and metabolism 
could result in different amounts of DNA damage being induced in each case. Without 
directly measuring the level of platinated DNA in each cell-line we would not be able to 
determine whether changes observed in the p53 function were due to differences in the 
levels of DNA damage. With ionising radiation the problems of uptake and metabolism
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Cell line Relative p53 
protein level.8
Percentage of 
apoptotic cells.b
Relative CIP1 
mRNA levels.0
A2780 1 22 1
A2780/cp70 1.66 (+/- 0.5) 1 0.29
A2780/MCP1 1.36 (+/- 0.5) 4 0.52
A2780/MCP2 0.81 (+/- 0.35) 2 0.55
A2780/MCP3 1.03 (+/- 0.3) 1 0.32
A2780/MCP4 1.01 (+/- 0.45) 1 0.58
A2780/MCP5 1.35 (+/- 0.6) 8 0.33
A2780/MCP6 0.72 (+/- 0.2) 7 0.49
A2780/MCP7 1.03 (+/- 0.3) 20 0.95
A2780/MCP8 0.92 (+/- 0.25) 1 0.66
A2780/MCP9 0.64 (+/- 0.25) 1 0.56
Table 3.8 Analysis of p53 dependent variables in A2780 and cisplatin resistant 
derived cell lines.
Comparison of basal TP53 protein expression and two indicators of basal p53 function in 
parental A2780, A2780/cp70 and A2780/MCP1 - MCP9.
Legend
a. p53 protein level, relative to A2780, as determined by laser densitometry of autoradiographic 
images. Protein detected by Western immunoblot using DOl antibody. Mean of 5 experiments 
( +/- one standard error).
b The percentage of total cells undergoing apoptosis 72hrs after treatment with
40|IM cisplatin as detected by flow cytometry of fluorescently labelled DNA strand breaks.
Values show means of duplicate experiments with 15,000 cells counted per experiment.
Data supplied by A. Mcllwrath. Dept Medical Oncology. Glasgow University. 
c. Relative basal levels of Cipl mRNA determined by Northern blot analysis by hybridisation to 
Cipl cDNA probe. Standardisation was by rehybridisation against G3PDH probe.
Data supplied by L. Gallagher. Dept. Medical Oncology. Glasgow University.
do not apply and it is assumed that each cell receives an equivalent level of DNA 
damage.
To evaluate the changes in cell cycle progression after ionising radiation a 
simultaneous flow cytometric analysis of DNA content and DNA synthesis ( determined 
by propidium iodide staining and BrdUrd incorporation respectively) was made. The 
use of pulses of BrdUrd and the ability of flow cytometry to analyse single cells 
provides a dynamic assessment of the cell cycle. Using this method the fraction of cells 
in G l, S, and G2/M phases can be easily measured and distinctions can be made 
between a Gl arrest and an S-phase arrest (Kastan et al. 1991a). In the protocol used ( 
see Chapter 2.9.2) 5 x 105 cells, of each cell-line, were plated in duplicate for irradiated 
and control end-points. Flow cytometry was carried out on a fluorescence activated cell 
sorter (FACS). For each sample at least 20,000 cells were counted and a histogram of 
total DNA content versus replicated DNA plotted using appropriate software. The 
different phases of the cell cycle ( G l, S, G 2) can be identified on the histogram and the 
effects of exposure to ionising radiation, on progression through the cell cycle, can also 
be visualised. In the A2780 control cells the progression from G l, through S-phase to 
G2 can be clearly seen ( figure 3.13(a) ). After ionising radiation there is a decrease in 
the number of cells in S-phase in A2780 ( figure 3.13(b) ) and an accumulation of cells 
in G2. This is consistent with the possession of functional p53 which acts to prevent 
cells entering S-phase. The A2780/cp70 controls show similar progress through the cell 
cycle to that seen with A2780 ( figure 3.13(c) ). However, after irradiation a much 
higher proportion of cells continue to progress into S-phase, ( figure 3.13(d) ). As an 
example of an A2780/MCP cell-line, A2780/MCP9 cells also show evidence of a 
reduction in new DNA synthesis after irradiation and an accumulation of cells in Gl and 
G2 phases of the cycle, ( figures 3.13(e) & (f)).
The percentage of cells in each phase of the cell cycle for the cell-lines 
displayed is shown in the table in figure 3.13. This confirms that;
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Figure 3.13 Changes in cell cycle dynamics in A2780 and derived cell-lines after 
irradiation
Cell-cycle histograms are displayed for control and post-irradiation cells in each of 
A2780, A2780/cp70 and A2780/MCP9 lines. Cell cycle analysis was accomplished by
i
flow cytometric measurement of cells after bromodeoxyuridine ( BrdUrd ) incorporation, 
during a 4h pulse, and propidium iodide ( P I ) staining. The different components of the 
cell cycle can be differentiated on the histogram as indicated in (a). The percentage of 
cells in each part of the cycle can then be determined.
After irradiation there is a decrease in the number of cells entering S-phase in A2780 
whereas in A2780/cp70 there is no significant difference over control. A2780/MCP9 
shows some degree of decreased entry into S-phase.
Figure 3.13
(a ) A 2 7 8 0  c o n t r o l
G2
Gl
B r d U r d  F I T C  - ►
(c )  A 2 7 8 0 / c p 7 0  c o n t r o l
B r d U r d  F I T C  — ►
(b ) A 2 7 8 0  2 G y
B r d U r d  F I T C  — ►  
(d )  A 2 7 8 0 / c p 7 0  2 G y
B r d U r d  F I T C
(f)  A 2 7 8 0 / M C P 9  2 G y(e )  A 2 7 8 0 / M C P 9  c o n tr o l
B r d U r d  F I T C B r d U r d  F I T C ►
C on trol s Irradiated 2Gy
A 2 7 8 0 A 2 7 8 0 /
cp 70
A 2 7 8 0 /
M C P 9
A 2 7 8 0 A 2 7 8 0 /
cp70
A 2 7 8 0 /
M C P 9
%G1 58.7 52.5 45.8 65.6 48.3 56.3
% S 32.9 35.4 48.8 20.7 37.3 39.6
% G 2 7.3 9.1 1.0 12.6 11.5 5.0
(a) in A2780 there is accumulation of cells in Gl and G2 and a fall in the number in S- 
phase after irradiation,
(b) A2780/cp70 displays no significant change in the percentage of cells in each phase 
of the cycle after irradiation.
These results are consistent with previous observations on these cell-lines, (Brown et al.
1993). In the case of the A2780/MCP9 cell line there is a reduction in the number of 
cells entering S-phase after irradiation, but this is less than that observed in A2780. This 
suggests some degree of loss of p53 function in this cell line.
Three separate analyses of the differences in cell-cycle progression after 
irradiation, were performed on A2780, A2780/cp70 and the A2780/MCP cell lines. In 
order to compare the differences between the cisplatin resistant cell lines and A2780, the 
cumulative data from all three independent cell cycle experiments was analysed, (this 
data can be found in appendix A). The mean of the fraction of S-phase cells present in 
each cell line after 2Gy irradiation was calculated as well as the standard error of the 
mean ( Table 3.9 ). The results show that over the three experiments approximately 
50% more cells enter S-phase after irradiation of A2780/cp70 than with A2780. A 
similar result is observed for all but one of the A2780/MCP cell-lines with a 
proportionally larger number of cells entering S-phase after radiation than in A2780. It 
would appear, therefore, that there has been a reduction in the ability of cells from these 
lines to inhibit DNA replication after a DNA damaging stimulus.
As the cell-cycle data is not likely to conform to a normal distribution, a non- 
parametric method was used to asses the significance of the differences in relative mean 
fraction of cells in S-phase after irradiation, between cell-lines. Using a Wilcoxon rank 
sum test the comparison between A2780 and each of the cisplatin resistant derivatives 
was significant (0.05>p>0.01) in all but two cell lines. A2780/MCP7 showed no 
significant difference in its response to radiation when compared to A2780. With 
A2780/MCP9 more cells entered S-phase after irradiation than in the case of A2780 in
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Cell Lines Mean fraction of cells 
in S-phase 24hr after 
2Gy radiation 
(+/- S.E.)
Relative change in % S- 
phase cells after 2Gy 
radiation compared to 
A2780
A2780 0.60 (0.07) 1.0
A2780/cp70 0.90 (0.16) 1.5
A2780MCP1 0.81 (0.07) 1.35
A2780MCP2 0.76 (0.17) 1.27
A2780MCP3 0.79 (0.1) 1.32
A2780MCP4 1.06 (0.25) 1.77
A2780MCP5 0.80 (0.17) 1.33
A2780MCP6 0.77 (0.24) 1.28
A2780MCP7 0.60 (0.09) 1.0
A2780MCP8 0.76 (0.05) 1.27
A2780MCP9 0.64 (0.1) 1.07
Table 3.9 Effects of ionising radiation on entry into S-phase in cells from A2780, 
A2780/cp70 and A2780/MCP cell lines.
The mean of the fraction of cells entering S-phase after 2Gy ionising radiation was calculated 
from duplicates of each cell line compared to non-irradiated controls. This was accomplished 
using FACS analysis with at least 20,000 cells counted per cell line,. The analysis was 
performed in each of 3 separate cell-cycle assays and the mean fraction of cells in S-phase, 24hr 
after irradiation, was calculated. This was then compared to the mean fraction of S-phase cells 
after irradiation in A2780 to obtain the relative change in S-phase fraction.
two out of the three experiments. In the final experiment no evidence of a loss of cell- 
cycle arrest at Gj was observed. Over the three experiments the loss of G! arrest in this 
cell-line approached but did not reach statistical significance (p> 0.05).
Analysis of the data for the cisplatin resistant cell-line A2780/MCP5 reveals a 
change in the status of the Gi/S checkpoint over the temporal course of the three 
experiments. A period of five months lapsed between the first and second cell cycle 
experiments and, although the cells were not continuously grown over this period of 
time, a significant number of cell doublings took place. The second and third repetitions 
of the cell cycle experiment were approximately one month apart during which time the 
cells had been grown continuously in culture. This represents approximately 20 
additional cell doublings for each line between these two time points. For A2780/cp70 
and most of the A2780/MCP cell lines a relative increase in the number of cells 
progressing into S-phase after irradiation is observed in the first cell cycle assay and is 
reproduced in the subsequent experiments. As shown in Table 3.10, A2780 and 
A2780/MCP7 display an obvious decrease in the relative number of post-radiation S- 
phase cells in all three experiments. A2780/MCP5 shows very little difference to A2780 
in the first two cell cycle assays. However, with the further period of culturing of the 
cells between the second and third experiments this cell-line developed an obvious 
increase in the number of cells progressing into S-phase after radiation. This suggests 
that the further culture of this cell-line has brought about an decrease in the ability to 
arrest in Gl after irradiation.
3.6.3 Characterisation of apoptosis in cisplatin resistant A2780 cells as a
measure of p53 function.
To further determine if cisplatin resistant derivatives of A2780 displayed 
differences in p53 function as compared to the parental cell-line, the ability of cells to 
undergo apoptosis after exposure to cisplatin was measured. This work was carried out
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Fraction of S-phase cells 24h after 2Gy ionising 
radiation compared to non-irradiated controls.
Cell Line Passage I Dec 1994
Passage II 
May 1995
Passage III 
June 1995
A2780 0.51 0.73 0.56
A2780/MCP7 0.42 0.69 0.68
A2780/MCP5 0.58 0.67 1.15
Table 3.10 Changes in post-irradiation cell-cycle characteristics of A2780/MCP5 
with prolonged growth in culture
The table shows the fraction of cells in each line entering S-phase after 2Gy of ionising radiation 
as compared to non-irradiated control cells. Three separate experiments were performed, with a 
substantial period of continuous cell culture occurring between experiments. For A2780 and 
A2780/MCP7 it can be seen that there is a significant reduction in the number of cells entering 
S-phase after irradiation which remains relatively constant between experiments. With 
A2780/MCP5, however, there is no change in the fraction of cells entering S-phase post­
irradiation between the first two experiments but a significant increase in the fraction of cells 
entering S-phase in the third. This suggests some change occurring in A2780/MCP5 resulting in 
a reduction in the post-irradiation delay of cell entry into S-phase.
in collaboration with A.McIlwrath. It has been shown previously that the apoptotic 
response to cisplatin induced DNA damage in A2780 cells is dependent on functional 
p53 ( A. Mcllwrath. Pers. Comm.). A widely used biochemical marker for apoptosis is 
the non-random fragmentation of DNA. This is normally detected by the initial 
appearance of 300-kbp and 50-kbp fragments of DNA followed subsequently, in most 
but not all cases, by the intemucleosomal cleavage to 180-200 bp integers ( the DNA 
ladder ) (Oberhammer et al. 1993). Using field-inversion gel electrophoresis to separate 
these fragments it was shown that between 48 and 96 hours after exposure to 40pM 
cisplatin A2780 cells displayed the appearance of 300-kbp and 50-kbp fragments. The 
A2780/cp70 cells displayed markedly less DNA fragmentation after the same cisplatin 
exposure. No nucleosomal sized DNA fragments were observed in either cell type. To 
allow quantification of this apparent reduction in apoptosis a flow cytometric assay was 
used. This technique, known as a TUNEL assay (Gorczyca et al. 1993) relies on the 
principle of end-labelling of DNA fragments with a fluorescent tag ( FITC ) using 
terminal deoxytransferase ( TdT ) which can then be detected in the flow cytometer. 
Labelling of total DNA with propidium iodide allows analysis of the number of cells 
with fragmented DNA in the cell population as a whole and displays a characteristic 
pattern on the cell histogram. Seventy-two hours after exposure to equitoxic 
concentrations of cisplatin it was shown that there was little increase in the number of 
apoptotic A2780/cp70 cells compared to controls. With A2780 on the other hand a 
significant proportion of apoptotic cells were observed at this time point. Similar 
measurements were made for the A2780/MCP cell-lines the results of which are shown 
in Table 3.8. There would appear to be a reduction in the number of cells engaging 
apoptosis after exposure to cisplatin for all the A2780/MCP cell-lines except MCP7. In 
the A2780/MCP cell-lines no measurements have been made of the actual levels of 
DNA damage induced by exposure to a specific concentration of cisplatin. Therefore, 
the diminished apoptotic response observed in these cells when compared to A2780 
may be as a result of differences in the uptake or metabolism of cisplatin or in the signal 
that engages an apoptotic response.
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3.6.4 Determination of basal and induced Cipl/W afl mRNA levels in
cisplatin resistant A2780 cell-lines.
TP53 is involved in the transcriptional regulation of the Cipl/W afl gene and is 
necessary for radiation induced Gl arrest (El-Deiry et al. 1994). To determine the basal 
levels of expression of Cipl/W afl in A2780 and derived cell-lines, detection of mRNA 
was performed using a Northern blot technique. This work was carried out in 
collaboration with L. Gallagher. A plasmid containing the Cipl/Wafl cDNA ( pCEP- 
WAF1-S ) was used as the probe for detection of Cipl/Wafl mRNA. It had been shown 
that A2780/cp70 cells possessed a reduced basal level of Cipl/Wafl mRNA as 
compared to A2780 (Gallagher, 1996). A2780/cp70 cells also displayed a much smaller 
increase in the rise in the level of this specific mRNA after 2Gy of y-radiation or 
exposure to lpM  cisplatin for 1 hour when compared to A2780 (Gallagher, 1996). 
When the basal levels of Cipl/Wafl mRNA were determined by Northern blotting in 
the A2780/MCP cell-lines a reduced expression of this gene was observed in all the 
lines compared to A2780. However, the expression of Cipl/Wafl mRNA was greatest 
in the A2780/MCP7 cell-line. ( Table 3.8).
3.7. CONCLUSIONS.
The data presented in this chapter reveals, for the first time, the possibility of an 
association between microsatellite mutation and resistance to cisplatin and doxorubicin 
in tumour cell lines. However the detection and analysis of microsatellite mutation is 
fraught with potential sources of error. Could it be that the microsatellite mutation 
detected is artefact and that microsatellite instability does not exist in these cell lines?
Two areas of significant controversy exist in the analysis of microsatellite 
mutation;
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(a); How does one define microsatellite mutation and microsatellite instability and 
identify them practically?
(b); How does one differentiate between the appearance of a mutation in a microsatellite 
repeat representing a random event and that associated with defective mismatch repair?
One of the practical problems that arises in interpretation of microsatellite 
mutations is differentiating true mutations from artefacts that can arise during the 
process of analysis. “Stutter” bands, caused by slippage of Taq polymerase during PCR, 
and aberrant migration of amplified DNA through polyacrylamide gels are two potential 
sources of artefact. Practical techniques employed to reduce such sources of error have 
included using high fidelity polymerases, fluorescently labelled PCR primers and 
automated DNA sequencers. In this work the reproducibility of changes in microsatellite 
size was used as the best indicator that such a change had not arisen artefactually during 
analysis. In cases in which interpretation of the autoradiograph was not clear assessment 
by an independent observer was obtained.
The determination of microsatellite instability depends on showing that the 
frequency of mutation detected at microsatellite repeat sequences, in a particular cell 
line, is greater than that expected in a normal cell. This can be calculated by finding the 
percentage of microsatellite loci that show mutations out of the total studied and 
comparing to the frequency expected in normal cells. However the question arises as to 
how many microsatellite loci have to be studied in order for instability to be 
determined? For example does the detection of a microsatellite mutation at one of two 
loci studied constitute microsatellite instability? Recent evidence suggests that the 
mutation rate of microsatellite sequences in normal tissues, such as peripheral T- 
lymphocytes and fibroblasts, may be as high as 3 x 10' per allele, which is an order of 
magnitude higher than previously quoted values (Heame et al. 1992; Shibata et al. 1994; 
Hackman et al. 1995). This frequency of microsatellite mutation is similar to that 
observed in some sporadic tumours previously defined as displaying an RER+
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phenotype (Hackman et al. 1995). Thus the detection of a single microsatellite mutation 
is not sufficient to allow differentiation between cells with functional and non­
functional mismatch repair. In the literature to date the term microsatellite instability has 
been applied to cell lines or tumours in which as few as two microsatellite loci have 
been studied. It has been suggested that the minimum criteria for determining 
microsatellite instability should be the detection of mutations occurring in at least two 
out of five microsatellite repeat sequences (Thibodeau et al. 1993).
The drug resistant derivatives of A2780, OVl/p and MCF7 display mutations in 
at least two microsatellite loci out of, up to, fourteen studied. The cisplatin resistant 
lines A2780/SCP6 and A2780/MCP1-6 and 9 also show mutation in at least two out of 
the ten or eleven loci studied. These lines, therefore, all fulfil the criteria for displaying 
true microsatellite instability.
A problem that frequently arises when studying microsatellite instability in cell 
lines is that of polyclonality. Cells from a line cultured over a prolonged period are 
likely to develop some genetic differences from each other due to mutation, hence 
becoming a polyclonal population. In the case of microsatellite sequences, even when 
the cell line possesses normal mismatch repair, with time mutation will result in sub­
populations within the line which display differences in the length of microsatellite 
repeats. One result of this is that studies between derivatives of a cell line could detect 
differences in the microsatellites arising as a result of its polyclonal nature but interpret 
them as being due to instability. This problem can be resolved by analysing the 
microsatellite repeats in a series of sub-clones derived from the line (Shibata et al. 
1994). If the sub-clones are derived from a single clone of the original cell-line then the 
detection of multiple microsatellite mutations not present in the parent clone represents 
further replication errors occurring during growth of the sub-clones (Shibata et al.
1994). The results from the sub-cloning of the A2780 and A2780/cp70 cell-lines 
strongly suggests that the latter has developed an RER+ phenotype not seen in the 
parent line. Counting the number of mutations arising in the 165 microsatellite alleles
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studied in A2780 sub-clones, allows calculation of a spontaneous mutation frequency 
for microsatellites in this line of less than 6 x 10"3/ allele. A2780/cp70 on the other hand 
shows a mutational frequency two orders of magnitude higher than this. Sub-clone 
analysis has not been done for the line A2780/AD. However, the observation of 
mutations at two of fourteen microsatellite loci in the resistant cell-line combined with 
the low rate of spontaneous mutation in A2780 suggests ( but does not prove ) that this 
line also displays acquisition of an RER+ state. A similar argument can be advanced for 
the A2780/MCP and SCP cell lines showing microsatellite mutations. Without further 
determination of the spontaneous frequency of microsatellite mutation in the OVl/p and 
MCF7 cell-lines the significance of the frequent mutations observed in their drug 
resistant derivatives remains uncertain.
One of the reasons behind choosing highly polymorphic microsatellite markers, 
on four different chromosomes, for this study was to maximise detection of loss of 
heterozygosity ( LoH ). Despite this only three cases of LoH were observed in all the 
loci studied throughout the four drug resistant tumour cell lines. Loss of heterozygosity 
has been reported frequently on chromosomes 2,3,6 and 17 in ovarian tumours in other 
studies (Jacobs and Lancaster, 1996). Thus, the low frequency of LoH in these cell lines 
is not likely to be the result of studying loci in which LoH does not result in a specific 
growth advantage to the cell. It has been hypothesised, that cell lines displaying 
microsatellite instability can show apparent LoH, if the change in the size of one allele 
of a heterozygous pair results in both alleles ending up the same length, i.e. apparently 
homozygous (Contegiacomo et al. 1995). This may be what is observed with OV1/DDP 
in which the autoradiographic signal from the single remaining allele of D2S121 
appears denser than does the corresponding allele in OVl/p.
During analysis of the drug resistant cell-lines the chromosomal locations of two 
of the mismatch repair genes, hMSH2 and hMLHl, were resolved (Bronner et al. 1994; 
Fishel et al. 1993). hMSH2 is located on chromosome 2p22-21 whereas hMLHl if 
found at 3p21-23. It has been shown that mutations in hMSH2 and hMLHl are
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responsible for >80% of tumours in HNPCC (Han et al. 1995; Liu et al. 1994). Certain 
microsatellite markers were shown to be closely linked to these genes, e.g. D2S123 with 
hMSH2 and D3S1298 with hMLHl (Papadopoulos et al. 1994; Peltomaki et al. 1993). 
These microsatellites were therefore included in the characterisation of the drug resistant 
cell-lines. The aim was to determine whether LoH could be detected at either of these 
loci and thus suggest the possible involvement of either of these genes in the phenotypes 
observed. Unfortunately both loci were homozygous in all of the cell-lines and therefore 
uninformative for LoH although microsatellite mutation was observed. It has been 
shown that LoH of linked markers is not a feature of either the 2p or 3p forms of 
HNPCC (Aaltonen et al. 1993; Lindblom et al. 1993) although LoH at 3p21.3-23 has 
been observed in sporadic non-small cell lung cancer (Neville et al. 1996), oral cancer 
and oesophageal cancer. One report shows microsatellite instability associated with LoH 
at 3p21 in non-small cell lung cancer (Wieland et al. 1996).
It would also appear that in general cells which display microsatellite instability 
do not accumulate the chromosomal rearrangements and deletions associated with 
frequent loss of heterozygosity (Yee et al. 1994; Thibodeau et al. 1993). The low 
frequency of LoH observed in the RER+ drug resistant cell lines studied here would 
tend to confirm this observation.
The high frequency of microsatellite instability observed in the A2780/MCP cell 
lines is very striking. This data along with that from the other drug resistant derivatives 
of A2780, MCF7 and OVl/p suggests a possible association between selection for drug 
resistance and selection for an RER+ phenotype. It should be noted however that not all 
cell lines selected for drug resistance show microsatellite instability. In a recent analysis 
of different ovarian, lung and testicular cancer cell lines with their cisplatin resistant 
derivatives, none of the resistant lines displayed any evidence of microsatellite mutation 
( G. Hirst. Pers com m .).
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The data from the clonogenic and MTT assays prove, conclusively, that the 
A2780 cell lines selected using exposure to cisplatin show greater resistance to the 
cytotoxic effects of this drug than A2780. As stated , the repeats of the clonogenic and 
MTT assays were carried out several months apart each time. The cell lines had 
undergone further rounds of cell division and growth between each of the assay repeats. 
During these assays all cells were cultured using cisplatin free medium. The data from 
each of the clonogenic assays and the MTT dose/response curves can be seen in 
Appendix A. The results indicate that not only do the cell lines show greater resistance 
to cisplatin but that this is a stable phenotype that persists despite growth in the absence 
of the drug. It is important to show this as it suggests that the resistant phenotype has 
arisen through stable genetic change.
The other significant association to arise from these results is that observed 
between the presence of an RER+ phenotype and a reduction, or loss, of certain p53 
dependent functions. In the cisplatin resistant A2780 cell-lines analysed, which 
displayed evidence of microsatellite mutation or instability, there was a reduction in p53 
dependent apoptosis and cell-cycle arrest after DNA damage. It is important to note that 
not all apoptosis is p53 dependent (Clarke et al. 1993). However, the loss of an 
apoptotic response to DNA damage in A2780 cells transfected with dominant negative 
p53 mutants, indicates that apoptosis is p53 dependent in these cells (Vasey et al. 1996). 
Among all the cisplatin resistant A2780 cell-lines selected by multiple drug exposure, 
A2780/MCP7 was the only line not to display microsatellite mutation. It appeared to 
possess levels of p53 activity, using all three measures of p53 function analysed, similar 
to that of parental A2780 cells. This implies that this cell-line may have acquired its 
resistance to cisplatin by mechanisms different to those seen in RER+ cisplatin resistant 
A2780 cell-lines.
The A2780/MCP cell lines, other than MCP7, all show loss of DNA damage 
induced p53 function as characterised by the three assays employed. A2780/cp70 tended 
to show, in general, significant loss of p53 activity in all three assays. Other lines
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displayed variable degrees of loss of p53 activity, depending on the assay used. For 
example, A2780/MCP9 shows very little loss of Gj arrest after ionising radiation but 
marked reduction in the basal expression of Cipl and the ability to induce apoptosis 
after cisplatin damage. A2780/MCP5 shows a markedly reduced level of basal Cipl 
mRNA expression ( table 3.9 ). At the same time after development of this cell line that 
the Cipl mRNA was extracted it also displayed a level of post-irradiation Gi arrest 
similar to that of A2780. Further expansion of this cell-line, by growth in culture, was 
associated with loss of radiation induced inhibition of DNA synthesis and reduced 
apoptosis by cisplatin. Thus the further growth in culture appeared to be associated with 
loss of these p53 mediated responses. With the obvious exception of A2780/MCP7, it 
would appear that all the A2780/MCP lines except MCP5 developed phenotypes of 
microsatellite instability, cisplatin resistance and loss of p53 dependent functions during 
the original selection with cisplatin. A2780/MCP5 on the other hand has only developed 
the full phenotype of lost p53 function after further expansion of the RER+ cell-line.
As stated in this chapter the cell-cycle characteristics of the cisplatin resistant 
cell-lines were analysed using 2Gy ionising radiation as the source of DNA damage. 
The reasons for this have been described. However, although the A2780/MCP cell-lines 
all showed resistance to cisplatin compared to parental A2780 cells it is unknown as to 
whether they show greater resistance to ionising radiation. A2780/cp70 and other cell- 
lines selected for resistance to cisplatin do demonstrate cross-resistance to multiple 
cytotoxic agents including ionizing radiation, melphalan, doxorubicin, etoposide and 
mitoxantrone (Vasey et al. 1995; Hamaguchi et al. 1993). This implies that the 
A2780/MCP cell-lines could well display resistance to ionizing radiation, although this 
remains to be tested formally. Assessing the cell-cycle parameters of each cell line 
treated with equitoxic doses of cisplatin would be another experiment that would help 
clarify the p53 dependent functions of these cells.
There is, however, no indication as to how the development of an RER+ 
phenotype and abnormal p53 function are associated. It has already been stated that at a
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cDNA level the sequence of A2780/cp70 is identical to that of A2780 (Brown et al.
1993). However, TP53 accumulates in the nuclei of the former cell-line suggesting 
stabilisation of the protein. This accumulation of TP53 in A2780/cp70 is confirmed by 
the results presented here; however there would appear to be no consistent correlation 
between basal p53 protein levels and p53 function in the A2780/MCP cell lines. One 
possibility is that, in some way, development of an RER+ phenotype increases the 
likelihood that a p53 defective clone will be selected for during exposure to cisplatin. 
Although the p53 gene has not been sequenced in the A2780/MCP cell lines it may be 
that defective p53 function in these lines is not a result of mutation in the p53 protein. 
There is some evidence to suggest that in certain tumour types there is an inverse 
correlation between the presence of an RER+ phenotype and mutations in p53 (Uchida 
et al. 1994; Strickler et al. 1994). It may be that the presence of the RER+ phenotype 
results in inactivation of the p53 gene or protein by other mechanisms thus removing the 
necessity for selection of mutants in these cell lines.
The A2780/cp70 cell line has been grown over many years in culture and 
displays the most prominent RER+ phenotype of all the cisplatin resistant A2780 cell 
lines studied. It would appear likely that this has arisen due to a growth advantage for 
the RER+ cells during culture, with the result that they now constitute the whole 
population of A2780/cp70 cells. In the A2780/MCP cell lines, having undergone less 
expansion in culture since initial selection, RER+ cells have had less time to exert a 
growth advantage. These lines may therefore be a mixture of RER+ and RER- cells. 
This could explain the intermediate levels of resistance to cisplatin and the reduced loss 
of p53 dependent functions when compared to A2780/cp70. Further growth in culture 
might increase the proportion of RER+ cells in the population. This could be an 
explanation for the apparent loss of p53 functions with further culturing of the 
A2780/MCP5 cell line. The existence of mechanisms of cisplatin resistance inA2780 
cell lines that do not depend on the acquisition of an RER+ phenotype or the loss of p53 
functions is indicated by A2780/MCP7.
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Addendum to Chapter 3
The cisplatin resistance ( as measured by clonogenic assay) and p53 dependent DNA 
damage responses of A2780, A2780/cp70 and the A2780/MCP cell lines has previously 
been published ( Table 4. Anthoney et al. 1996 ). The published data on fold resistance 
to cisplatin, relative p53 protein level and S-phase fraction of cells after 2Gy ionising 
radiation differs quantitatively from that presented in this chapter ( tables 3.5, 3.8, 3.9 ). 
The published results represent an interim analysis of data obtained from a smaller 
number of experiments than those presented in the thesis. Further experiments were 
performed between publication of the paper and writing of the thesis.
Although there is a difference in the numerical values presented between the two sets of 
data there is no significant change in the conclusions that can be drawn. Thus all the 
A2780/MCP cell lines show increased resistance to cisplatin compared to A2780, with 
A2780/MCP1 having a greater fold resistance in the final analysis as compared to the 
interim data. No consistent difference in the levels of p53 in the A2780/MCP cell lines as 
compared to A2780 were observed in either set of data. Finally, each of the A2780/MCP 
cell lines showed evidence of a loss of inhibition of entry into S-phase after 2Gy which 
was similar in both sets of data. As discussed in the paper by Anthoney et al, one possible 
explanation for differences in the data sets is that the A2780/MCP cell lines appear to 
evolve, with regards to loss of p53 function, with prolonged growth in culture.
CHAPTER 4
CHARATERISATION OF M ISM ATCH REPAIR DEFECT IN  CISPLATIN  
RESISTANT OVARIAN CARCINOMA CELL LINES
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4.1 INTRODUCTION.
A significant association has been identified between the phenotype of 
resistance, or tolerance, to certain types of cytotoxic anti-cancer agents and the 
replication error ( RER+ ) phenotype, characterised by an increased mutation rate at 
microsatellite repeat sequences. Evidence for this comes from tumour cell lines resistant 
to alkylating agents (Branch et al. 1995), as well as from the cisplatin and doxorubicin 
resistant lines presented in the previous chapter. The RER+ phenotype has since been 
shown to arise from defects in the process of mismatch repair, characterised by the 
finding of mutations in genes homologous to those known to be involved in prokaryotic 
mismatch repair (Modrich and Lahue, 1996). Tumour cell lines with alkylation 
tolerance have been shown to harbour mutations in mismatch repair genes. 
Confirmation that mutations in these genes actually result in defective mismatch repair 
comes from the use of in vitro repair assays (Boyer et al. 1995). The whole story is not 
cut and dried however. A significant percentage of HNPCC tumours expressing an 
RER+ phenotype do not display mutations in any of the known mismatch repair genes 
(Rhyu, 1996). This suggests that there are components of the mismatch repair pathway 
as yet uncharacterised, mutations of which may play a role in the development of the 
malignant phenotype and perhaps anti-cancer drug tolerance. Therefore it is important to 
attempt to characterise the underlying genetic and biochemical defects in mismatch 
repair in the RER+ cisplatin resistant A2780 cell lines.
A variety of different biochemical and genetic methods have been employed to 
characterise the involvement of mismatch repair gene mutations in certain forms of 
cancer. Genetic linkage analysis in HNPCC kindreds, and PCR utilising degenerate 
primers was involved in the identification of hMSH2 and hMLHl (Lindblom et al. 
1993; Peltomaki et al. 1993). Degenerate PCR, with primers targeted for conserved 
regions of known bacterial and yeast mismatch repair genes, allowed the identification 
of the coding sequences for the genes (Bronner et al. 1994; Fishel et al. 1993). 
Subsequent confirmation that germ-line and somatic mutations in these genes were
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found in individuals affected with HNPCC came from sequencing genomic or cDNA 
from normal and tumour tissues (Leach et al. 1993). The hPMSl and hPMS2 genes 
were identified during a search for homology with bacterial and yeast mismatch repair 
genes in a human gene database (Papadopoulos et al. 1994).
Identification of homologues of the E.coli. MutS protein have made use of the 
ability of such proteins to bind to mismatches in DNA. In these experiments, binding of 
a protein to an oligonucleotide DNA-duplex containing a mismatch results in retardation 
of the electrophoretic migration of the duplex compared to unbound oligonucleotide. 
Using protein purification and HPLC techniques, followed by gel retardation assays 
with mismatched oligonucleotides, GTBP ( hMSH6) (Palombo et al. 1995) and an, as 
yet, uncharacterised A-T mismatch binding protein (Stephenson and Karran, 1989) have 
been isolated.
Biochemical assays of mismatch repair have been used to determine whether 
RER+ cell lines display defective repair. Complementation studies with cell lines 
having defined mismatch repair mutations, allows isolation of the defective repair 
components in any RER+ line. The mismatch repair assays use a variety of DNA 
templates with single base-base or more complex insertion/deletion mismatches 
engineered into them. Addition of such templates to nuclear extracts from the cell line 
under study allows measurement of the rate of mismatch repair. To detect that repair has 
occurred the mismatch is engineered into a “reporter” region that allows differentiation 
between repaired and unrepaired DNA. In one assay the mismatch is constructed in a |3- 
galactosidase reporter gene, in either a mammalian shuttle vector (Parsons et al. 1993) 
or M l3 phage (Umar et al. 1994). After repair in the nuclear extract, the DNA construct 
is introduced into mismatch repair deficient E.coli and the difference in the ratio of blue 
to white colonies or plaques counted. This ratio is determined by the restoration of (3- 
galactosidase function on removal of the mismatch. Other types of reporter constructs 
have been used in assays of mismatch repair.
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Development of an RER+ phenotype is a very frequent event in the selection of 
cisplatin resistant clones of the A2780 cell line, as demonstrated in chapter 3. This 
RER+ status is determined only by the presence of microsatellite instability. It is 
therefore necessary to characterise the mismatch repair function of these cisplatin 
resistant A2780 derived cell lines. The following sections present data on the 
biochemical and molecular analysis of mismatch repair in these cell lines.
4.2 CHARACTERISATION OF MISMATCH BINDING COMPONENTS OF
A2780,A2780/CP70 AND A2780/MCP CELL LINES.
4.2.1 Immunoblot analysis of mismatch binding proteins.
Immunological detection of mismatch repair proteins has been used to 
characterise the mismatch repair system in tumour cell lines (Palombo et al. 1995). This 
allows a gross comparison of the cellular protein levels but does not provide information 
on the functional state of such proteins in the cell.
To determine whether differences exist in the detectable levels of the mismatch 
binding proteins hMSH2 and hMSH6 ( GTBP ), in A2780 and its cisplatin resistant 
derivatives, an immunoblot analysis was performed. Protein extracts were prepared 
from confluent cultures of each cell line as detailed in chapter 2, section 2.3. The 
concentration of protein in each extract was determined using a modified Bradford assay 
(Bradford, 1976). An equal quantity of total cell extract was then subjected to gel 
electrophoresis and Western blot analysis.
A polyclonal antibody, prepared from rabbits injected with a GST fusion 
polypeptide corresponding to amino acid residues 27 - 158 of hMSH2 (Palombo et al. 
1995),was used in the detection of hMSH2 protein. This was kindly supplied by Dr. J. 
Jiricny ( Istituto di Ricerche di Biologia Molecolare. Pomezia, Italy.). When this 
antibody was used to probe the Western immunoblot membrane a specific signal was
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detected with each of the cell lines. A doublet band running at about lOOkDa was 
observed. This is the predicted size of the hMSH2 protein although in previous 
experiments using nuclear extracts a single band of this size has been observed in HeLa 
cells (Palombo et al. 1995). As can be seen in figure 4.1 hMSH2 is detected in each of 
the cell lines analysed although the level appears to vary between the lines. A relatively 
strong signal for hMSH2 is observed for A2780, A2780/cp70 and A2780/MCP1 & 
MCP3 to 6. The other A2780/MCP lines show apparently reduced levels of hMSH2 
protein. However, when the same membrane was probed with an antibody against 
vinculin, the same variation in protein levels between the cell lines was observed.
The level of vinculin expression in cells is consistent and it acts as a control for 
protein loading and transfer in the experiment. The A2780/MCP cell lines which 
appeared to express low levels of hMSH2 also displayed low signals with vinculin 
antibody. This suggests that the differences in the hMSH2 levels between the A2780 
cell lines arises from unequal transfer of protein to the Western membrane and not from 
true differences in hMSH2 levels. The levels of hMSH2 detected in A2780 and 
A2780/cp70 were similar. It is therefore unlikely that differences in the RER status of 
these lines arises from altered levels of hMSH2.
The hMSH2 protein is known to form a heterodimeric complex, known as 
hMutSa (Drummond et al. 1995), with another protein hMSH6 ( GTBP ). Western 
immunoblot analysis of the levels of hMSH6 in the cisplatin resistant A2780 cell lines 
was performed using a polyclonal antibody raised against amino acids 750-928 of the 
hMSH6 protein ( supplied by Dr. J. Jiricny ). As can be seen from figure 4.1(b) hMSH6 
also appears to be present in all of the cell lines. The same pattern of variation in the 
level of protein between the cell lines is seen as for hMSH2. The signal is weakest in 
those lanes which show the lowest vinculin levels ( A2780/MCP2,7,8 and 9 ) suggesting 
that the difference between hMSH6 levels in the cells arises due to unequal protein 
transfer and does not represent true variation between the cells. A2780 and A2780/cp70
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( a )  h M S H 2
1 2 3 4 5 6 7 8 9 10 11
9 « 0
( b )  h M S H 6  ( G T B P )
1 2 3 4 5 6 7 8 9 10 11
( c )  V i n c u l i n  
1 2 3 4 5 6 7 8 9 10 1 1
F i g u r e  4.1 B a s a l  l e v e l s  o f  h M S H 2  a n d  h M S H 6  p r o t e i n  i n  A 2 7 8 0  a n d  c i s p l a t i n  
r e s i s t a n t  d e r i v e d  c e l l - l i n e s .
W e s t e r n  i m m u n o b l o t  r e p r e s e n t i n g  b a s a l  l e v e l s  o f .  ( a )  h M S H 2 ,  ( b )  h M S H 6  a n d ,
( c )  v i n c u l i n  p r o t e i n s  i n  t h e  c e l l  l i n e s  i n d i c a t e d .  E q u a l  a m o u n t s  o f  c e l l u l a r  t o t a l  
p r o t e i n  e x t r a c t  w e r e  a n a l y s e d  p e r  c e l l - l i n e .  I m m u n o d e t e c t i o n  o f  v i n c u l i n  w a s  u s e d  
t o  c o n t r o l  f o r  e q u i v a l e n c e  o f  t o t a l  p r o t e i n  o n  t h e  W  e s t e r n  b l o t .
L e g e n d .
( 1 )  A 2 7 8 0 / M C P 1  ( 2 )  A 2 7 8 0 / M C P 2  ( 3 )  A 2 7 8 0 / M C P 3  ( 4 )  A 2 7 8 0 / M C P 4
( 5 )  A 2 7 8 0 / M C P 5  ( 6 )  A 2 7 8 0 / M C P 6  ( 7 )  A 2 7 8 0 / M C P 7  ( 8 )  A 2 7 8 0 / M C P 8
( 9 )  A 2 7 8 0 / M C P 9  ( 1 0 )  A 2 7 8 0 / c p 7 0  ( 1 1 )  A 2 7 8 0
show similar protein levels, again suggesting that the RER+ phenotype is not due to 
differences in the level of hMSH6.
To determine whether alterations in the levels of hMSH2 or hMSH6 proteins 
were associated with the RER+ phenotype observed in the A2780/AD cell line 
immunoblot analysis was performed using the same antibodies. A2780, A2780/cp70, 
A2780/MCP1 and 5 were also run for comparison ( figure 4.2 ). Differences in the 
signals obtained with hMSH2 and hMSH6 are seen between the cell lines with 
A2780/AD showing a reduced signal with hMSH6. However, when the signal to 
vinculin protein is analysed it would appear that there is a reduced level of A2780/AD 
protein on the membrane compared to the other cell lines. Again, therefore, it can be 
assumed that the differences in hMSH6 and hMSH2 observed between A2780/AD and 
the other lines arises from unequal protein transfer and does not represent a true 
variation.
The results from the hMSH6 and hMSH2 immunoblot assays would suggest, 
therefore, that differences in the levels of these proteins between A2780 and cisplatin or 
doxorubicin resistant derivatives are not responsible for the RER+ phenotype observed.
4.2.2 Mismatch binding activity in cisplatin resistant A2780 cell lines.
The results of the preceding section suggest that no significant differences exist 
in the levels of hMSH2 or hMSH6 between the various cisplatin resistant A2780 
derived cell lines. They do not, however, give any indication as to the ability of these 
proteins to bind to mismatches occurring in DNA. Therefore a gel-retardation assay was 
employed to identify whether components of cell extracts from A2780 and derived cells 
could bind to specific DNA mismatches. This work was performed in collaboration with 
Dr. R. Brown and A. Mcllwrath, with advice and assistance from the laboratory of Dr. 
P. Karran.
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h M S H 2
1 2 3 4 5
M W  #
h M  S H 6
1 2 3 4 5
in m  m
V i n c u l i n
1 2 3 4 5
F i g u r e  4 . 2  B a s a l  l e v e l s  o f  h M  S H 2  a n d  h M S H 6  p r o t e i n s  i n A 2 7 8 0 / A D  
A 2 7 8 0  a n d .  c i s p l a t i n  r e s i s t a n t ,  d e r i v e d  c e l l - l i n e s
W e s t e r n  i m m u n o b l o t  r e p r e s e n t i n g  b a s a l  l e v e l s  o f  h M S H 2 , h M S H 6  a n d  v i n c u l i n  
p r o t e i n s  i n  t h e  c e l l  l i n e s  i n d i c a t e d .  E q u a l  a m o u n t s  o f  c e l l u l a r  t o t a l  p r o t e i n  e x t r a c t  
w e r e  u s e d  f o r  e a c h  l i n e .  E a c h  i m a g e  r e p r e s e n t s  t h e  s a m e  b l o t  p r o b e d  w i t h  a n t i b o d y  
t o  t h e  s p e c i f i c  p r o t e i n  i n d i c a t e d .  I m m u n o d e t e c t i o n  o f  v i n c u l i n  w a s  u s e d  t o  c o n t r o l  
f o r  d i f f e r e n c e s  i n  t h e  a m o u n t  o f  t o t a l  p r o t e i n  o n  t h e  b l o t .
L e g e n d .  ( 1 ) A 2 7 8 0 ,  ( 2 )  A 2 7 8 0 / c p 7 0 ,  ( 3 )  A 2 7 8 0 / A D ,
( 4 )  A 2 7 8 0 / M C P I ,  ( 5 )  A 2 7 8 0 / M C P 5 .
Gel-retardation assays have been used previously to identify proteins that can 
bind to specific mismatches in synthetic oligonucleotides. Jiricny et al. (Jiricny et al. 
1988) used this method to identify a 200kDa complex that bound specifically to G/T 
mismatches and later identified this as GTBP (Hughes and Jiricny, 1992). Stephenson 
and Karran (Stephenson and Karran, 1989) distinguished both GAT and A/C mismatch 
binding proteins in extracts from a human Burkitt’s lymphoma cell line by a similar 
procedure.
In the present assay a synthetic 34-mer oligonucleotide was synthesised that 
contained either a complementary G/C pairing at nucleotide number 16 ( homoduplex ) 
or a mismatch, either G/T or A/C, at the same position (heteroduplex ). End-labelled 
oligonucleotide was added to cell extracts that had been previously exposed to poly(dI* 
dC) and 40fmol of unlabelled nonmismatched oligonucleotide to remove non-specific 
DNA binding proteins. The reaction was left for 20 minutes at room temperature and the 
products electrophoresed on non-denaturing polyacrylamide gels prior to detection by 
autoradiography.
Oligonucleotide that is not bound by protein migrates quickly through the gel 
and can be observed at the bottom of the autoradiograph ( figure 4.3 ). Addition of 
labelled heteroduplex oligonucleotide ( A/C mismatch ) resulted in the formation of a 
specific retardation complex which was observed in lane 1 of all three cell lines. If, 
however, a labelled heteroduplex oligonucleotide ( G/T mismatch ) was added to the 
cell extract a different retardation complex, consisting of a more slowly migrating band, 
was observed ( A2780 lane 2 ). If the A2780 cell extract was pre-incubated with a 100- 
fold excess of unlabelled G/T mismatched oligonucleotide prior to addition of the 
labelled heteroduplex, then the mismatch specific retardation complex was not observed 
( A2780 lane3 ) showing that this complex was specific for G/T mismatches. The 
A2780/AD cell line also showed formation of this G/T mismatch specific retardation 
complex at a level equivalent to that seen with A2780 ( A2780/AD lane 2 ). 
A2780/cp70, however, showed a greatly reduced level of this retardation complex (
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F i g u r e  4 . 3  D e t e c t i o n  o f  m i s m a t c h  b i n d i n g  p r o t e i n s  i n  c e l l  e x t r a c t s  f r o m  A 2 7 8 0 .
A 2 7 8 0 / c p 7 0  a n d  A 2 7 8 0 / A D  b y  g e l  r e t a r d a t i o n .
C e l l  e x t r a c t s  f r o m  t h e  c e l l  l i n e s  i n d i c a t e d  w e r e  i n c u b a t e d  w i t h  e n d - l a b e l l e d  o l i g o n u c l e o t i d e s  
c o n t a i n i n g  e i t h e r  A / C  o r  G / T  m i s m a t c h e s .  B i n d i n g  o f  p r o t e i n s  t o t h e  m i s m a t c h  w a s  i n d i c a t e d  b y  
r e t a r d a t i o n  o f  t h e  o l i g o n u c l e o t i d e  o n  t h e  g e l  a s  c o m p a r e d  to u n b o u n d  o l i g o n u c l e o t i d e .  S p e c i f i c i t y  
o f  b i n d i n g  t o a p a r t i c u l a r  m i s m a t c h  w a s  d e t e r m i n e d  b y  p r e - i n c u b a t i o n  o f  t h e  c e l l  e x t r a c t  w i t h  
u n l a b e l l e d  o l i g o n u c l e o t i d e  c o n t a i n i n g  t h e  s a m e  m i s m a t c h .
A l t h o u g h  n o t  s h o w n ,  n o  s p e c i f i c  r e t a r d a t i o n  c o m p l e x e s  w e r e  o b s e r v e d  u s i n g  c o m p l e t e l y  m a t c h e d ,  
l a b e l l e d ,  h o m o d u p l e x  o l i g o n u c l e o t i d e s .
L e g e n d  L a n e l .  A / C  m i s m a t c h e d  o l i g o n u c l e o t i d e  
L a n e 2 .  G / T  m i s m a t c h e d  o l i g o n u c l e o t i d e
L a n e 3 .  G / T  m i s m a t c h e d  o l i g o n u c l e o t i d e  ( p r e - i n c u b a t i o n  w i t h  u n l a b e l l e d  
m i s m a t c h e d  o l i g o n u c l e o t i d e  )
A2780/cp70 lane 2 ). This suggests that the A2780/cp70 cells are defective in a G/T 
mismatch binding function that is present in A2780 whilst still retaining separate A/C 
mismatch recognition. This result was reproducible using independently isolated cell 
extracts from each cell line, suggesting that degradation of proteins during extraction 
were unlikely to be a cause of the lack of A2780/cp70 G/T mismatch binding.
4.3 ASSESSMENT OF MISMATCH REPAIR ACTIVITY IN A2780
DERIVED CELL LINES USING AN IN VITRO REPAIR ASSAY.
The RER+ phenotype is evidence of a defect in the mismatch repair system 
within a cell. The ability to detect the presence of mismatch repair proteins, such as 
hMSH2, by immunological assays indicates that a cell is able to transcribe and translate 
the appropriate gene. It does not determine, however, the functional state of the resultant 
protein. To assess the function of the mismatch repair system in A2780 and its drug 
resistant derivatives a biochemical assay of mismatch repair was used. The in vitro 
mismatch repair assay was performed in collaboration with Dr. James Drummond and 
Dr. Paul Modrich ( Duke University, Durham, N.Carolina, USA.) on cells provided 
from this laboratory.
The basis of the in vitro assay is measurement of the rate of repair of a synthetic 
mismatched template by extracts of the cell line under study. The template used in this 
assay was based on the phage flM R (Su et al. 1988). A 6440 base-pair heteroduplex 
was formed from flM R containing a strand specific break at position 6440/0 ( figure 4.4 
). It has been shown previously that in mammalian cells a strand break is sufficient to 
determine the directionality of mismatch repair (Holmes et al. 1990) Depending upon 
which strand of the heteroduplex the break resided determined whether it was 3’ or 5’ to 
the mismatched bases ( figure 4.4 ). At a position in the heteroduplex 808 bases from 
the strand break a variety of mismatched bases could be engineered. These included 
single base-base mismatches and di, tri and tetranucleotide insertion/deletion
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F i g u r e  4 . 4  H e t e r o d u p l e x  s u b s t r a t e  f o r  i n - v i t r o  m i s m a t c h  r e p a i r  a s s a y
D i a g r a m  a t i c  a  1 r e p r e s e n t a t i o n  o f  t h e  f l M R ( n )  p h a g e  c o n s t r u c t  u s e d  a s  a  s u b s t r a t e
in t h e  i n - v i t r o  m i s m a t c h  r e p a i r  a s s a y .  T h e  p h a g e  i s 6 4 4 0  b a s e - p a i r s  l o n g  a n d  c o n t a i n s
a s t r a n d  s p e c i f i c  b r e a k  a t  b a s e - p a i r  6 4 4 0  a n d  a s i n g l e  b a s e - b a s e  o r  d i n u c l e o t i d e  
i n s e r t i o n / d e l e t i o n  m i s m a t c h  a t  b a s e - p a i r  5 6 3 2 .  T h e  m i s m a t c h  l i e s  w i t h i n  t h e  
o v e r l a p p i n g  r e c o g n i t i o n  s i t e s  f o r  t h e  r e s t r i c t i o n  e n d o n u c l e a s e s  i n d i c a t e d .
( T a k e n  f r o m  H o l m e s ,  J.  e t  a l .  1 9 9 0  ).
L e g e n d .  0  =  m  i s p a i r  r e s i d i n g  o n  o p e n  s t r a n d  o f  h e t e r o d u p l e x  
w i t h i n  X h o l  r e s t r i c t i o n  s i t e .
C  =  m i s p a i r  r e s i d i n g  o n  c o v a l e n t l y  c l o s e d  s t r a n d  o f  h e t e r o d u p l e x  
w i t h i n  H i n d l l l  r e s t r i c t i o n  s i t e .
mismatches. The mismatches were engineered in such a way as to lie within, and 
disrupt, the sequence of two overlapping restriction endonuclease recognition sites. The 
presence of a mismatch at these sites prevents cleavage of the DNA by the restriction 
enzyme. With the template used in this experiment, correction of the mismatch on the 
open (O) strand e.g. reversion to G/C, results in restoration of the Xhol restriction site. 
If the mismatch is corrected on the opposite (C) strand e.g. reversion to A/T, the Hindlll 
site is restored.
In the mismatch repair assay, template DNA is incubated for 15 minutes with a 
nuclear extract of the cell line ( chapter 2, section 2.10.2 ). The proportion of template 
DNA that can be digested with either of the restriction enzymes after the incubation, is 
taken as a measure of the repair of the mismatch in the heteroduplex. If a defect in 
mismatch repair is observed then complementation, using either purified mismatch 
repair complexes or nuclear extracts from cells with defined mismatch repair mutations, 
can be performed to identify the missing or mutated component of repair.
Four cell lines were used in the in vitro mismatch repair assay, A2780, 
A2780/cp70, A2780/AD and A2780/MCP1. This assay was performed by Dr. J.
Drummond. Two different types of template were employed in the reaction, with either 
a GAT mismatch or a CA dinucleotide loop mismatch arranged with the strand break 
either 3' or 5' to it. The results of the assays with these cell lines can be seen in figure 
4.5. In A2780 a normal level of repair is observed for both mismatches and either 
orientation of strand break. When the strand break is 3’ to the mismatch all three drug- 
resistant cell lines show complete loss of detectable repair activity. When the strand 
break is 5’ to either type of mismatch, A2780/cp70 and A2780/MCP1 have a slight 
reduction in repair activity compared to A2780 whereas A2780/AD repairs slightly 
more efficiently. This therefore suggests that a specific defect in 3’ directed mismatch 
repair exists in these drug resistant ovarian cancer cell lines. To determine where the 
defect leading to abnormal 3’ directed mismatch repair lay, the cell extracts were 
complemented with either 220ng of purified hMutSa ( hMSH2/hMSH6 ) or 160ng of
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hMutLa ( hMLHl/hPMS2) and the repair activity measured. As can be seen in figure
4.5 complementation with hMutSa did not result in any restoration of repair function in 
these cell lines. Addition of hMutLa, however, fully restored the repair function in 
A2780/AD to levels similar to A2780 and brought about a significant increase in the 
levels of repair seen in A2780/cp70 and A2780/MCP1. Complementation with hMutSa 
when repairing mismatches from a 5’ orientated strand break did not result in any 
change in repair activity whereas hMutLa resulted in a slight but not significant 
increase in repair.
To further define the defect in the mismatch repair activities of these cell lines 
complementation using nuclear extracts from cells with known mutations in mismatch 
repair genes was performed. MT1 cells have been shown to harbour defects in the 
GTBP subunit of hMutSa (Drummond et al. 1995). Addition of a nuclear extract of 
MT1 cells to extracts of A2780/cp70, A2780/AD and A2780/MCP1 restored repair of 3’ 
orientated mismatches ( Figure 4.6 ). RKO cells are colorectal carcinoma cells deficient 
in hMutLa activity, due to a homozygous, or hemizygous, chain termination mutation 
in hMLHl. Addition of extracts from the RKO cells did not restore the repair function 
of A2780 derived cell lines ( Figure 4.6 ).This further indicates that the likely defect in 
3’ directed mismatch repair involves a component of hMutLa, most likely hMLHl.
4.4 IMMUNOBLOT ANALYSIS OF THE MutLa COMPONENTS hMLHl
AND_hPMS2 IN DRUG RESISTANT A2780 CELL LINES.
The results of the complementation studies in the in vitro repair assay, implicate 
the hMutLa complex as the defective component of mismatch repair in A2780/cp70, 
A2780/AD and A2780/MCP1. Defective hMutLa function can arise from mutation in 
the hMLHl or hPMS2 genes, whose products form the hMutLa heterodimer. Mutations 
in these genes can either result in production of a non-functional protein or a reduction
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Figure 4.6 C h a r a c t e r i s a t i o n  o f  m i s m a t c h  r e p a ir  d e f e c t s  in  A 2 7 8 0 ,  d r u g  r e s i s t a n t ,  c e l l  
l i n e s ,  b y  c o m p l e m e n t a t i o n .
A n  in  v i t r o  m i s m a t c h  r e p a ir  a s s a y  w a s  p e r f o r m e d  in  w h i c h  r e p a ir  o f  th e  G - T  o r  - C A -  
m i s m a t c h  o n  t h e  p h a g e  c o n s t r u c t  w a s  d i r e c t e d  f r o m  3 ’ t o  t h e  l e s i o n .  T h e  a m o u n t  o f  
r e p a ir e d  D N A ,  in  f m o l ,  a f t e r  a  1 5  m i n u t e  r e a c t i o n  w a s  d e t e r m i n e d .  C o m p l e m e n t a t i o n  o f  
e a c h  r e a c t i o n  w i t h  c e l l  e x t r a c t s  o f  R K O  c e l l s  ( M u t L - a l p h a  d e f i c i e n t  ) a n d  M T 1  c e l l s  
( M u t S - a l p h a  d e f i c i e n t ) e n a b l e d  c h a r a c t e r i s a t i o n  o f  t h e  d e f e c t  in  3 '  m i s m a t c h  r e p a ir .
in the amount of protein within the cell. Reduction in the intracellular concentration of 
either protein can result in loss of hMutLa function.
To determine whether gross differences in the levels of hMLHl or hPMS2 
proteins exist between A2780 and its cisplatin and doxorubicin resistant derivatives, 
Western immunoblot analysis was performed. Specific monoclonal antibodies to 
hMLHl and hPMS2 are available commercially. G168-15 ( PharMingen Labs, 
Torreyville, CA. USA ) is a monoclonal antibody raised against full length hMLHl 
protein. In the immunoblot assays performed with this antibody, extracts from two 
different cell lines were used as controls. The MCF7 cell line was recommended as a 
positive hMLHl control ( manufacturers data sheet). The endometrial carcinoma cell 
line AN3CA has previously been shown to lack detectable hMLHl mRNA (Umar et al.
1994) and to be defective in mismatch repair due to lack of hMLHl function ( J. 
Drummond. Personal Communication ). This line was used, therefore, as a negative 
control.
The results of an hMLHl immunoblot of cell extracts from A2780, A2780/cp70, 
A2780/MCP1 to MCP9 and A2780/AD, as well as positive and negative controls, is 
shown in figure 4.7. Three of the cell line, A2780, A2780/MCP8 and MCF7 show a 
specific band on the immunoblot with an apparent molecular weight of approximately 
80kDa, which is that expected for hMLHl. Each of these cell lines also show a more 
intense band, with an apparent molecular weight of about 45kDa. This smaller band is 
not observed in any of the cell lines which do not display the full-sized hMLHl, even 
after prolonged enhanced chemiluminescence exposure. The hMLHl immunoblot also 
detects two bands in the A2780/AD cell line. These have an apparent molecular weight 
intermediate between that of hMLHl and the 45kDa band seen in A2780, A2780/MCP8 
and MCF7. If the immunoblot is exposed to enhanced chemiluminescence and then 
autoradiographed for an extended period of time similar bands are observed in all cell 
lines. It is highly likely that these bands represent non-specific hybridisation of the 
antibody.
115
V i n c u l i n
I I I I I I I I I
I I I I
5 6 7 8
I I I I
I I 
10 11 
I I
•v
I I I
12  13  14
I I I
*
h M L H l
I I 
12 13
F i g u r e  4 . 7  B a s a l  l e v e l s  o f h M L H l  p r o t e i n  i n  A 2 7 8 0  a n d  d e r i v e d  c e l l  l i n e s  
s e l e c t e d  f o r  r e s i s t a n c e  t o  c i s p l a t i n  a n d  d o x o r u b i c i n .
W e s t e r n  i m m u n o b l o t  r e p r e s e n t i n g  b a s a l  l e v e l s  o f  h M L H l  a n d  v i n c u l i n  p r o t e i n  
in t h e  c e l l  l i n e s  i n d i c a t e d .  I m m u n o d e t e c t i o n  o f  v i n c u l i n  w a s  u s e d  t o c o n t r o l  f o r  
e q u i v a l e n c e  o f  t o t a l  p r o t e i n  o n  t h e  W e s t e r n  b l o t .  M C F  7 a n d  A N 3 C A  c e l l  l i n e s  
a c t e d  a s  p o s i t i v e  a n d  n e g a t i v e  c o n t r o l s  f o r  h M L H l  r e s p e c t i v e l y .  C e r t a i n  g e l  l a n e s  
a r e  n u m b e r e d  t o p  a n d  b o t t o m  f o r  e a s e  o f  i d e n t i f i c a t i o n .
L e g e n d .
1 A 2 7 8 0 / M C P 1.  2 : - A 2 7 8 0 / M C P 3 .  3 : -  A 2 7 8 0 / M C P 5 .  4 : - A 2 7 8 0 / M C P 7 .
5 : -  A 2 7 8 0 / M C P 9 .  6 : -  A N 3 C A .  7 : -  A 2 7 8 0 .  8 : - A 2 7 8 0 / A D .  9 : - A 2 7 8 0 / M C P 2 .  
1 0 : -  A 2 7 8 0 / M C P 4 1 1 : -  A  2 7 8 0 / M  C P 6 .  1 2 : - A 2 7 8 0 / M  C  P 8 .  1 3 : - M C F 7 .
1 4 : -  A 2 7 8 0 / c p 7 0
1 4 4  k I)
- 7 7 k D
- 4 0 k D
As the 45kDa band is specific only to those cell lines which possess full length 
hMLHl protein it was postulated that it might represent either a truncated version of the 
protein or a degradation product. The cell extracts in the original immunoblot were 
made using a high salt extraction technique ( Chapter 2, section 2.3 ). To determine 
whether the presence of the 45kDa band depended on the extraction conditions used for 
making cell extracts a direct cell-lysis method was used (Harlow and Lane, 1988). This 
technique is less likely to result in protein degradation as it involves less manipulation 
of the cell extract and cellular proteases are directly inhibited by the high concentration 
of SDS. The result of an immunoblot using the directly lysed cells shows an increase in 
the amount of non-specific bands of intermediate weight between hMLHl and the 
45kDa signal ( data not shown). The 45kDa band is still present in the same cell lines as 
before although appears to be less intense than when extracted using the high salt lysis 
buffer. From the results of these assays it is presumed that the 45kDa band is either a 
specific breakdown product of hMLHl, that is not simply due to degradation, or 
represents a shortened form of the protein found in cells of at least two different 
lineages ( A2780 and MCF7 ). In either case it is only observed in those cells which 
display full length hMLHl.
hMLHl combines with hPMS2 in a 1:1 stoichiometry to form hMutLa. In view 
of the lack of detectable hMLHl protein in nine out of ten cisplatin resistant A2780 cell 
lines and the A2780/AD line, we proceeded to look for expression of hPMS2 protein in 
these cells. Figure 4.8 shows the autoradiographic images from a Western immunoblot 
exposed to (a). hMLHl and (b). hPMS2. The monoclonal antibody Ab-1 ( Clone 9 ) ( 
Calbiochem, Cambridge, Mass. USA. ) raised against full length hPMS2 protein was 
used to detect this protein on the blots. The hMLHl immunoblot shows a consistent 
result, in that detectable full length protein is only observed with A2780, A2780/MCP8 
and the positive control line MCF7. Exactly the same picture is seen with hPMS2, in 
that only these cell lines show a band of the expected molecular weight of about 95kDa. 
None of the other cell lines show any evidence of reaction with this antibody. Therefore
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F i g u r e  4 . 8  B a s a l  l e v e l s  o f h M L H  1 a n d  h P M  S 2  i n  A 2 7 8 0  a n d  d e r i v e d
c e l l  l i n e s  s e l e c t e d  f o r  r e s i s t a n c e  t o  c i s p l a t i n  a n d  d o x o r u b i c i n .
W e s t e r n  i m m u n o b l o t  r e p r e s e n t i n g  b a s a l  l e v e l s  o f .  ( a )  h M L H l  a n d  ( b )  h P M S 2  in t h e  
c e l l  l i n e s  i n d i c a t e d .  E q u a l  a m o u n t s  o f  c e l l u l a r  t o t a l  p r o t e i n  e x t r a c t  w e r e  a n a l y s e d  p e r  
l i n e .  M C F 7  a n d  D L D  1 w e r e  u s e d  a s  p o s i t i v e  c o n t r o l s  f o r  t h e s e  p r o t e i n s .  P r o t e i n  s i z e s  
w e r e  e s t i m a t e d  u s i n g  a p p r o p r i a t e  m o l e c u l a r  s i z e  m a r k e r s .
L e g e n d : -
1 A 2 7 8 0 / M C P 1 . 2 : - A 2 7 8 0 / M C P 2 .  3 : - A 2 7 8 0 / M C P 3 .  4 : - A 2 7 8 0 / M C P 4 .
5 : -  A 2 7 8 0 / M C P 5 6 : -  A 2 7 8 0 / M C P 6 .  7 : -  A 2 7 8 0 / M C P 7 .  8 : - A 2 7 8 0 / M C P 8 .
9 : - A 2 7 8 0 / M C P 9 .  1 0 : -  A 2 7 8 0 / c p 7 0  1 1 A 2 7 8 0 .  1 2 : -  A 2 7 8 0 / A D .  1 3 : -  D L D  1.
1 4 : -  M C F 7 .
it would appear that there is a complete absence of the components of the hMutLa 
heterodimer in all but one of the A2780 derived anti-cancer drug resistant cell lines.
4.5 WESTERN IMMUNOBLOT DETERMINATION OF hMSH2 AND 
hMLHl IN CISPLATIN RESISTANT A2780/SCP CELL LINES.
As previously discussed the A2780/SCP cell lines were derived by exposure of
A2780 cells to a single concentration of 15pM cisplatin for 24 hours. Investigation of
these cell lines revealed a stable but low degree of resistance to cisplatin and the 
presence of microsatellite mutations in three of the lines. One of the lines, A2780/SCP6 
was considered to have an RER+ phenotype in view of the high frequency of 
microsatellite mutation observed. Using the same antibodies described in sections 4.1 
and 4.4 a number of the A2780/SCP cell lines were investigated with regards to their 
hMSH2 and hMLHl status. Figure 4.9 shows the results of these investigations. The 
levels of hMSH2 protein detected vary little amongst the different A2780/SCP cell lines 
or with A2780 or A2780/cp70. A2780 shows a detectable band with hMLHl antibody 
whereas A2780/cp70 shows no evidence of detectable protein. The A2780/SCP cell 
lines all show evidence of detectable hMLHl protein, including A2780/SCP6, which is 
RER+, and A2780/SCP5 which displayed microsatellite mutation at one locus out of ten 
studied. These results indicate that loss of detectable hMLHl protein may not always 
represent the defect in mismatch repair selected for in cisplatin resistant A2780 cells.
4.6 IMMUNOHISTOCHEMICAL DETECTION OF hMLHl PROTEIN IN 
A2780 AND CISPLATIN RESISTANT A2780 DERIVED LINES.
Immunoblotting techniques are useful in determining characteristics of protein 
antigens such as their presence and relative quantity within a cell. However, such 
variables as the method of protein extraction or protein denaturation may alter the
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(a) h M L H l
1 2 3 4 5 6 7
(b) h M S H 2
1 2 3 4 5 6 7
• * *  -
Figure 4.9 B a s a l  l e v e l s  o f  h M L H l  a n d  h M S H 2  i n  A  2 7  8 0  c e l l  l i n e s  s e l e c t e d  
f o r  r e s i s t a n c e  t o  c i s p l a t i n  b y  s i n g l e  s t e p  s e l e c t i o n  p r o c e s s .
W e s t e r n  i m m u n o b l o t  r e p r e s e n t i n g  t h e  b a s a l  l e v e l s  o f  ( a )  h M L H  1 a n d  ( b )  h M S H 2  
i n  t h e  c e l l  l i n e s  i n d i c a t e d .  E q u a l  a m o u n t s  o f  c e l l u l a r  t o t a l  p r o t e i n  e x t r a c t  w e r e  
a n a l y s e d  p e r  c e l l  l i n e .  A u t o r a d i o g r a p h i c  i m a g e s  r e p r e s e n t  t h e  s a m e  i m m u n o b l o t  
p r o b e d  w i t h  t h e  t w o  d i f f e r e n t  a n t i b o d i e s .
Legend.
( 1 )  A 2 7 8 0  ( 2 )  A 2 7 8 0 / c p 7 0  ( 3 )  A  2 7 8 0 / S C  P 2  ( 4 )  A 2 7 8 0 / S C P 1 0
( 5 )  A  2 7 8 0 / S C  P 4  ( 6 )  A 2 7 8 0 / S C P 6  ( 7 )  A 2 7 8 0 / S C P 1
sensitivity of this technique. In addition, immunoblotting gives no information as to the 
subcellular localisation of the protein of interest. Immunohistochemical detection of 
proteins within whole cells allows a determination of the subcellular localisation of the 
protein under investigation. It also provides another method by which the presence or 
absence of a particular protein within a cell can be assessed. In collaboration with A. 
Mcllwrath in our laboratory an immunohistochemical analysis of hMLHl was 
performed on the A2780 derived cell lines.
lx l0 5 cells from each line were processed by the method described in chapter 2 ( 
section 9.1 ). Analysis of the cells treated with hMLHl antibody was performed using 
confocal microscopy. The use of propidium iodide as a counter stain enables 
identification of the nucleus within the cell. This allows determination of the sub­
cellular localisation of the particular protein under study. An example of the results 
observed with A2780 and its derived cell lines is shown in figure 4.10. With A2780 
intense propidium iodide staining, localised to the nucleus, is observed in all cells. The 
signal from hMLHl antibody is also localised to the nucleus and again is present in all 
cells. A similar picture is seen with A2780/MCP8, with the majority of cells staining 
strongly for nuclear hMLHl. A2780/cp70, on the other hand, shows no evidence of 
hMLHl staining within the cells despite a good nuclear signal for propidium iodide in 
the cells. In A2780/MCP2 the majority of cells displayed no staining for hMLHl. 
However, one or two small groups of cells did reveal a positive nuclear hMLHl signal, 
suggesting some heterogeneity for the presence of hMLHl within the cell population. 
To determine the heterogeneity of hMLHl protein levels amongst cells within each line, 
a total of 400 cells were analysed from three different high power fields, for the 
presence of nuclear hMLHl staining. The results of this are shown in table 4.1.
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h M L H l P r o p i d i u m  I o d i d e
A2 7 8 0
h M L H  1 P r o p i d i u m  I o d i d e
A2 7 8 0 / c p 7 0
h M L H l  P r o p i d i u m  I o d i d e
A2 7 8 0 / M CP 8
h M  L H  1 P r o p i d i u m  I o d i d e
A 2 7 8 0 / M C P 2
F i g u r e  4 . 1 0  I m m u n o h i s t o c h e m i c a l  d e t e c t i o n  o f b a s a l  h M L H l  l e v e l s  i n  A 2 7 8 0  
a n d  c i s p l a t i n  r e s i s t a n t  d e r i v e d  c e l l  l i n e s .
C o n f o c a l  m i c r o g r a p h s  r e p r e s e n t i n g  t h e  b a s a l  e x p r e s s i o n  o f  h M L H  1 p r o t e i n  in f i x e d  c e l l s  o f  
A 2 7 8 0 ,  A 2 7 8 0 / c p 7 0 a n d  A 2 7 8 0 / M C P  8 & 2.  L e f t  a n d  r i g h t  f r a m e s  i n e a c h  p a n e l  r e p r e s e n t  
t h e  s a m e  m i c r o s c o p i c  f i e l d ,  v i e w e d  f o r  h M  L H  1 ( l e f t  ) o r  P r o p i d i u m  I o d i d e  ( r i g h t  ). T h e  
p r o p i d i u m  i o d i d e  b i n d s  t o D N A  a n d  a c t s  a s  a c o n t r o l  f o r  c e l l  s t a i n i n g . .
( T h e s e  m i c r o g r a p h s  w e r e  p r o d u c e d  in c o l l a b o r a t i o n  w i t h  A m a n d a  M c l l w r a t h  ).
A2780 derived cell lines
A2780 cp70 MCP1 MCP2 MCP3 MCP4 MCP5 MCP6 MCP7 MCP8 MCP9
>90% -ve -ve 2.3% -ve -ve 0.8% -ve 2.5% >90% -ve
Table 4.1 Expression of hMLHl protein in A2780 derived cells.
Legend; The percentage of cells staining positive for hMLHl, out of 400 cells counted using 
confocal laser microscopy, is presented on the lower line. A -ve result indicates that no cells 
were observed that displayed staining for hMLHl antibody.
It can be seen, therefore, that the majority of cell lines which showed no evidence of 
hMLHl by immunoblot analysis also show no detection of protein using 
immunohistochemistry. A2780 and A2780/MCP8, which are the only two cell lines to 
show the presence of hMLHl by immunoblot, show strong staining for the protein in 
nearly all cells. Three of the A2780/MCP cell lines do, however, indicate the presence 
of hMLHl within a small percentage of the cell population. The A2780/MCP cell lines 
were derived from a clonal population of A2780 cells. However, during the selection 
process for resistance to cisplatin the population of cells was not further sub-cloned. The 
result of this is that the A2780/MCP cell lines that resulted from this selection process 
are not a clonal population of cells. It is likely that they consist of cells that are 
heterogeneous with regards to the mechanisms by which they have developed resistance 
to cisplatin. As indicated in the previous section, not all A2780 cells selected for 
cisplatin resistance, which display evidence of microsatellite mutation, need have 
developed this through loss of hMLHl. It is possible, therefore, that the small numbers 
of hMLHl positive cells observed in A2780/MCP2, 5, and 7, arise due to the non-clonal 
nature of the lines.
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4.7 CONFIRMATION OF THE IDENTITY OF A2780/MCP7 AND 
A2780/MCP8 CELL LINES USING MICROSATELLITE PCR.
The results from the immunoblot analysis of hMLHl and hPMS2 in the A2780 
derived cisplatin resistant cell lines, show that only A2780/MCP8 possessed detectable 
levels of either protein. This result was surprising in that A2780/MCP8 had been shown 
to display an increased frequency of microsatellite mutation and was also deficient in 
p53 functions as compared to A2780 ( Chapter 3 ). On the other hand, A2780/MCP7 
which had not shown any mutations at the microsatellite loci studied, and had levels of 
p53 function most similar to A2780, appeared to be deficient in hMLHl and hPMS2. 
One explanation for this could have been that at some point after the initial 
characterisation of the microsatellite instability status of the cell lines the A2780/MCP7 
and A2780/MCP8 lines had inadvertently been switched. To ascertain whether such a 
switch had occurred the following experiment was performed. A2780, A2780/MCP7 
and A2780/MCP8 cells, from the same stocks used to produce the protein extracts for 
Western immunoblotting, were grown and genomic DNA extracted. This DNA was 
labelled as 1996 DNA. The original genomic DNA stocks used to perform the 
microsatellite analysis was available for these cell lines and was labelled as 1994 DNA. 
In the original study of microsatellite mutations in these cell lines the only locus at 
which A2780/MCP8 showed an alteration from A2780 was D2S123. Therefore 
duplicate samples of 1994 and 1996 DNA from all three cell lines were amplified at this 
locus using the previously described PCR protocol ( Chapter 2, section 7.1 ) and the 
products electrophoresed on a polyacrylamide gel. The resulting autoradiograph is 
shown in figure 4.11. As can be seen there is a shift in the size of the microsatellite 
alleles between A2780 and A2780/MCP8 in the original 1994 DNA. No difference is 
observed between A2780/MCP7 and A2780. When comparison is then made to the 
DNA samples from 1996, no change is observed in the state of the microsatellite alleles. 
This would therefore suggest that no switch in these cell lines has occurred since the
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Figure 4.11 D e t e r m i n a t i o n  o f  t h e  i d e n t i t y  o f  A 2 7 8 0 / M C P  c e l l  l i n e s  u s i n g  
c o m p a r a t i v e  a n a l y s i s  o f  m i c r o s a t e l l i t e  r e p e a t  s e q u e n c e s .
C o m p a r is o n  o f  th e  m ic r o s a t e l l i t e  a l l e l e  D 2 S 1 2 3  in  D N A  f r o m  A 2 7 8 0 ,  A 2 7 8 0 / M C P 7  a n d  
A 2 7 8 0 / M C P 8  b e t w e e n  1 9 9 4  to  1 9 9 6 .  D N A  fr o m  th e  c e l l  l in e s  o b t a in e d  in  1 9 9 4  ( 9 4  ) a n d  th a t  
o b t a in e d  fr o m  th e  s a m e  c e l l  l in e s  c u l t u r e d  in  1 9 9 6  ( 9 6  ) w a s  a m p l i f i e d  b y  P C R  u s in g  p r im e r s  
f o r  th e  l o c u s  D 2 S 1 2 3  a n d  s e p a r a te d  b y  g e l - e l e c t r o p h o r e s i s .  T o  a l l o w  c o m p a r is o n  o f  th e  a l l e l e s  a  
D N A  s i z e  la d d e r  w a s  a ls o  in c lu d e d  in  th e  e l e c t r o p h o r e s i s .
N o  d i f f e r e n c e  is  o b s e r v e d  in  th e  s i z e  o f  th e  a l l e l e  in  e a c h  c e l l  l in e  b e t w e e n  D N A  fr o m  1 9 9 4  a n d  
1 9 9 6 .  T h e  s h i f t  in  a l l e l e  s i z e  in  A 2 7 8 0 / M C P 8  c o m p a r e d  to  A 2 7 8 0  c o n t in u e s  to  b e  o b s e r v e d .
original microsatellite analysis and that the results observed in the hMLHl and hPMS2 
immunoblots are accurate.
4.8 NORTHERN BLOT ANALYSIS OF EXPRESSION OF MISMATCH 
REPAIR GENE mRNA IN DRUG RESISTANT A2780 DERIVED CELL LINES.
The absence of detectable hMLHl and hPMS2 protein in A2780/cp70 and all 
but one of the A2780/MCP lines is something of a surprise. It seems unlikely that 
whatever selection pressures are acting upon these cells should result in the loss of two 
genes acting within the same DNA repair pathway. It would therefore be of interest to 
determine whether the absence of hMLHl and hPMS2 proteins within these cell lines is 
a consequence of abnormal gene expression. It has been shown previously that 
mutations arising within a gene, that result in certain alterations of the mRNA, render it 
unstable. Thus the mRNA is rapidly degraded within the cell and is undetectable by 
standard techniques (Lim et al. 1992). To further define the defects arising in the 
cisplatin resistant cell lines we proceeded to analyse the mismatch repair genes, at the 
level of their mRNA expression, by Northern blot analysis.
Total RNA was isolated from A2780, A2780/cp70, and A2780/MCP1-9 cells 
using a commercial kit based on the method of Chomczynski and Sacchi (Chomczynski 
and Sacchi, 1987). Total RNA was also extracted from MCF7 and AN3CA cells to act 
as positive and negative controls respectively. The Northern blot was performed as 
decribed in Chapter 2, ( section 4 .1 ). To allow determination of the size of a particular 
mRNA species, an RNA ladder was electrophoresed concurrent with the other RNA 
samples. The distance migrated by each of the known RNA standards was measured 
during UV transillumination of the ethidium bromide stained gel. A plot of distance 
migrated versus RNA size was then constructed. This gives an approximate guide to the 
size of any RNA species detected.
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To confirm that transfer of non-degraded total RNA from the agarose gel to the 
membrane was equal for all lines, the membrane was initially probed with a cDNA 
clone of the glyceraldehyde-3-phosphate dehydrogenase ( GAPDH) gene (Tso et al. 
1985). GAPDH is found in essentially constant and equivalent levels in most cells, thus 
allowing it to be used as an internal control for gene expression. To detect hybridisation 
to specific RNA species on the membrane, the GAPDH cDNA was radiolabelled with a
32PdCTP by random priming ( Chapter 2, section 3.2). Figure 4.12(a) shows the pattern 
of hybridisation of the GAPDH probe to the membrane. There were no significant 
differences in the levels of the signal obtained with the GAPDH probe between the cell 
lines, suggesting efficient transfer of the RNA to the membrane. It can be assumed, 
therefore, that equal amounts of non-degraded mRNA from each cell line, are present on 
the Northern membrane.
To determine the level of expression of hMSH2 mRNA a probe consisting of the 
cDNA for this gene was used to screen the membrane. hMSH2 cDNA was obtained 
from Prof. B. Vogelstein ( Johns Hopkins University, Baltimore, USA ) cloned into a 
pB SK(+/-) plasmid. The hMSH2 cDNA was excised from the plasmid vector by 
restriction digestion and purified before radiolabelling. Hybridisation to the same 
Northern membrane as used for GAPDH was performed and the result of this 
hybridisation can be observed in figure 4.12(b). A specific signal of equivalent intensity 
is observed with all the cell lines. The migration distance of the band gives an RNA 
species which is consistent with the size of the hMSH2 mRNA. These results confirm 
those of the Western immunoblot for hMSH2 and suggest equivalent expression of this 
gene among A2780 and its drug resistant derivative lines.
A cDNA probe, consisting of 750bp from the 5’ end of hMLHl, was prepared 
from MCF7 cells and radiolabelled. The results of hybridising the Northern blot 
membrane with this probe are observed in Figure 4.12(c). The signal intensity from the 
membrane as a whole is low which might be a result of the small size, and hence lower 
specific activity, of the probe in this hybridisation. A number of bands with calculated
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Figure 4.12 Determination o f the basal levels o f mRNA for hMSH2, hMLHl 
and hPMS2 in A2780 and its drug resistant derived cell lines.
A comparison of the basal level o f gene expression for each of the mismatch repair 
genes, hMSH2, hMLHl and hPMS2, in A2780 and its derived cell lines was made using 
northern blot analysis. To control for efficient transfer o f mRNA from gel to membrane, 
and against degradation of RNA during processing, determination o f the level o f 
GAPDH mRNA in each cell line was made.
The arrow in hMLHl represents the approximate molecular weight o f hMLHl mRNA 
Legend
(1) A2780 (2) A2780/cp70 (3) A2780/MCP1 (4) A2780/MCP2 (5) A2780/MCP3 (6) 
A2780/MCP4 (7) A2780/MCP5 (8) A2780/MCP6 (9) A2780/MCP7 
(10) A2780/MCP8 (11) A2780/MCP9 (12)MCF7 (13)AN3CA
10 11 12 13
GAPDH
10 11 12 13
M
hMSH
hMLHl
3 4 5 6 7 8
.  1 1
9  10 11 12 13
hPMS2
sizes different from that expected for hMLHl mRNA are observed and persisted despite 
stringent washing of the membrane. These represent non-specific hybridisation of the 
probe. A very faint signal could be detected in the lanes corresponding to A2780 and 
MCF7 running at an estimated size in keeping with that expected for hMLHl mRNA. 
This band could not be detected in any of the other cell lines, including A2780/MCP8. 
The significance of this result in terms of the levels of hMLHl mRNA is unclear due to 
the difficulty in differentiating signal from background.
To determine the levels of hPMS2 mRNA in the cell lines a cDNA probe, 
consisting of an 800bp segment from the 5’ end of the gene, was prepared from MCF7 
cells. Figure 4.12(d) shows the result of hybridisation of the radiolabelled hPMS2 probe 
to the Northern membrane. A highly specific signal is obtained from each of the cell 
lines with little background hybridisation. This suggests that mRNA is produced from 
the hPMS2 gene in each of the lines, and with relatively equal efficiency. However, the 
size of hPMS2 mRNA calculated from the signal detected on the Northern blot was 
larger than would have been expected from the known size of hPMS2 cDNA. At the 
time that this experiment was performed no hPMS2 deficient cell line was available to 
use as a negative control, with the result that it could not be determined whether this 
signal was specific for cells with hPMS2 only. It has been shown that hPMS2 is 
produced in a number of different mRNA forms, varying in the size of the 5’ upstream 
sequences and the length of the poly-A tail (Nicolaides et al. 1995b). This could explain 
the larger size of the mRNA species detected with this hybridisation.
4.9 ANALYSIS OF THE EXPRESSION OF MISMATCH REPAIR GENE
mRNA IN A2780 DRUG RESISTANT CELL LINES USING RT-PCR.
The Northern blot analysis in the previous section would tend to suggest that 
those cell lines which do not show hMLHl protein also show no expression of hMLHl 
mRNA. The same cell lines, however, do express hPMS2 mRNA which does not result
123
in detectable protein. Unfortunately the poor signal quality from hMLHl probes, and 
the unexpectedly larger estimated size of hPMS2 mRNA, makes it difficult to draw 
definite conclusions from these experiments. To clarify further the gene expression of 
hMLHl and hPMS2 in the cisplatin resistant A2780 derived cell lines, the more 
sensitive technique of RT-PCR has been used. An equal amount ( 2 or 5pg ) of total 
RNA extract from each cell line was used to form cDNA by reverse transcription ( 
Chapter 2, section 7.2 ) using oligo-d(T) primers. It is important to determine whether 
reverse transcription has proceeded equally well in all cell lines. This is to ensure that 
differences in the levels of specific mRNA detected between lines are real and not due 
to differences in the efficiency of reverse transcription between lines (Rashtchian, 
1994). To accomplish this, PCR primers that amplify ubiquitous genes are used. (3-actin 
is the most commonly used control gene because its mRNA is present in high levels in 
nearly all cells and tissues. PCR primers which amplify a 838bp region of (3-actin cDNA 
were used for this purpose. To detect the presence of mRNA from hMLHl, hMSH2 and 
hPMS2, specific PCR primers were designed to amplify a region of the corresponding 
cDNA. The sequences of these primers are shown in chapter 2, ( section 1.10 ). The 
PCR reactions were performed using the optimal annealing temperature for the primer 
pair used.
When using RT-PCR in a semi-quantitative manner, it is important to determine 
an optimal number of cycles that lies on the exponential section of the amplification 
curve (Gause and Adamovicz, 1994). The reason for this is that once the reaction 
reaches its plateau ( due to utilisation of all the primer or polymerase enzyme ) no 
further amplification occurs. Although different cell lines might, therefore, start off with 
varying levels of gene specific mRNA, if too many cycles of amplification are allowed 
they will all attain the plateau phase thus tending to equalise the amounts of PCR 
product obtained. In view of the result from the Northern assay, suggesting that the 
majority of the cisplatin resistant cell lines displayed no hMLHl mRNA, this RT-PCR 
assay was not intended to be used semi-quantitatively but instead to detect gross
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differences in the levels of RNA. Notwithstanding this, however, it was observed that 
35 cycles of PCR probably represented the plateau phase for all the different primer 
pairs and hence 30 cycles were used in most cases. An equal volume of the products 
from each reaction were run on a 2% agarose gel, stained with ethidium bromide and 
visualised under UV transillumination.
The results of these RT-PCR reactions are shown in figure 4.13. Amplification 
with hMLHl specific primers shows that A2780, A2780/MCP8 and the positive control 
line MCF7 all express equivalent amounts of mRNA. The remainder of the cisplatin 
resistant cell lines, except A2780/MCP5, show no detectable PCR products, as is the 
case with the negative control, AN3CA. This suggests that no hMLHl mRNA is 
expressed in these cells. A2780/MCP5 shows a very small amount of correctly sized 
PCR product suggesting that hMLHl mRNA may be expressed but at levels greatly 
reduced to that found in A2780. This has been confirmed for A2780/MCP5 and some of 
the other cisplatin resistant cell lines ( MCP2,3,6,7 and 9 ) by amplification with a 
greater number of PCR cycles. It should be remembered that A2780/MCP2, 5 and 7 
were cell lines that showed small numbers of hMLHl positive cells by 
immunohistochemistry. The non-clonal nature of the A2780/MCP cell lines was 
proposed as an explanation for this finding. The RT-PCR technique is extremely 
powerful in detecting small quantities of mRNA. It may be, therefore, that the very 
small amount of amplification obtained in some of the A2780/MCP cell lines by 
hMLHl RT-PCR, arises from small numbers of cells, in the non-clonal population, 
which retain functional hMLHl.
RT-PCR using primers specific to hPMS2, produces equivalent levels of product 
DNA in each of the cell lines ( figure 4.13 ). This suggests that there is no significant 
difference in the levels of hPMS2 mRNA amongst the A2780 derived cell lines. This 
result, along with that of the Northern blot analysis, indicates that the lack of detectable 
hPMS2 protein in the cisplatin resistant A2780 cell lines is not due to reduced gene 
expression. The results of RT-PCR using hMSH2 specific primers indicate that
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equivalent amounts of mRNA are observed in all of the A2780 derived cell lines and 
parental A2780. This result is consistent with the data from Western and Northern blot 
analysis for hMSH2 in these cell lines. With the |3-actin primers good amplification of 
equivalent levels of product are observed in all lines except A2780/MCP9 and AN3CA 
where slightly lower amounts of product are observed. This suggests that the amount 
and quality of starting mRNA were relatively equal in all lines. It is therefore unlikely 
that the results observed in the hMLHl RT-PCR are due to degradation of the mRNA 
during processing.
4.10 SOUTHERN BLOT CHARACTERISATION OF STRUCTURE OF
hMLHl GENE IN A2780 AND A2780/CP70.
The lack of hMLHl mRNA in the cisplatin resistant A2780 cell lines could arise 
through gross alteration of the hMLHl gene. To assess whether any differences existed 
in the genomic structure of hMLHl between A2780 and A2780/cp70 a Southern blot 
was performed. 25pg of genomic DNA from both cell lines was digested to completion 
with the restriction enzymes EcoRI and Hindlll. The final products of digestion were 
separated on a 0.8% agarose gel by electrophoresis. The DNA within the gel was 
denatured and transferred to a nylon membrane by capillary action. After blotting of the 
DNA onto the membrane it was fixed into position.
The primer used to probe the Southern blot was a cDNA fragment consisting of 
732 bp from the 5’ end of the hMLHl gene. Purified cDNA was radiolabelled by
•3 9
random priming using a  PdCTP. The autoradiographic results obtained from this 
Southern analysis are presented in figure 4.14. A specific band of approximately 6.6kb 
is observed in the hybridisation to EcoRI digested DNA. There is no apparent difference 
in the size of the bands observed from A2780 and A2780/cp70. With DNA digested 
using Hind III a specific band of about 4.4kb is observed in both A2780 and 
A2780/cp70, again showing no obvious differences. These results would suggest that no
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Figure 4.14 U s e  o f  S o u t h e r n  b l o t  a n a l y s i s  t o  d e t e r m i n e  t h e  g r o s s  s t r u c t u r e  o f  t h e  
h M L H l  g e n e  in  A 2 7 8 0  a n d  A 2 7 8 0 / c p 7 0 .
T o t a l  g e n o m i c  D N A  f r o m  A 2 7 8 0  a n d  A 2 7 8 0 / c p 7 0  w a s  d i g e s t e d  t o  c o m p l e t i o n  u s i n g  
t h e  r e s t r i c t i o n  e n d o n u c l e a s e s  E c o R I  a n d  H i n d l l l .  A f t e r  e l e c t r o p h o r e s i s  t h e  D N A  
f r a g m e n t s  w e r e  S o u t h e r n  b l o t t e d  a n d  h M L H l  g e n e  f r a g m e n t s  d e t e c t e d  u s i n g  a n  e n d -  
l a b e l l e d  p r o b e  s p e c i f i c  f o r  t h e  5 ’ e n d  o f  t h e  g e n e .  T h e  s p e c i f i c  g e n e  f r a g m e n t s  d e t e c t e d  
b y  h y b r i d i s a t i o n  t o  t h e  p r o b e  s h o w  n o  d i f f e r e n c e  b e t w e e n  A 2 7 8 0  a n d  A 2 7 8 0 / c p 7 0  
T h e  a p p r o x i m a t e  s i z e  o f  e a c h  g e n e  f r a g m e n t  ( i n  k i l o b a s e p a i r s  )  i s  i n d i c a t e d
specific gross alterations have occurred in the region of hMLHl genomic DNA covered 
by the specific probe.
4.11 CONCLUSIONS.
Defects of mismatch repair are considered to be responsible for development of 
the RER+ phenotype in tumour cells. The data presented in this chapter help to 
characterise the defects in the mismatch repair system responsible for the RER+ 
phenotype observed in the cisplatin and doxorubicin resistant derivatives of A2780. The 
results show that the majority of A2780 cell lines with an RER+ phenotype, display 
complete absence of the protein components of the hMutLa complex involved in 
mismatch repair. This results in a specific defect in the repair of single base/base and 
insertion/deletion mismatches, when repair is directed from 3’ to the damage. It is also 
shown that there is a lack of expression of the hMLHl gene in these cells, with no 
obvious gross rearrangement of the gene to account for it. Wild-type levels of mRNA 
for the hPMS2 component of hMutLa appears to be expressed.
The results of the in  v i t r o  mismatch repair assay, provide definitive evidence that 
the RER+ phenotype observed in the cisplatin and doxorubicin resistant A2780 cell 
lines, is a result of defective mismatch repair. However, the evidence that purified 
hMutLa complements the mismatch repair defect in these cell lines is surprising, in 
view of the results of the mismatch binding assay. The A2780/cp70 cell line shows loss 
of a specific G/T mismatch binding complex that is present in parental A2780 and 
A2780/AD cells. It would also appear, from preliminary studies, that the A2780/MCP 
cell lines display no loss of G/T mismatch binding as defined by the same assay 
(A.McIlwrath & R.Brown. personal communication ). However, the results with 
A2780/cp70 are reproducible using independently isolated cell extracts. The anomaly 
arises that, under the conditions of the mismatch repair assay, A2780/cp70 cells can 
repair G/T mismatches once hMutLa has been added to the extracts. This indicates that
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under these conditions there is recognition of G/T mismatches, whereas under the 
conditions of the mismatch binding assay no binding is observed.
The results of Western blot studies on A2780/cp70 cells show that they would 
appear to possess hMSH2 and hMSH6 proteins at levels equivalent to those in A2780. 
The A2780/cp70 cells have also been shown to lack expression of hMLHl at both 
protein and mRNA levels, further suggesting that this is the cause of defective mismatch 
repair in these cells. One possible explanation for the anomaly existing between the 
results of the in vitro repair assay and the mismatch binding assay, is that hMutSa 
cannot bind stably to a mismatch in the absence of hMutLa, under the conditions 
existing in the assay. However, if this is the case then it must be specific only for 
A2780/cp70, as the other cell lines with loss of hMutLa activity show no loss of G/T 
mismatch binding. One way to test for this would be to perform a mismatch binding 
assay in A2780/cp70 cell extracts that have been complemented with hMutLa and see if 
it restores binding to G/T mismatches. Another possibility is that the conditions present 
in the mismatch binding assay inhibit the binding of hMutSa to G/T mismatches, 
despite there being no abnormality in the complex itself. Again this does not explain the 
specificity of this finding to A2780/cp70 cells.
A2780/cp70 has been cultured repeatedly since its original isolation. If, as is 
highly possible, the RER+ phenotype developed early during the selection process, then 
the increased genomic mutation rate could have resulted in the accumulation of 
mutations in functional genes, as well as in microsatellite and other repeat sequences. It 
is possible, therefore, that A2780/cp70 harbours a mutation or mutations in other genes 
which effect, directly or indirectly, the binding of G/T mismatches, leading to the results 
observed in the mismatch binding assay. It is now known that other proteins involved in 
mismatch binding exist (Gaffney and Jones, 1989), and that these may be involved in 
determining the specificity of mismatch binding within a cell (Risinger et al. 1996).
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Confirmation of the defect in the hMutLa component of mismatch repair in the 
RER+ A2780 cell lines is provided by the Western immunoblot and 
immunohistochemistry data. This reveals that in all but one of the cisplatin resistant cell 
lines, and in the doxorubicin resistant line, derived from A2780 there is essentially no 
detectable hMLHl or hPMS2 protein. As stated previously, it would appear highly 
unlikely that under the selection pressures exerted by exposure to cisplatin or 
doxorubicin, independent mutations would occur in two components of the same repair 
pathway. Northern blot and RT-PCR studies show that, at the level of gene expression, 
those cells which show no hPMS2 protein produce levels of mRNA similar to that 
found in A2780. In cells in which no hMLHl protein is detected there is an absence of 
hMLHl mRNA. This finding would appear to exclude the possibility that hMLHl 
protein is involved in the transcriptional regulation of hPMS2, as the gene is expressed 
in the absence of hMLHl protein. It would also tend to rule out expression of the 
hMLHl and hPMS2 genes occurring in a conjugate manner.
Perhaps a more likely explanation of these results is that the stability of hPMS2 
protein is, in some way, dependent on the presence of hMLHl protein and in its absence 
is degraded. It has been suggested that the individual components of hMutSa are less 
stable than when present in the heterodimeric complex (Drummond et al. 1995). To 
determine whether reduced hPMS2 stability in the absence of hMLHl is possible, it 
would be interesting to study the expression of hPMS2 in other cell lines which lack 
hMLHl expression. The endometrial carcinoma cell line, AN3CA, is an ideal candidate 
as it is known to lack hMLHl expression at the level of the mRNA. There is some 
evidence to suggest that this other hMLHl deficient cell line shows absence of hPMS2 
protein (Drummond et al. 1996). It would also be interesting to determine whether 
hMLHl is unstable in cell lines with an inherent defect of hPMS2 expression. Such cell 
lines have now been identified, e.g. HEC-l-A and evidence suggests that they possess 
normal levels of full length hMLHl protein (Drummond et al. 1996).
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The lack of hMLHl protein would appear to arise from a lack of expression of 
the gene, in view of the absence of detectable mRNA in the RER+ cell lines. The 
Southern blot analysis of A2780 and A2780/cp70 suggests that there has been no gross 
structural rearrangement of the hMLHl gene within the latter line, such as a deletion, to 
account for the lack of expression. Previous studies have shown that mis-sense or 
nonsense mutations within a gene can result in synthesis of a mRNA species that is 
quickly degraded within the cell (Lim et al. 1992). This would appear to be the most 
likely candidate for the type of mutational lesion occurring within the hMLHl gene, in 
view of the lack of mRNA. Characterisation of the hMLHl gene, in the RER+, A2780 
cell lines, by SSCP and DNA sequencing, for example, will hopefully determine 
whether such mutations exist.
One major anomaly arises from the results in this section. The results in chapter 
3 revealed that of all the A2780/MCP cell lines derived by selection against cisplatin, 
A2780/MCP7 was the one that showed no evidence of microsatellite instability and had 
the least abnormality of p53 function. In the results presented in this section, however, 
A2780/MCP7, although not having been shown to have defective mismatch repair in the 
in vitro assay, has no detectable hMLHl gene expression or hMutLa protein. 
A2780/MCP8, on the other hand, which displayed microsatellite mutation at one locus 
on chromosome 2, and appeared to have defective p53 function, displays levels of 
hMutLa protein equal to that in A2780. The most likely cause of this anomaly was an 
inadvertent swapping of the cell lines at some point after the original microsatellite 
analysis. This does not appear to be the case, as repeat analysis of the microsatellite 
locus originally displaying mutation in A2780/MCP8 continued to display this 
difference in DNA obtained from A2780/MCP8 cells used in the Western immunoblot 
assay. The A2780/MCP7 cells used in the Western blot assay also retained the same 
pattern of microsatellite alleles as in the original analysis. A possible explanation for the 
microsatellite instability and loss of p53 dependent functions in A2780/MCP8 is that the 
defect in mismatch repair exists in a component of the repair apparatus other than
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hMLHl. This cell line has not been subjected to the in vitro repair assay and therefore 
the actual component which is responsible for the defective repair is unknown. It is 
harder to define a possible explanation for the results observed with A2780/MCP7. 
Although no microsatellite mutations were observed in the original study, with this cell 
line, it is possible that by looking at a greater number of loci, evidence of microsatellite 
instability would have been detected. However, why there has not been an associated 
loss of p53 dependent functions in this line, as in all the others that have loss of hMutLa 
, is unclear.
The selective loss of 3’ directed mismatch repair observed with the RER+, 
A2780 drug resistant cell lines, is a novel finding having only previously been detected 
in the hMLHl deficient AN3CA cell line ( J. Drummond. Personal communication ). It 
differs from the biochemical phenotype of other hMLHl deficient cell lines, such as the 
colorectal tumour line H6, which is unable to correct mismatches when repair is directed 
from either 3’ or 5’ to the lesion (Parsons et al. 1993). The basis of this selective loss of 
3’ directed mismatch repair in hMLHl and hPMS2 deficient, A2780 cell lines is 
unclear. Another way of looking at the same question is to ask why the RER+, A2780 
cell lines retain 5’ directed repair, despite lacking hMLHl and hPMS2. As in the case of 
eukaryotic MutS homologues, it is thought that the MutL component of eukaryotic 
mismatch repair is more complicated than in the prokaryotic situation (Kolodner, 1996). 
It may be that there are a number of different mammalian proteins that are involved in 
the steps of mismatch repair performed by prokaryotic MutL. Some of these may 
determine the directionality of repair. It is possible that the RER+ A2780 cells possess 
an activity that supports 5’ directed mismatch repair in the absence of hMutLa. This 
activity may not be present in other hMLHl null cells such as the H6 cell line. Another 
explanation could arise from the different types of hMLHl mutation in these cells. It 
would appear that the RER+ A2780 cells express no hMLHl protein. H6 cells, on the 
other hand, possess a hemizygous or homozygous UAA chain termination mutation and 
produce an amino terminal fragment of the hMLHl polypeptide. It could be that the
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presence of such hMLHl fragments in H6 cells inhibit 5’ directed repair, resulting in 
total loss of mismatch repair. Further characterisation of the defects in mismatch repair 
by in vitro repair assay, in tumour cell lines with different mismatch repair gene 
mutations, may help characterise the determinants of repair directionality.
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CHAPTER 5
GENERAL DISCUSSION
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The results presented in this thesis can be summarised in two main conclusions;
(1). An association exists in certain tumour cell lines between resistance to the 
clinically important anti-cancer drugs cisplatin and doxorubicin, and the loss of 
mismatch repair as characterised by microsatellite instability. The development of an 
RER+ phenotype occurs at high frequency during the selection for cisplatin resistance, 
either by single or multiple exposures to the drug, in the A2780 ovarian carcinoma cell 
line.
(2). The RER+ phenotype observed in the cisplatin resistant A2780 cell lines is the 
result of a loss of mismatch repair activity, specific for repair occurring from a direction 
3’ to the DNA mismatch. In nearly all cases this occurred concurrently with loss of 
expression of hMLHl, at both the mRNA and protein levels, and of hPMS2 protein. 
Those cells with loss of mismatch repair also display a reduction in specific p53 
mediated functions; ionising radiation induced G1 arrest, basal and induced expression 
of Cipl and an apoptotic response to cisplatin induced DNA damage.
The following general discussion will attempt to define the relevance of these findings 
in the context of our current understanding of mismatch repair and cisplatin resistance. 
It will also explore the potential clinical implications of an association between 
mismatch repair and drug resistance in ovarian and other tumours.
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5.1 MISMATCH REPAIR DEFICIENT CELL LINES
5.1.1 Frequency of selection of RER+ and drug resistant cell lines
The discovery that cisplatin and doxorubicin resistant clones of independently 
derived ovarian and breast carcinoma cell lines display high levels of microsatellite 
mutation compared to parent lines is an intriguing result. Defects in mismatch repair 
with associated microsatellite instability have been detected frequently in ovarian 
tumour cell lines (Boyer et al. 1995; Orth et al. 1994). However, the RER status of the 
A2780 cell line had not previously been characterised and the results presented show 
that it has a proficient mismatch repair activity. The RER status of the other tumour cell 
lines used in the initial investigation, MCF7 and OVl/p (IGROV1), has also not been 
characterised to date. It has been shown, by immunoblotting, that MCF7 has normal 
levels of several mismatch repair proteins (A.McIlwrath, personal communication ) and 
would therefore be assumed to have normal repair function. Confirmation of this, 
however, awaits clonal analysis of microsatellite mutations in MCF7 and MCF7/AD or 
measurement of the in vitro mismatch repair function of these cell lines. Therefore, 
although there is a reasonable likelihood that the microsatellite instability observed in 
MCF7/AD and OV1/DDP is a feature of the resistant and not the parental lines this, as 
yet, can only be defined categorically for A2780/cp70, A2780/MCP1-9 and A2780/AD. 
It should be noted that not every tumour cell line selected for resistance to cisplatin or 
doxorubicin displays evidence of microsatellite instability. In a study of each of two 
ovarian, lung and testicular cell lines, and their cisplatin resistant derivatives, no 
evidence of microsatellite mutation was observed at a variety of dinucleotide repeat 
sequences ( G.Hirst. personal communication.).
One of the most significant observations to arise from this work, was the high 
frequency with which an RER+ phenotype developed during selection for cisplatin 
resistance in A2780 cells. This raised the possibility that an association might exist
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between the two phenomena. A similar high frequency of RER+ phenotype 
development has been suggested from studies on other drug resistant cell lines. In cells 
that lack methyltransferase activity, exposure to alkylating agents, such as MNNG, is 
toxic. An association between tolerance to methylating agents and defects in the 
mismatch repair system was originally proposed from studies performed on E.coli 
(Holmes et al. 1990) and has subsequently been shown in mammalian cell lines which 
are tolerant to 0 6MeG and 6-TG (Kat et al. 1993; Branch et al. 1993). In a series of 
MGMT deficient HeLa cells exposed to cytotoxic levels of MNNG, 5 out of 8 subclones 
displayed resistance not due to re-induction of the methyltransferase activity 
(Gothgoldstein, 1987). This resistance in the HeLa cells was shown to be due to 
tolerance of the methylation damage, induced by MNNG, as similar levels of DNA 
methylation were observed in the resistant and parental cell lines. A similarly high 
frequency of selection of methylation tolerance, 6 out of 9 clones, was observed in 
Chinese hamster ovary cells selected for resistance to increasing concentrations of 6TG 
over a period of months (Aquilina et al. 1990). Cross resistance was also shown to 
MNU, with no evidence of methyltransferase activity as a cause. This phenotype has 
been shown to be due to loss of a specific G-T mismatch binding complex (Branch et al. 
1993).
5.1.2 Mechanism of development of drug resistant, RER+ phenotype.
Thus the evidence suggests that selection for resistance to certain types of 
alkylating agent can be associated with the appearance of an RER+ phenotype at high 
frequency. By what mechanism does exposure to alkylating agent appears to result in 
development of an RER+ phenotype? Most of the alkylating agents in question are 
mutagenic as well as cytotoxic. Therefore it could be that exposure of tumour cells to 
these agents results in mutations which lead to an RER+ phenotype. Subclones of an 
MGMT HeLa cell line, pre-treated with a sub-lethal dose of MNNG, were shown to
136
display greater resistance to an additional exposure to MNNG than non-pre-treated 
subclones (Gothgoldstein, 1987). This was taken to suggest that resistance could be 
induced by MNNG treatment. Many of the cell lines studied for cisplatin and 
methylation tolerance have been developed by exposure to increasing concentrations of 
drug. Exposure to the lower drug doses could result in the occurrence of mutations 
which increase the resistance to subsequent higher doses. This has been suggested as the 
basis for induction of cisplatin tolerance in ovarian 2008 cancer cells (Aebi et al. 1996). 
However, the results from the A2780 clones selected by a single exposure to cisplatin 
show that this can also result in an RER+ phenotype. This would, perhaps, argue against 
drug tolerance being induced by exposure to the specific alkylating agent.
The other possibility is that cells with an RER+ phenotype arise spontaneously 
in the tumour cell population. These would have a strong survival advantage under the 
selection pressures induced by exposure to specific drugs. Why such cells should arise 
so frequently in the tumour population is unclear. However the cell lines studied have 
all been cultured, in vitro, over long periods of time, with the attendant likelihood of 
accumulating multiple mutations.
5.2 MISMATCH REPAIR AND DRUG RESISTANCE
5.2 1 Mismatch repair and cellular sensitivity to cisplatin.
The data presented in this thesis supports the premise that defects in the 
mismatch repair apparatus of the cell may contribute to the development of resistance to 
cisplatin. Corroboration of this concept has come from a recent study using a different 
ovarian carcinoma cell line and its cisplatin resistant derivative. Aebi et al (Aebi et al. 
1996) used the 2008 cell line and two cisplatin resistant derivatives, selected by 
exposure to increasing concentrations of drug. 2008 cells and those of the cisplatin
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resistant derivative 2008/C 13*5.25 both displayed detectable hMSH2 and hMLHl by 
Western immunoblot and showed no evidence of microsatellite instability. Both lines 
were sensitive to the methylating agent MNNG and to 6-TG. Cells of the cisplatin 
resistant derivative 2008/A, however, were shown to have lost hMLHl protein; 
displayed microsatellite instability; demonstrated an increased mutation rate at the 
HPRT locus and were also resistant to MNNG. As it has recently been shown that the 
A2780/cp70 and A2780/MCP1 cell lines are resistant to MNU and have an increased 
HPRT mutation rate ( G.Hirst. Pers. comm. ) the 2008/A cell line virtually mirrors the 
phenotypic characteristics of the cisplatin resistant derivatives of A2780.
The same study also presents further evidence for the importance of mismatch 
repair in determining the sensitivity to cisplatin. Tumour cell lines that were isogenic 
apart from the presence or absence of functional mismatch repair, were studied for their 
resistance to cisplatin. HCT116 colorectal carcinoma cells lack functional hMLHl and 
HEC59 endometrial carcinoma cells lack hMSH2, both cell lines being deficient in 
mismatch repair. These lines displayed about 2 fold greater resistance to cisplatin 
compared to identical lines where functional mismatch repair had been restored by 
introduction of the required mismatch repair genes using chromosome transfer ( 
chromosome 3 in the case of HCT116 and chromosome 2 for HEC59 ). Although the 
mismatch repair deficient cells were only two fold resistant to cisplatin changes of < 2- 
fold in cisplatin sensitivity are sufficient to result in the clinical failure of this drug 
(Andrews et al. 1990) and are similar to the levels of resistance observed with the 
A2780/MCP lines. Therefore an association between defective mismatch repair and 
cisplatin resistance has been observed not only in resistant derivatives selected from 
independent ovarian carcinoma cell lines but also in different tumour cell lines with no 
prior exposure to cisplatin.
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5.2.2 Recognition of platinated DNA by mismatch repair proteins.
The bacterial mismatch repair pathway has been implicated in the cellular 
response to a variety of different types of DNA damage. Thus it is able to recognise 
damage arising from the action of MNNG (Karran and Marinus, 1982), cisplatin (Fram 
et al. 1985 ) and UV irradiation (Feng and Hays, 1995; Feng et al. 1991). If, as the 
evidence presented in chapters 3, 4 and above suggests, the mismatch repair system in 
humans also plays a role in the response to DNA damage induced by cisplatin, then 
recognition of such damage would seem to be required as the first step.
It has been well established that bacterial MutS protein, and its homologues in 
yeast and human cells, is able to recognise and bind to mismatches in DNA (Drummond 
et al. 1995; Su et al. 1988). It has also been shown that mismatch recognition complexes 
in cell extracts can bind to base pairs containing 0 6-MeG and 6-TG (Griffin et al. 1994). 
There is now evidence to support the concept that mismatch recognition complexes 
from human cells can recognise DNA damage caused by cisplatin. Specific 
oligonucleotides containing single base mismatches, methylated base mismatches or a 
variety of platinated DNA adducts, were constructed in one study and their recognition 
by purified hMutSa determined by retardation of the oligonucleotide during gel 
electrophoresis (Duckett et al. 1996). Purified hMutSa recognised 0 6-MeG/C, O6- 
MeG/T and 0 4-MeT/A adducts with an affinity one order of magnitude less than the 
recognition of G/T mispairs in the oligonucleotides studied. Oligonucleotides that 
contained a l,2-d(GpG) intrastrand platinum crosslink, where the platinated bases were 
paired with dCpC on the complementary strand, were also bound by purified hMutSa 
with a similar level of affinity. Oligonucleotides with l,2-d(ApG) or l,3-d(GpTpG) 
platinated adducts were bound very poorly by hMutSa.
A similar selectivity has also been demonstrated for the binding of purified 
hMSH2 protein to platinated oligonucleotides in vitro (Mello et al. 1996). Those 
oligonucleotides treated with the clinically active compounds cisplatin and Pt(en)Cl2
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were found to bind to purified hMSH2 protein. Such compounds are able to form 1,2 
intrastrand cross-links at adjacent purine nucleotides. Oligonucleotides formed by 
treatment with transplatin or , compounds which cannot form 1,2 intrastrand links and 
show no clinical activity, did not bind to hMSH2 protein. It was also shown that 
hMSH2 protein bound specifically to a lOObp oligonucleotide containing a single 1,2 
d(GpG) platinum adduct.
A further gel retardation study has shown that the presence of a cisplatin adduct 
alone might not be sufficient to bring about mismatch protein binding. It was observed 
that cell extracts of mismatch repair competent cells, and purified hMutSa, only bound 
to a 1,2 d(GpG) cisplatin adduct when it was paired with a d(CpT) on the 
complementary strand ( Karran,P. pers. comm. ). That is when it was in the form of a 
mismatch. The combination of a bulky DNA adduct associated with a mismatch has 
been called a compound lesion ( Freidberg 1995 ). When d(CpC) were the 
complementary bases, very little binding to the platinated oligonucleotides was 
observed. Binding was specific for this form of mismatched cisplatin adduct, as other 
combination of bases complementary to 1,2 intrastrand crosslink resulted in no 
detectable binding. It should be noted that extracts from cells lacking hMSH6 and 
hMSH2 showed no evidence of binding to platinated DNA.
What significance can be obtained from these results and how do they relate to 
the data presented in this thesis? Perhaps most importantly they confirm that DNA 
platinum adducts can be recognised by the mismatch repair system. It may be that it is 
not the platinum adduct per se that is recognised by mismatch repair proteins, but rather 
the conformational change in DNA structure that they produce. It has been shown, using 
X-ray crystallography, that introduction of a 1,2 d(GpG) cisplatin cross-link into an 
oligonucleotide leads to bending of the helix with formation of a unique fusion between 
A and B forms of DNA (Takahara et al. 1995). There is conflicting evidence as to the 
degree of distortion caused in DNA by simple base/base mismatches (Kalnik et al. 
1988; Bhattacharyya and Lilley, 1989). However, it does appear that larger
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insertion/deletion mismatches do substantially distort the DNA helix (Bhattacharyya 
and Lilley, 1989b). Therefore, it is very possible that mismatch proteins, that recognise 
the structural DNA alterations caused by mismatches, could also recognise that caused 
by cisplatin DNA adducts. The evidence that mismatch repair proteins can bind to 
cisplatin adducts in DNA provides evidence, of a mechanistic nature, to link mismatch 
repair and cisplatin sensitivity.
5.2.3 DNA replication, damage processing and mismatch repair.
The suggestion that mismatch recognition proteins may bind to cisplatin 
adducts, especially as part of a mismatched complex lesion, is interesting. In the case of 
methylating agents, it has been shown previously that the 0 6MeG lesion produced by 
methylation of DNA, is not in itself toxic to the cell (Aquilina et al. 1993). A model has 
been constructed to explain the mechanism of cytotoxicity of such lesions and the basis 
of methylation tolerance in mismatch repair deficient cells (Karran and Bignami, 1992). 
In this model 0 6MeG, when formed by DNA methylation, will remain paired with 
cytosine until replication, in the absence of repair by MGMT. At replication there is a 
strong possibility that 0 6MeG will pair with thymine instead of cytosine, as the thermal 
stability’s of each base pair are about the same (Gaffney and Jones, 1989). The 
0 6MeG/T base pair is recognised as a mismatch by the mismatch repair system, which 
removes the thymine from the newly synthesised daughter strand and attempts to repair 
the lesion. However, it is most likely to fill the gap with another thymine, for the 
reasons discussed above, and it is proposed that repeated cycles of this futile mismatch 
repair may lead to the formation of further DNA damage, perhaps strand breaks, 
resulting in cell death (Karran and Bignami, 1992).
Could such a mechanism also be involved in the cytotoxicity observed after 
exposure to cisplatin? Circumstantial evidence supports the possibility that replication 
of platinated DNA is required before toxicity is observed. Studies in immature rat
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thymocytes have shown that the ability of cisplatin to induce apoptosis, and thus its 
cytotoxicity, is much greater with proliferating cells as opposed to quiescent cells 
(Evans et al. 1994). It was shown that this phenomenon was not related to alterations in 
the levels of DNA platination or repair. The proposal was made that the molecular 
events that coupled DNA damage to the engagement of apoptosis were not active in 
quiescent thymocytes. A dependence on replication was not observed for other cytotoxic 
agents, such as etoposide. One possible explanation for this phenomenon is that 
replication of platinated DNA is required to produce a cytotoxic lesion, whereas it is not 
required for agents that produce more directly toxic forms of damage such as strand 
breaks. If replication of cisplatin adducts is required for induction of cytotoxicity, in a 
manner analogous to 0 6-MeG, then it could explain the enhanced binding of hMutSa to 
intrastrand d(GpG) adducts paired with d(CpT) ( Karran,P. Pers. Comm. ). Cisplatin 
induced formation of intrastrand d(GpG) adducts, in non-replicated DNA, may not act 
as a strong enough signal for hMSH2 binding. Post- replication, however, the formation 
of mispairs in the newly synthesised strand opposite the d(GpG) adduct could result in 
enhanced hMSH2 binding, thus inducing futile attempts at mismatch repair.
One argument raised against such a model for replicative processing of cisplatin 
damage is that platinated adducts in the DNA would act as an absolute block to 
progression of the replication complex. There is, however, increasing evidence to 
indicate that replication can proceed past bulky adducts in the DNA. A steady state 
replication assay, which measures the inhibition of DNA chain elongation as a function 
of the number of platinum-DNA adducts present following cisplatin treatment, was used 
to study the ability of cells to replicate past cisplatin adducts (Mamenta et al. 1994). 
Using the ovarian carcinoma cell lines 2008 and A2780 it was shown that the 
replication apparatus was able to bypass cisplatin adducts more readily in cisplatin 
resistant derivatives, 2008.C13 and A2780/DDP, than in the parental lines. This 
phenomenon has also been observed for A2780/cp70 cells ( S. Channey, Pers. Comm.).
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This “replicative bypass” was proposed to account for part of the cisplatin tolerance 
seen in the resistant cell lines.
A number of biochemical studies have looked at the ability of DNA polymerases 
to bypass different lesions in the DNA during replication. DNA polymerase 6 has been 
shown to bypass UV radiation induced DNA adducts, under the influence of 
proliferating cell nuclear antigen ( PCNA ) (Oday et al. 1992). The use of anti-PCNA 
antibodies have also implicated the importance of DNA polymerase 6 or e in the 
processing of 0 6MeG lesions in DNA (Ceccotti et al. 1996). More recently, it has been 
shown using cell free systems, that whereas chain elongation by DNA polymerase a , 6 
and e are effectively terminated by bulky adducts such as d(GpG) cisplatin or N-2- 
acetylaminofluorene (AAF), DNA polymerase |3 can replicate past such lesions 
(Thomas et al. 1995; Hoffmann et al. 1995). DNA polymerase (3, which is 
predominantly involved in DNA repair synthesis, can also extend the arrested 
replication products of the other three DNA polymerases (Hoffmann et al. 1995). 
Another example of replication past cisplatin adducts has been observed using structures 
that resemble the DNA replication fork, in vitro. The presence of d(GpG) cisplatin 
adducts in such a ‘forked DNA’ construct did not act as a barrier to replication. 
Cisplatin adducts on single stranded DNA effectively inhibited replication (Hoffmann et 
al. 1996).
The ability to replicate past an adduct in the DNA is also referred to as 
translesion synthesis. Such translesion synthesis of DNA occurs with either the insertion 
of the correct base, or bases, opposite the adduct or with insertion of mismatched bases. 
The evidence presented above suggests that replication past cisplatin adducts in DNA is 
possible with concomitant formation of mismatches.
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5.2.4 Nucleotide excision repair, Mismatch repair and cisplatin adducts.
The preceding sections have presented evidence that mismatch repair proteins 
can recognise platinum adducts in DNA, in the form of 1,2 intrastrand crosslinks. It has 
also suggested that such lesions do not act as an absolute block to replication but form 
mismatches, once replicated past, which may represent a more complex form of DNA 
damage. Mismatch proteins have been shown to bind to such complex damage. It is 
generally accepted that nucleotide excision repair ( N ER) is the main process by which 
cisplatin adducts are removed from DNA. Research referred to in chapter 1 also 
suggests that differences in NER between cell lines might be involved in the 
determination of cisplatin sensitivity or resistance. Is there any evidence to suggest that 
the efficiency of repair of ‘complex’ cisplatin adducts from replicated DNA, that is 
those paired with non-complementary bases, determines cisplatin sensitivity? Could 
binding of mismatch proteins alter the repair of such complex lesions?
Cisplatin forms a number of different types of DNA adduct. The majority are 1,2 
intrastrand adducts, either between adjacent guanines ( 65% ) or an adenine and guanine 
( 25% ) (Fichtinger-Schepman et al. 1985). Although it has generally been though that, 
due to their prevalence, these adducts are the determinants of cisplatin cytotoxicity, it is 
also possible that one or more of the less common adducts is more important (Eastman, 
1987b). Although repair of platinum adducts has been shown to occur using cell extracts 
in vitro, there is evidence to suggest that 1,2 d(GpG) adducts are not efficiently repaired 
(Bedford et al. 1988). An in vitro assay using M l 3-phage with a single 1,2 d(GpG) 
cisplatin adduct showed no repair, using HeLa cell extracts which could efficiently 
repair an AAF lesion on the same DNA construct (Szymkowski et al. 1992). It was 
shown that this lack of repair occurred at the stage of recognition of the DNA damage 
by the repairosome complex formed in excision repair. It was proposed that this could 
be due to blocking of recognition by proteins binding to the DNA damage, for example 
HMG group proteins. It has been shown recently that HMG proteins can block excision 
repair of 1,2 d(GpG) and 1,2 d(ApG) cisplatin adducts on DNA (Zamble et al. 1996).
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However, the same study also demonstrated that 1,2 d(GpG) cisplatin adducts were 
repaired 3x less efficiently than 1,3 d(GpNpG) cisplatin lesions in cell free systems 
containing no HMG protein. The 1,2 d(GpG) adduct is known to cause less 
conformational disruption to the DNA helix than 1,3 d(GpNpG) (Bellon et al. 1991). It 
may be that the reduced conformational disturbance caused by 1,2 d(GpG) results in 
lack of recognition by the exinuclease system.
Such a hypothesis has been given support by work showing that 1,2 d(GpG) and
1,2 d(ApG) cisplatin adducts are repaired up to 15-fold less efficiently than 1,3 
d(GpNpG) adducts (Moggs et al. 1997) .This difference was also shown to arise at a step 
preceding, or coincident with, endonucleolytic cleavage. Fractionation of cell extracts to 
remove HMG proteins did not alter the differential rates of repair. When the 1,2 d(GpG) 
cisplatin adduct was mismatched with a thymine on the complementary strand, to form 
a complex lesion which is presumed to cause greater distortion to the DNA helix, the 
rate of repair increased dramatically. This occurred for cell extracts from mismatch 
repair proficient and deficient cells suggesting that mismatch repair proteins do not 
influence the NER of complex lesions. In confirmation of this last point, it has been 
shown that mismatch repair deficient cells repair complex lesions containing UV 
photoproducts and 1,2 d(GpG) cisplatin adducts as well as wild type HeLa cells (Mu et 
al. 1997). Addition of purified hMutSa or hMutLa to complement the mismatch repair 
defect did not enhance the NER of complex lesions.
In total this evidence tends to suggest that formation of a complex cisplatin 
adduct, perhaps by translesion synthesis, can enhance its rate of repair and that this is 
absolutely dependent on NER, with no involvement of mismatch repair. It would also 
suggest that binding of mismatch repair proteins to cisplatin adducts, either matched or 
mismatched on the complementary strand, does not shield such lesions from the 
exinuclease. Since the mismatch repair status does not appear to influence the efficiency 
of NER of cisplatin adducts, it suggests that differential repair of these lesions does not
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underlie cisplatin resistance in the A2780 cell lines. It will be of interest to characterise 
the NER of simple and complex cisplatin adduct lesions using A2780 cell line extracts.
5.2.5 Cell cycle checkpoints, Mismatch repair and Cisplatin resistance.
The previous section has presented evidence that cisplatin adducts with 
mismatched bases on the complementary strand are repaired exclusively by NER. 
However, it is known that mismatch repair proteins bind to cisplatin DNA adducts and 
that defects in mismatch repair can result in increased resistance to the drug. It may be 
that the mismatch repair system is not involved with repair of these adducts but, as has 
been suggested previously (Kat et al. 1993), signals the presence of DNA damage to 
downstream effectors of repair and/or cell death. If this is the case, is there any evidence 
linking defects in mismatch repair with alterations in the cellular processes that monitor 
DNA damage, and ultimately result in cell survival or cell death?
The suggestion that cisplatin resistant cells with abnormal mismatch repair may 
also display abnormalities of the DNA damage response pathway arose from known 
features of the A2780/cp70 cell line. A2780/cp70, with no difference in the sequence of 
the p53 gene compared to its parental line, displays a loss of the p53 dependent G1 
arrest after exposure to ionising radiation or cisplatin (Mcllwrath et al. 1994a). This 
suggests that p53 mediated functions are inhibited by a mechanism other than mutation 
of the gene in these cells. The results presented in this thesis confirm the loss of the 
radiation induced G1 cell cycle arrest in A2780/cp70, and also show that these cells 
have altered induction of the Cipl gene after exposure to cisplatin and a reduction in 
apoptosis after cisplatin. The RER+ A2780/MCP cell lines also show this phenotype 
suggestive of altered p53 function, although it is not known for certain whether these 
lines possess wild-type p53 gene sequence or not. The one A2780/MCP cell line which 
was RER- displayed p53 mediated responses similar to that of parental A2780 cells.
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This suggests that there is a correlation between the loss of mismatch repair and 
abnormalities of p53 function.
Evidence exists to support an association between loss of mismatch repair and 
defects in cell cycle damage response mechanisms in different cell types. Goldmacher et 
al in their initial studies on methylation tolerance displayed differences in the cell cycle 
progression of MT1 and TK6 cells exposed to isotoxic doses of MNNG (Goldmacher et 
al. 1986). On exposure to MNNG parental, RER-, TK6 cells underwent a single cell 
division and arrested at or immediately after their second S phase. At this “G2” arrest, a 
proportion of cells died whereas the remainder appeared to be able to regain a normal 
cell cycle. MT1 cells, since shown to have an RER+ phenotype, appeared to arrest cell 
division immediately after addition of MNNG, and this “arrest” lasted for up to 4 days. 
The cells then started to grow but initially at a slower rate compared to controls.
More recently the response of colorectal tumour cells lines to 6TG and MNNG 
has been studied with regards to cell cycle response and cell viability. The HCT116 cell 
line ( defective hMLHl ) and its derivatives, with either wild-type chromosome 3 or 2 
introduced by chromosome transfer, were grown in the presence of 6TG (Hawn et al. 
1995) The RER+ cell lines, HCT116 and HCT116+chr2, displayed greater resistance to 
the effects of 6TG than RER- HCT116+chr3 cells. This was not associated with 
differences in the incorporation of 6TG into the DNA but did correlate directly to the 
status of the mismatch repair system. When the cell cycle characteristics of these lines 
was determined it was observed that HCT116+chr3 displayed a marked arrest in G2 
after exposure to 6TG whereas HCT116 and HCT116+chr2 cells accumulated in Gl. 
Additional studies on these, and additional, cell lines by the same group have displayed 
the loss of a damage induced G2 arrest in RER+ cells after treatment with MNNG 
(Carethers et al. 1996). HCT116+chr3 and another RER- colorectal cell line, SW480, 
arrest in G2 after exposure to MNNG. This arrest occurs at the first G2 period after 
damage, unlike the situation observed with TK6. HCT116, HCT116+chr2 and 2774 ( an
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ovarian carcinoma cell line with no functional hMSH2 ) cells, which show loss of this 
MNNG induced G2 arrest although do not appear to accumulate in Gl.
Full cell cycle profiles have been performed on A2780, A2780/cp70 and 
A2780/MCP1 after exposure to varying concentrations of cisplatin ( Brown,R. et al. 
Oncogene, in press). A2780 cells show a marked increase in the proportion of G2-M 
cells after treatment with 20pM and 40pM cisplatin, indicative of a G2 arrest. 
A2780/cp70 and A2780/MCP1 show considerably less of a G2 arrest at these cisplatin 
doses. A2780 cells also show a cisplatin induced reduction in the number of cells 
entering DNA replication from Gl (early S-phase cells ), which is lost in the cisplatin 
resistant lines. Therefore, it would appear that cells deficient in mismatch repair, lose 
the ability to arrest the cell cycle after DNA damage induced by both methylating agents 
and cisplatin.
The loss of the G2 arrest in mismatch repair deficient cells, can potentially be 
explained if mismatch repair is involved in processing of DNA damage during 
replication, as proposed above. That is, if futile attempts to repair the mismatch 
generated by a methyl adduct,or a cisplatin intrastrand crosslink, could result in the 
generation of strand breaks. These act as potent signals to the damage recognition 
pathway with a resultant arrest at G2 with concomitant repair or cell death by apoptosis. 
Obviously, if the mismatch repair system cannot process the DNA damage then no 
signal to arrest in G2 is produced and the cell cycle proceeds. This could also account 
for the reduced apoptosis observed in the RER+ A2780/MCP cell lines as the G2 arrest 
is the point at which entry into apoptosis is initiated. Loss of the Gl checkpoint in the 
cisplatin resistant A2780 cell lines, as a consequence of defective mismatch repair, is 
more difficult to explain. The Gl checkpoint is dependent on the function of p53 and 
genes transcriptionally transactivated by it. As shown previously (Brown et al. 1993), 
A2780/cp70 has wild type p53 sequence. The p53 sequence of the A2780/MCP cell 
lines has not yet been established although those which are RER+ display a p53 
phenotype similar to that of A2780/cp70. Evidence is now accumulating which suggests
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that p53 may be more closely involved in certain DNA repair processes, such as 
mismatch repair, than was previously recognised.
5.2.6 The involvement of p53 in DNA repair.
As indicated previously, the involvement of p53 in regulation of cell cycle 
checkpoints and induction of apoptosis is well established if not fully understood. 
However, there have been a number of recent reports that suggest that p53 may have a 
more direct role in DNA damage recognition and repair, indicating that it has functions 
upstream of its role in cell-cycle checkpoint regulation. It has been shown by a number 
of groups that p53, and specifically the C-terminal portion of the protein, can bind to 
DNA ( and RNA ) single strands and termini (Oberosler et al. 1993; Bakalkin et al.
1994). This DNA binding activity of p53 is also associated with DNA renaturation and 
strand transfer. As DNA ends, and single strands, are the type of structural damage that 
would be expected after, for example, exposure to ionising radiation, it has been 
suggested that p53 might concentrate at the sites of such damage and play a role in DNA 
repair or recognition. Another recent finding is that the transcriptional transactivation 
function of p53 can be activated by binding of short ( 16-40 base ) oligonucleotides to 
the C-terminal domain (Jayaraman and Prives, 1995). The suggestion is made that the 
release of short oligonucleotides, of about 30 bases, during nucleotide excision repair ( 
NER) could lead to the functional activation of p53. The basis for this hypothesis is that 
p53 has been shown to interact with the XPB and XPD proteins, both of which are 
components of the TFIIH complex involved in NER and transcription (Wang et al.
1995). XPB and XPD are helicases involved in unwinding the DNA duplex, allowing 
access to the damaged DNA of other proteins involved in NER. Binding of p53 to XPB 
and XPD, again via its C-terminal domain, inhibits the function of the helicases. This 
would appear to be important for normal NER as fibroblasts from Li-Fraumeni patients 
( heterozygous for mutant p53 ) have deficient repair of UV-induced pyrimidime dimers
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by NER (Wang et al. 1995). This cumulative evidence suggests that p53 can play a 
direct role in recognition and repair of certain forms of DNA damage.
Is there any evidence that p53 is involved in mismatch repair at a point upstream
of its cell-cycle effects? Electron microscopy and gel-retardation studies have shown
that p53 can bind directly to certain forms of mismatched DNA (Lee et al. 1995). In this
analysis it was shown that full length p53, and a 14kD C-terminal fragment, could bind 
CCC CACACACA
to / \ or / \ DNA loops in vitro, in the form of monomers, dimers and
tetramers. The binding appeared to be specific for mismatched DNA and was not just 
due to the single strand nature of the DNA in the mismatch. Perhaps surprisingly p53 
did not bind to single base G/T mismatches under the same conditions. There is no 
evidence, as yet, as to whether such binding of p53 to these mismatches results in 
alteration of p53 function.
In cells with defective mismatch repair, it can be postulated that post-replication 
mismatches persist within the cell until the next round of replication. If this were the 
case then they would be present at higher numbers than in mismatch repair proficient 
cells. If p53 can bind to mismatched DNA the possibility arises that it will undergo 
sequestration by the mismatches in RER+ cells. This could result in accumulation of 
p53 in the nucleus, as bound p53 is less likely to undergo Ubiquitin mediated 
degradation than if in the free state. Furthermore, if p53 bound to mismatches was not 
activated by binding then it could result in abnormalities of p53 mediated functions such 
as cell-cycle checkpoint control and apoptosis. These correlate with the phenotypic 
characteristics of A2780/cp70, with wild type sequence p53 which shows nuclear 
accumulation ( W. Gallagher. Pers. communication ) and loss of various p53 mediated 
functions. There is no additional evidence to suggest that this is the reason for the 
abnormal p53 function in A2780/cp70 and no reports of nuclear p53 accumulation with 
associated loss of p53 mediated functions have come from other RER+ cell lines, 
although they may not have been looked for.
150
A more direct strand of evidence linking p53 directly with mismatch repair is the 
identification of sequences homologous to the p53 consensus binding sequence in the 
promoter region of the hMSH2 gene (Scherer et al. 1996). Using gel mobility shift 
experiments it was shown that purified wild type p53 bound to the hMSH2 promoter 
consensus sequences in vitro with an affinity stronger than that of the classical 
consensus sequence. The effects of binding of p53 to these consensus sequences is as 
yet unknown.
It is becoming increasingly obvious from the results of a wide range of studies, 
that components of specific DNA repair processes may have functions within other 
pathways of DNA repair with which they have not previously been associated. As 
indicated above p53 interacts with XPB and XPD to influence NER and probably 
transcription coupled NER. In a study in E.coli to determine which genes were 
important in regulating transcription coupled NER, it was shown that mutations in mutS 
and mutL resulted in the loss of the preferential repair of the transcribed strands of 
active genes (Mellon and Champe, 1996). The proposal is made that the mutS and mutL 
proteins are involved in coupling of NER to RNA polymerase, stalled by a lesion on the 
actively transcribed strand of a gene, perhaps by stabilising some form of repair 
intermediate. Perhaps more importantly, it has subsequently been shown that there is a 
similar link between mismatch repair and transcription coupled NER in humans. 
Tumour cell lines with mutations in hMSH2, hMLHl or hPMS2 were proven to have 
loss of transcription coupled repair of UV induced pyrimidine dimers (Mellon et al.
1996). Chromosome transfer of a normal copy of hMLHl, into a cell with no functional 
copy of the gene, restored preferential repair of the actively transcribed DNA strands. 
Although no evidence exists to indicate that p53 and mismatch repair proteins interact in 
the process of transcription coupled repair it is another potential point of overlap.
There exist a number of other tenuous links between mismatch repair and p53 
which, however, add to the overall impression that there may be some form of more or 
less direct interaction. These will be touched upon in the next section.
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5.2.7 Cisplatin resistance and non-mismatch binding components of
mismatch repair
The discussion presented so far pertains to data showing that platinated DNA 
can be bound by mismatch binding proteins. It also raises the possibility that the 
mismatch repair pathway is in some way involved with processing this form of DNA 
damage leading to interaction with downstream effectors of the damage response 
pathway. However, the data presented in chapter 4 shows that differences in the 
sensitivity to cisplatin between sensitive and resistant derivatives of A2780 are due to 
defects in hMutLa and not the mismatch binding components of mismatch repair. The 
most intriguing result is that of the in vitro mismatch repair assay, showing that the 
RER+ cisplatin resistant A2780/cp70 and MCP1 cells have a specific defect in repair of 
mismatches, when repair is directed from the 3’ direction. The central question thrown 
up by these results is how a defect in hMutLa results in loss of mismatch repair directed 
from one side of a lesion but not the other.
As far as is known hMutLa does not possess any function that would explain the 
selective loss of 3’ directed mismatch repair observed in the cisplatin resistant A2780 
cell lines. However, it is highly likely that hMutLa does interact with other components 
of the mismatch repair apparatus (Kolodner, 1996). Some of these will be involved 
specifically in repair occurring from either a 3’ or 5’ direction, and could include the 
signal which determines repair strand selectivity, as well as the repair exonucleases. 
There is no clear data as to how the eukaryotic mismatch repair apparatus selects the 
correct DNA strand to repair. However, several recent reports have shed some light on 
the identity of the exonucleases that could, potentially, be involved in mismatch repair. 
It has been suggested that the exonuclease function of human mismatch repair will 
display redundancy (Kolodner, 1996). That is, the possible involvement of more than 
one form of exonuclease in both 3’ and 5’ directed reactions.
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Studies in the yeasts S.cereviseae and S.pombe have identified several proteins 
which could act as exonucleases in the mismatch repair reaction. The RAD27 protein, 
which is a 5’—>3’ endo/exonuclease, has been proposed to be associated with mismatch 
repair as mutations in the gene cause a mutator phenotype (Johnson et al. 1995). 
However, mutations in RAD27 have a 3 to 5-fold synergistic effect with mutations in 
the other, known, mismatch repair genes, suggesting that they work in different 
pathways. RAD27 has been shown to be involved in processing other forms of DNA 
damage and also the 5’ ends of Okazaki fragments (Sommers et al. 1995). Additional 
studies have shown that RAD27 is important in DNA replication and repair, with 
mutations resulting in increases in the spontaneous mutation rate, increased sensitivity 
to DNA-damaging agents, increased recombination and alterations of the cell cycle 
(Vallen and Cross, 1995). The redundancy in exonuclease function can be seen by the 
fact that the EXOl gene has been proposed as another 5’-» 3’ exonuclease in 
S.cereviseae. This gene was identified using yeast two-hybrid screening techniques, 
with MSH2 as a bait protein, and by coimmunoprecipitation (Kolodner, 1996). 
Mutations in this gene lead to a weak mutator phenotype and it is likely that it acts in an 
MSH2 dependent pathway.
A human candidate for a mismatch repair 5’—> 3’ exonuclease has recently come 
to light by yeast two-hybrid experiments using PCNA protein. This acts as a 
processivity factor in cellular functions such as DNA replication and nucleotide excision 
repair. It was shown that PCNA binds to hMLHl and, to a lesser extent, hMSH2 in the 
yeast two-hybrid system (Umar et al. 1996). A mis-sense mutation in yeast PCNA also 
confers a strong mutator phenotype, and results from yeast PCNA/MLH1 double 
mutants would suggest that PCNA acts in the mismatch repair pathway. Using an in 
vitro human mismatch repair assay it was shown that PCNA acts at a step in repair prior 
to synthesis of the new DNA strand. Interestingly, it has been shown that PCNA can 
bind to, and stimulate the activity of, FEN1 (Li et al. 1995). FEN1 is a 5’ exonuclease 
that is structure specific and has been shown to be the equivalent of the yeast RAD27
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exonuclease mentioned above (Harrington and Lieber, 1994). It would be interesting to 
hypothesise that the lack of hMLHl in cisplatin resistant A2780 cells might disrupt the 
recruitment of PCNA, FEN1 and, possibly, other proteins involved in exonucleolytic 
removal of mismatched DNA.
In passing, it is also interesting to remember that PCNA interacts with p21, the 
product of the Cipl gene, which plays a pivotal role in regulating arrest of the cell cycle 
after DNA damage. The interaction between mismatch repair proteins and PCNA could 
link this form of DNA repair to cell cycle regulation, a link that appears to be disrupted 
in the hMLHl deficient A2780 cell lines.
If loss of hMLHl brings about a defect in 3’—>5’ mismatch repair this raises the 
possibility that hMLHl interacts, directly or indirectly, with a 3’—>5’ exonuclease. 
Although to date no exonuclease with this specificity has been directly linked to 
mismatch repair, perhaps the most intriguing candidate for such an exonuclease is p53 
protein. It has been shown recently that wild type, but not mutant, p53 has a 3’—>5’ 
exonuclease action on double stranded oligonucleotides. This action was mapped to the 
central core of the p53 molecule (Mummenbrauer et al. 1996). Although p53 appears to 
display multiple functions from the same protein, it has been shown to have a DNA 
binding domain with a structure similar to that of the catalytic domain of the major 
apurinic/apyrimidinic repair endonuclease in E.coli. (Cho et al. 1994). The possibility 
arises that p53 could play a role as a 3 *—>5* exonuclease in mismatch repair. If the 
enrolment of p53 into this exonuclease function was dependent on the presence of wild 
type hMLHl, then mutations in the latter protein could result in a specific loss of 3*—>5* 
mismatch repair. This would be in keeping with the results from A2780/cp70 and 
A2780/MCP1. Although no evidence exists to show that p53 directly interacts with 
hMLHl protein, or with hMutLa, such interaction could be investigated by 
coimmunoprecipitation reactions or using the yeast two-hybrid approach.
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5.3 MISMATCH REPAIR DEFECTS AND CLINICAL DRUG RESISTANCE
The original association between mutation of microsatellite sequences, 
mutations in genes of the mismatch repair system and the familial cancer syndrome 
HNPCC opened a new chapter in the characterisation of the causes of cancer. Of equal 
importance however was the discovery that an increased frequency of microsatellite 
mutation was also found in a significant percentage of sporadic colorectal tumours (Kim 
et al. 1994). This suggested that the mechanisms underlying the inherited cancer 
predisposition could also be responsible for tumours arising purely from somatic 
mutations. This has been reinforced by an ever increasing number of reports describing 
the presence of microsatellite mutations in sporadic tumours from a range of different 
tissues. One question arising from these findings is whether the association between 
defects in mismatch repair and the development of tumours, both sporadic and 
hereditary, could be utilised in a clinically beneficial manner.
5.3.1 Analyses of microsatellite instability in sporadic tumours.
Microsatellite instability has been detected as a feature of tumours from a wide 
variety of tissue types. These have included tumours of the pancreas and stomach (Rhyu 
et al. 1994; Han et al. 1993); endometrium and uterus (Risinger et al. 1995; Risinger et 
al. 1993); ovary (King et al. 1995); kidney (Thrashbingham et al. 1995; Uchida et al.
1994); lung (Shridhar et al. 1994; Merlo et al. 1994); Bladder (Gonzalez-Zulueta et al. 
1993); breast (Yee et al. 1994; Aldaz et al. 1995); cervix (Larson et al. 1996) and 
lymphoma (Peng et al. 1996). The results presented in this thesis suggest that defects in 
mismatch repair, resulting in microsatellite instability, are associated with resistance to 
clinically important anticancer agents. This, along with data showing that RER+ 
tumours also display resistance to methylating agents, suggests that tumours with
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microsatellite instability might respond less well to treatment and thus carry a worse 
prognosis. Is there any evidence from the studies into microsatellite instability in 
different sporadic tumour types that this feature of the tumours carries prognostic 
significance?
One of the problems encountered in using microsatellite instability as a 
prognostic tool, is that there appears to be a significant variation in the frequency with 
which this phenotype arises within tumours of the same tissue type. For example, in 
carcinoma of the breast several studies have detected evidence of microsatellite 
mutation in around 20% of tumours (Contegiacomo et al. 1995; Yee et al. 1994) 
whereas others have shown negligible mutation levels (Jonsson et al. 1995). Several 
factors have been proposed as potential sources of such variation. Firstly there have 
been suggestions that defects in mismatch repair may be more significant as a cause of 
malignancy within certain histological subgroups of certain tumours. One study in 
breast carcinoma has detected an increased frequency of microsatellite mutation in 
invasive lobular carcinoma as opposed to invasive ductal carcinoma (Aldaz et al. 1995). 
In ovarian carcinoma there is a suggestion that endometriod and less common 
histological subtypes are associated more frequently with defects in mismatch repair 
(King et al. 1995; Fujita et al. 1995). It may be, therefore, that observed differences in 
the frequency of microsatellite instability in the same tumour type arise due to 
differences in the histological subtypes studied. Secondly the methods for detection of 
microsatellite mutations and their interpretation often differ between studies. This is 
observed with regard to the number and type of microsatellite loci studied, their 
chromosomal distribution and interpretation of subtle shifts in the size of alleles.
A third cause of differences in the reported rates of microsatellite instability 
within the same tumour type is that often various criteria have been used to determine 
what constitutes microsatellite instability. This latter point is important as it is becoming 
clear that microsatellite mutations can arise despite functional mismatch repair. Recent 
studies of spontaneous mutation at microsatellite repeats in cells without defects in
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mismatch repair show frequencies in the order of 3x1 O'3 mutations per allele (Hackman 
et al. 1995; Shibata et al. 1994). This is of the same order as that seen in a number of 
reports of microsatellite instability in sporadic cancer (Wooster et al. 1994).
Most tumours are clonal expansions of a single cell. Analysis of tumour DNA, 
therefore, can detect spontaneous somatic mutations that have arisen in a microsatellite 
sequence during previous replications of the precursor cell, before or during early clonal 
expansions of the tumour. The greater the observed frequency of microsatellite 
mutations within a tumour the more likely that a defect in mismatch repair is the 
underlying cause. Mutation rates in HNPCC are two orders of magnitude higher than 
the spontaneous background mutation rate mentioned above. A number of studies in 
colorectal cancer revealed that those tumours with only one microsatellite mutation 
detected had clinicopathological characteristics similar to those tumours with no 
evidence of microsatellite mutation (Lothe et al. 1993). This was different from the 
situation observed for tumours with more than one microsatellite mutation. As a result 
of this, several studies have used the criterion of requiring mutations at a minimum of 
two out of five microsatellite loci within a tumour to qualify for displaying 
microsatellite mutation.
A recent report from the 87th AACR meeting (Perucho, 1996) has suggested an 
even more stringent set of criteria for classification of microsatellite instability. This 
would involve the presence of more than one microsatellite alteration together with 
mutations in cancer genes that are targets of microsatellite instability, such as the type II 
TGFp gene. A perceived difficulty of this approach is in determining which of the 
genes, that are targets for microsatellite instability, are important in tumour development 
and, therefore, should be included in the analysis. To establish the prognostic 
significance of microsatellite instability in different forms of sporadic cancer future 
studies will have to attempt to standardise the methods and criteria used to detect 
microsatellite instability.
157
5.3.2 Prognostic significance of microsatellite instability in colorectal
cancer.
The first indications that the presence of microsatellite instability might have 
prognostic significance were observed in the initial reports associating this feature with 
hereditary and sporadic colorectal cancer (Lothe et al. 1993). The majority of tumours 
arising in hereditary non-polyposis colorectal cancer (HNPCC) do so in the proximal 
colon (Lynch et al. 1993). Unexpectedly it was also found that significantly more of the 
sporadic tumours which displayed an RER+ phenotype were from the colon proximal to 
the splenic flexure as opposed to the distal colon (Lothe et al. 1993). Colonic 
adenocarcinoma is, in general, more frequently found in the distal colon and rectum. 
Subsequently it has been shown that sporadic colorectal cancers which display an RER+ 
phenotype tend to share certain other clinico-pathological features. These include 
incidence at a younger age than in RER- tumours; diploid state; exophytic growth; large 
size at diagnosis; poor differentiation; extracellular mucin production and lymphoid 
reaction around the tumour (Kim et al. 1994). Intuitively it would be thought that 
tumours with characteristics of poor differentiation and large size at diagnosis would 
have a poor prognosis. However, the results of several independent studies now 
overwhelmingly suggest that RER+ colonic tumours have a significantly better 
prognosis than those that are RER- (Bubb et al. 1996; Kim et al. 1994; Lothe et al. 
1993).
It has also been shown that the presence of microsatellite instability has 
independent prognostic significance in sporadic colorectal cancer (Bubb et al. 1996). 
One explanation put forward for the better prognosis in these tumours arises from the 
observed inflammatory cell infiltrate surrounding the tumour cells. It may be that this 
represents a greater immunological host response to the RER+ colonic tumours which 
might prevent local or metastatic spread of the tumour (Kim et al. 1994). The hypothesis 
has been presented that mutations arising in RER+ tumours may affect genes which
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influence expression of tumour-associated antigens that elicit host immune responses. 
One report has shown that colonic carcinoma cells which are RER+ have an increased 
frequency of mutation in the [32-microglobulin gene (Bicknell et al. 1996). This gene 
encodes for a protein involved in antigen presentation on the surface of a cell. As most 
of the |32-microglobulin gene mutations in these cells are frameshifts, occurring at 
repeat sequences, it may be that the loss of mismatch repair increases the likelihood of 
mutation in this gene. Although the clinical results of loss of such antigen presentation 
are not clear, intuitively it would be thought that it would be associated with a poorer 
prognosis. However, it has also been suggested that cells with defects in DNA repair are 
better targets for cytotoxic T-lymphocytes (Townsend et al. 1994). This places a very 
strong selection pressure on such cells for those with mutations in antigen presentation. 
It may be that those tumours with additional mutations in the [32-microglobulin gene 
will represent a poor prognosis sub-group of RER+ colorectal cancers.
Another interesting feature of RER+ sporadic colonic tumours is that they tend 
to express wild-type p53 protein, as detected immunohistologically (Bubb et al. 1996), 
and display little evidence of significant loss of heterozygosity throughout the genome 
(Kim et al. 1994). This is significantly different from other colorectal tumours in general 
and specifically from RER- tumours of the proximal colon. It would therefore appear 
that RER+ sporadic colonic tumours represent a class separate from RER- sporadic 
tumours, in terms of prognosis and molecular carcinogenesis.
5.3.3 Prognostic significance of microsatellite instability in breast and
ovarian cancer.
The prognostic implications of microsatellite instability and abnormal mismatch 
repair have been investigated in tumour types other than colon, of which breast and 
ovary have, perhaps, accumulated the most data. Microsatellite instability has been 
reported to occur in up to 20% of sporadic breast carcinomas. Several of the studies
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have investigated whether the presence of microsatellite instability correlates with 
particular clinico-pathological parameters of the breast tumours. Two separate studies 
have identified that microsatellite instability is more likely to occur in invasive lobular 
carcinoma of the breast as opposed to invasive ductal carcinoma (Aldaz et al. 1995; 
Contegiacomo et al. 1995). Invasive lobular breast carcinoma has a greater risk of 
development of multifocal or subsequent contralateral breast tumours compared to 
ductal carcinoma (Silverstein et al. 1994). Microsatellite instability has also been shown 
to be associated with high S-phase fraction and aneuploidy (Kamik et al. 1995), lymph- 
node involvement and tumour size above 2cm at diagnosis (Contegiacomo et al. 1995). 
All these features tend to be associated with a worse prognosis. It should be noted that 
many of these studies have involved limited numbers of patients; therefore the 
significance of the results has to be viewed with some caution in view of this.
Only one study to date has looked at the association between microsatellite 
instability and survival in breast cancer (Paulson et al. 1996). This study is significant in 
that stringent criteria were used to determine the presence of microsatellite instability. A 
positive association was observed between microsatellite instability and larger tumour 
size, positive lymph-node status, aneuploidy and higher pathological stage at diagnosis. 
These poor prognostic features were reflected in the observation that the RER+ breast 
cancers were associated with reduced disease free and overall survival as compared to 
RER- tumours.
Microsatellite instability has been observed in up to 20% of ovarian carcinoma 
in a number of different studies. In common with the results from other tumour types 
most of these studies relate to small numbers of patients and often use different criteria 
to define microsatellite instability. However certain characteristics of RER+ ovarian 
tumours can be inferred from the accumulated data. Microsatellite instability would 
appear to occur more commonly in the genesis of the less common histological types of 
ovarian cancer. These include endometriod (Fujita et al. 1995), mixed mesodermal 
(Risinger et al. 1995) and immature teratoma (King et al. 1995) forms of ovarian
160
tumour. No definite association between presence of an RER+ phenotype and good or 
bad prognostic features has yet been determined for ovarian carcinoma. On the one hand 
microsatellite instability was found in a greater number of stage I tumours (King et al.
1995) or in borderline epithelial ovarian tumours (Tangir et al. 1996) suggesting 
improved prognostic significance. On the other hand, an RER+ phenotype was 
significantly associated with advanced clinical stage in endometriod ovarian carcinoma 
(Fujita et al. 1995).
No study has yet attempted to correlate the presence of microsatellite instability 
with survival for ovarian carcinoma. However the possibility that defects in mismatch 
repair, along with other abnormalities of DNA damage control such as non-functional 
p53, could result in resistance to chemotherapy and thus to poorer survival is raised in a 
study on gynaecological sarcomas (Risinger et al. 1995). The application of measures of 
DNA repair, damage recognition or cell cycle progression as prognostic indicators in 
ovarian cancer, particularly with regard to response to treatment, is currently under 
investigation. There are indications that mutant or non-functional p53 are associated 
with reduced survival in ovarian cancer (van der Zee et al. 1995) and with resistance to 
cisplatin chemotherapy (Righetti et al. 1996b). From the data presented in this thesis it 
is possible that microsatellite instability might represent a determinant of resistance to 
chemotherapy that could contribute to providing better prognostic information in 
ovarian cancer. For example, it has been suggested that the detection of defective 
mismatch repair in tumour cells might determine the type of chemotherapy administered 
to a particular patient. This arises from the discovery that ovarian carcinoma cells with 
defective mismatch repair were resistant to cisplatin and carboplatin but not to other 
platinum based drugs such as oxaliplatin and JM-216 (Fink et al. 1996).
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5.3.4 Potential therapeutic implications of mismatch repair defects in
tumours.
Could the presence of defective mismatch repair in tumour cells, as well as 
having potential prognostic significance, be utilized as a selective target for different 
forms of therapy? The “Holy Grail” of cancer therapy is a form of treatment toxic to 
tumour cells but with no deleterious effect on normal cells. Anything characteristic of 
tumour cells that distinguishes them from non-malignant cells could act as a target that 
would allow selective toxicity. Tumour cells that display an RER+ phenotype would be 
expected to have an increased number of mismatches in the DNA at any given time as 
compared to cells with functional mismatch repair. One possibility would be to develop 
treatments that targeted mismatches in DNA as these would be expected to accumulate 
in tumour cells to a greater extent than in normal cells. The use of peptides that can bind 
to mismatches as a vehicle to target drugs or radio-isotopes, with short LET 
characteristics, to tumour cells is one possible avenue to be explored.
5.4 CONCLUSIONS AND FUTURE DIRECTIONS
This thesis has provided evidence that defects in the mismatch repair system are 
associated with development of resistance to cisplatin and doxorubicin in ovarian and 
breast tumour cell lines. It has localised the defect in one series of cisplatin resistant 
ovarian cancer cell lines to the hMLHl protein. This defect has been characterised , at a 
functional level, as a specific loss in mismatch repair directed from 3’ to the lesion. In 
the context of recently published research it has been proposed that a functioning 
mismatch repair system may be involved in determining the sensitivity of a cell to DNA 
damaging agents such as cisplatin. Components of the mismatch repair system may act
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as a general sensor of DNA damage and interact with downstream effectors of DNA 
repair, cell cycle control and apoptosis.
The future investigation of the role of DNA mismatch repair in determining 
cellular drug sensitivity or resistance is likely to follow two main themes. Further 
characterisation of the mechanisms by which mismatch repair proteins are involved in 
recognising and processing chemical DNA damage is required. The way in which DNA 
damage recognition by mismatch repair proteins interacts with regulators of the cell 
cycle and apoptosis needs further clarification. In the cisplatin resistant A2780 cell lines, 
in vitro assays of NER and mismatch repair using DNA containing cisplatin adducts, 
either simple or mismatched, should help to answer some outstanding questions.
If the association between defective repair and cisplatin resistance is to be more 
than just a laboratory curiosity then investigation of its clinical significance is required. 
There is already early data on the relationship between tumour levels of mismatch repair 
proteins and response to cisplatin chemotherapy in ovarian cancer ( R. Brown. Pers. 
Comm.). Extension of this form of analysis to include different tumour types and larger 
numbers of patients will determine whether mismatch repair status will signify another 
important prognostic indicator in the management of cancer.
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